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Abstract 
Inositol-containing molecules and inositol phosphatases have diverse roles in cells. One 
of the inositol phospholipids phosphatases, PTEN (Phosphatase and Tensin Homolog 
deleted on Chromosome Ten), is a tumor suppressor and antagonizes the PI3K signaling 
pathway by dephosphorylating PI(3,4,5)P3 at the 3 position of the inositol ring. In testing 
predictions of a molecular dynamics simulation, a hydrophobic site adjacent to the active 
site on PTEN was identified and verified by protein kinetic studies. This hydrophobic site 
plays an important role in substrate and substrate analogue binding with one of residues, 
Arg47, critical for PTEN phosphatase activity. Mutations of Arg47 reduced enzyme 
activities toward both the short-chain substrate as monomers and micelles and long-chain 
phospholipid presented in vesicles. PI(4,5)P2, the product of PI(3,4,5)P3 
dephosphorylation, activates PTEN. Studies by others suggested this occurred when the 
product was bound to the N-terminal region of the protein (not visible in the crystal 
structure). However, no direct proof of this existed. The effect of PI(4,5)P2 on PTEN 
enzyme activities in different substrates systems was studied. 31P NMR was used to probe 
the spatial location and functional role of PI(4,5)P2 binding site. The fixed field 31P NMR 
and high resolution field cycling 31P NMR results indicated there are discrete sites for 
both substrate and activator lipids on PTEN, and both of sites are spatially separate from 
the hydrophobic site. The active site, adjacent hydrophobic site, and N-terminal activator 
binding site worked synergistically to regulate PTEN interacting with the membrane. 
Thermophilic and hyperthermophilic archaea and bacteria thrive at high temperatures. 
They often accumulate small organic molecules, called compatible solutes or osmolytes, 
to protect proteins from thermal denaturation. The thermoprotection mechanism of 
compatible solutes was explored using inositol monophosphatase (IMPase) from 
Archaeoglobus fulgidus as the model protein. The protective effect of unusual compatible 
solutes, di-inositol-1,1’-phosphate (DIP) and diglycerol phosphate (DGP), as well as 
common compatible solutes glutamate and other anions, on the IMPase thermostability 
was studied. Specific binding sites of glutamate ions on the IMPase were identified by 
crystallography and field cycling NMR. However, mutations at these discrete binding 
sites did not eliminate the thermoprotection, but reduced the thermal stability (Tm) of the 
protein. Our results indicate the specific binding of osmolytes to the protein exists, but 
they do not account for the thermoprotection.  
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Abbreviation 
A. fulgidus Archaeaoglubus fulgidus 
AHS adjacent hydrophobic site 
C2 protein kinase C conserved region 2 
CD circular dichroism 
CMC critical micelle concentration 
CSA chemical shift anisotropy 
DAG diacylglycerol 
Dansyl-PE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(5-
dimethylamino-1-naphthalene-sulfonyl) 
DGP diglycerol phosphate 
D-I-1-P D-myo-inositol 1-phosphate 
diC6PI 1,2-dihexanoyl-sn-glycero-3-phospho-(1’-myo-inositol) 
diC6PI(3,4)P2 1,2-dihexanoyl-sn-glycero-3-phospho-(1’-myo-inositol-3’,4’-
bisphosphate) 
diC6PI(4,5)P2 1,2-dihexanoyl-sn-glycero-3-phospho-(1’-myo-inositol-4’,5’-
bisphosphate) 
diC7PC 1,2-diheptanoyl-sn-glycero-3-phosphocholine 
diC8PI 1,2-dioctanoyl-sn-glycero-3-phospho-(1’-myo-inositol) 
diC8PI(3)P 1,2-dioctanoyl-sn-glycero-3-phospho-(1’-myo-inositol-3’-
phosphate) 
diC8PI(3,4)P2 1,2-dioctanoyl-sn-glycero-3-phospho-(1’-myo-inositol-3’,4’-
bisphosphate) 
diC8PI(4,5)P2 1,2-dioctanoyl-sn-glycero-3-phospho-(1’-myo-inositol-4’,5’-
bisphosphate) 
 v 
 
DIP di-myo-inositol-1,1’ phosphate 
DOPI(3,4)P2 1,2-dioleoyl-sn-glycero-3-phospho-(1’-myo-inositol-3’,4’-
bisphosphate) 
DOPI(4,5)P2 1,2-dioleoyl-sn-glycero-3-phospho-(1’-myo-inositol-4’,5’-
bisphosphate) 
DTT dithioreitol 
FBP fructose 1,6-bisphosphate 
G6P glucose-6-phosphate 
I(1,3,4,5)P4 or IP4 D-myo-inositol-1,3,4,5-tetraphosphate 
I(1,4,5)P3 or IP3 D-myo-inositol-1,4,5-triphosphate 
IMPase inositol monophosphatase 
IP inositol phosphate 
IPTG isopropyl-β-D-thiogalactopyranoside 
L-3,5-dd-diC8PI L-3,5-dideoxy-dioctanoyl-phosphatidylinositol 
L-I-1-P L-myo-inositol 1-phosphate 
LUV large unilamellar vesicle 
MTSL S-(2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl 
methanesulfonothioate 
NBP N-terminal PI(4,5)P2 binding patch 
NMR nuclear magnetic resonance 
PA phosphatidic acid 
PAGE polyacrylamide gel electrophoresis 
 vi 
 
PCR polymerase chain reaction 
PDZ post synaptic density protein, drosophila disc large tumor 
suppressor, and zonula occludens-1 protein 
PH pleckstrin homology 
PI phosphatidylinositol 
PI(3)P phosphatidylinositol 3-phosphate 
PI(3,4)P2 phosphatidylinositol 3,4-bisphosphate 
PI(3,4,5)P3 phosphatidylinositol 3,4,5-triphosphate 
PI(3,5)P2 phosphatidylinositol 3,5-bisphosphate 
PI(4,5)P2 phosphatidylinositol 4,5-bisphosphate 
PI3K phosphatidylinositol 3-phosphate kinase 
PLC phospholipase C 
POPC 1-palmitoyl-2-oleoyl-sn-glycero-phosphocholine 
PS phosphatidylserine 
PTEN phosphatase and tensin homolog deleted on chromosome ten 
Pyrene-PE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(1-
pyrenesulfonyl) 
SDS sodium dodecyl sulfate 
SUV small unilamellar vesicle 
TX-100 triton X-100 
WT wild type 
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Chapter 1  
 
Introduction 
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1.1 Inositol and inositol metabolism 
Inositol is the name of a group of cyclohexane hexols with nine possible stereoisomers. 
One of them, D-myo-inositol (Ins), or cis-1,2,3,5-tran-4,6-cyclohexanehexol, is 
extensively used in biology (Michell, 2008). Perhaps the best known function of myo-
inositol is that it is the building block of a series of second messengers, inositol 
phosphates and inositol-containing phospholipids (Downes & Macphee, 1990). 
Nowadays, about half of the 63 possible myo-inositol phosphomonoesters, or inositol 
polyphosphates (IPs), have been identified in eukaryotic cells (Agranoff, 2009).  
 
Figure 1.1 Structures of inositol and inositol phosphates (Irvine & Schell, 2001) 
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In order to prevent confusion in nomenclature, the ‘turtle’ analogy was introduced. The 
carbon with the axial hydroxyl group in the Haworth projection of D-myo-inositol is the 2 
position, the turtle head. The numbering in D convention proceeds anticlockwise with the 
equatorial hydroxyl linked to the D1 carbon as the turtle’s front right flipper (Agranoff, 
1978) (Figure 1.1). The simplest form of inositol-containing phospholipid in eukaryotes 
is phosphatidylinositol (PtdIns or PI) in which the phosphatidic acyl portion part is 
esterified to the hydroxyl group of inositol D1. The hydroxyl groups at D3, D4 and D5 
carbon of PI can be phosphorylated to generate a total of 7 phosphorylated PIs, termed 
phosphoinositides (PIPs) (Figure 1.2).  
The distribution of inositol and inositol-containing compounds among the three kingdoms 
of life, the eukarya, bacteria, and archaea, is quite different (Michell, 2011). Inositol, 
inositol polyphosphate and phosphoinositides are found in nearly all eukaryotes. Archaea 
also have inositols and use inositol-containing lipids for their cell membrane. However 
the structural features of the lipids differ from what is used in eukaryotes (see discussion 
below). Archaea also synthesize some unusual water soluble inositol-containing 
molecules, such as di-myo-inositol-1,1’-phosphate (DIP), that have distinctive functions 
(see discussion below). Inositol and inositol derivatives are seldom found in bacteria and 
appear restricted to only a few classes. PI is found in some mycobacteria where it is 
extensively modified and used in cell walls (Morita et al, 2011). Previously it was 
thought that phosphoinositides were only found in eukaryotes. Very recently it was 
reported that PI(3)P is synthesized in mycobacteria (Morita et al, 2010). 
 4 
 
 
Figure 1.2 Structures of phosphoinositides 
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Myo-inositol can be transported into cells from the environment, or synthesized de novo 
from D-glucose-6-phosphate (G6P). G6P is first cyclized to form D-myo-inositol-3-
phosphate (Ins3P or I3P), which is the same as L-inositol-1-phosphate, (L-I-1-P) by 
NAD+-dependent D-myo-inositol-3-phosphate synthase (MIPS). D-Ins3P is then 
dephosphorylated by inositol monophosphatase (IMPase) to myo-inositol (Michell, 2008) 
(Figure 1.3). The incorporation of inositol in phospholipids is catalyzed by 
phosphatidylinositol synthase, which condenses myo-inositol with CDP-diacylglycerol to 
produce PI (Antonsson, 1997). PI and seven phosphoinositides – phosphatidylinositol 
monophosphates (PI(3)P, PI(4)P, PI(5)P), phosphatidylinositol bisphosphates (PI(3,4)P2, 
PI(3,5)P2, PI(4,5)P2) and phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) can be 
interconverted by a series of kinase and phosphatase catalyzed reactions (Sasaki et al, 
2009) (Figure 1.3).  
The biosynthesis of inositol polyphosphates in eukaryotes is not very straight-forward. It 
appears that the center of inositol polyphosphate metabolism is myo-inositol-1,4,5-
triphosphate (I(1,4,5)P3 or IP3), the degradation product of PI(4,5)P2. I(1,4,5)P3 can be 
further phosphorylated or dephosphorylated to produce other water soluble inositol 
phosphates (Hatch & York, 2010; Irvine & Schell, 2001). An additional one or two 
phosphates can be attached to the phosphate group of inositol hexakisphosphate (IP6 or 
phytic acid), to form another group of water soluble inositol-containing compounds, the 
diphosphoryl-inositol phosphates or inositol pyrophosphates (PP-IPs) (Bennett et al, 2006; 
Chakraborty et al, 2011) (Figure 1.3). 
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Figure 1.3 Inositol and inositol containing molecules metabolism (Michelle, 2008) 
1.2 Function of inositol phosphates in eukaryotes 
Inositol phosphates have many functions in eukaryotic cells. The best characterized 
function of IPs is the use of I(1,4,5)P3 as a second messenger in calcium signaling 
(Berridge, 2009; Berridge et al, 2000; Streb et al, 1983). Membrane imbedded PI(4,5)P2 
is hydrolyzed by phospholipase C (PLC) to produce I(1,4,5)P3 and diacylglycerol (DAG). 
While DAG, still in the membrane, serves as a lipid second messenger, water soluble IP3 
can diffuse through the cytosol and bind to the IP3 receptor in the endoplasmic reticulum 
(ER) and other places where calcium is stored internally to stimulate the calcium release. 
In this signaling, IP3 works as the second messenger to pass the information from the cell 
membrane to intracellular organelles. This IP3/calcium signaling is involved in diverse 
cellular processes such as contraction, fertilization, proliferation and metabolism 
(Berridge, 2009).  
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Besides the involvement in the calcium signaling pathway, inositol phosphates have other 
functions in cells (Hatch & York, 2010). IP6 and IP5 kinase (IPK1), which accounts for 
IP6 production, and various protein factors mediate mRNA export and translation 
(Alcazar-Roman et al, 2006; Bolger et al, 2008; Tsui & York, 2010; York et al, 1999). 
IP6 and other inositol polyphosphates also regulate gene expression at different levels 
(Alcazar-Roman & Wente, 2008). IPs and PP-IPs also have roles in immune cell 
development, ion channel permeability, protein phosphorylation and other cellular 
processes (Barker et al, 2009; Burton et al, 2009; Mitchell et al, 2008; Sauer & Cooke, 
2010).  
1.3 Function of phosphoinositides in eukaryotes 
Unlike water soluble inositol phosphates, PI and PIPs only exist in membrane systems in 
eukaryotic cells. PI is generally thought to constitute less than 15% of the total 
phospholipids and the content of PIPs is even an order of magnitude lower than PI (Di 
Paolo & De Camilli, 2006). The spatial distribution of PIPs is heterogeneous throughout 
the cell, and each PIPs undergone rapid turnover (Di Paolo & De Camilli, 2006). All 
seven PIPs are found in mammalian cells, while PI(3,4,5)P3 is not found in plants and 
yeast lacks both PI(3,4)P2 and PI(3,4,5)P3 (Liu & Bankaitis, 2010). 
Although PI and PIPs are minor components of membrane phospholipids, 
phosphoinositides play major roles in cells by serving as the specific anchors for proteins 
through protein-phosphoinositide headgroup interactions (Kutateladze, 2010; Lemmon, 
2008). Phosphorylated inositol head groups are recognized by different protein domains 
(Table 1.1). By binding to PIPs these proteins are recruited to the membrane interface. 
There the proteins can catalyze the interconversion of the PIPs, or interact with other 
 8 
 
proteins to regulate different cellular functions ranging from cell signaling, membrane 
trafficking, cytoskeleton dynamics, nuclear events, ion channel and transporter functions 
(Bunney & Katan, 2010; Di Paolo & De Camilli, 2006; Gamper & Shapiro, 2007; 
Martelli et al, 2011; Mayinger, 2012). 
Table 1.1 Protein domains that bind different PIPs specifically (Kutateladze, 2010; 
Lemmon, 2008) 
PIPs Protein domains 
PI(3)P FYVE, PH, PX 
PI(4)P GOLPH3, PH, PTB, PX 
PI(5)P  
PI(4,5)P2 ANTH, ENTH, C2, FERM, PDZ, PH, PTB, PX, Tubby 
PI(3,4)P2 PH, PX 
PI(3,5)P2 PH, PROPPINs 
PI(3,4,5)P3 C2, PH, PX 
1.3.1 Phosphatidylinositol monophosphates: PI(3)P, PI(4)P and PI(5)P 
PI(3)P can be generated by phosphorylation of PI by class II and class III 
phosphoinositide 3-kinase (PI3K). It can also be produced by dephosphorylation of 
PI(3,4)P2 by PI 4-phosphatase and of PI(3,5)P2 by PI 5-phosphatase. It can also be 
dephosphorylated to PI by myotubularins (Sasaki et al, 2009). PI(3)P is found  mostly in 
endosomes. It is generally thought that this molecule mostly exists in resting cells as a 
constitutive pool to regulate endosome dynamics (Di Paolo & De Camilli, 2006) and is 
critical for sorting endosomes (Clague et al, 2009). This molecule can be recognized by 
and bound to FVYE (Fab1, YOTB, Vac1 and EEA1) domain containing proteins, 
including the components of endosome sorting machinery (Clague et al, 2009; 
Kutateladze, 2006). Recent reports have revealed PI(3)P is a new dynamic second 
messenger (Falasca & Maffucci, 2009). The stimulated pool of PI(3)P, which is 
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generated by the cellular stimulation, is involved in glucose transport, cell migration and 
other processes (Falasca & Maffucci, 2009). 
PI(4)P is one of the most abundant phosphoinositides in cells (Lemmon, 2008). It can be 
produced from phosphorylation of PI by PI 4-kinase, or dephosphorylation of PI(4,5)P2 
by PI 5-phosphatase. It can also be dephosphorylated by PI 4-phosphatase or Sac family 
phosphatase Sac1 (Sasaki et al, 2009). PI(4)P is found in Golgi as well as plasma 
membranes (Bunney & Katan, 2010). Initially it was thought that PI(4)P function is to 
serve as the precursor pool for PI(4,5)P2, but more and more studies show this molecule 
itself has many functions (D'Angelo et al, 2008). With the detection of many protein 
effectors of PI(4)P, this molecule is important for Golgi complex morphology and 
function, and it can regulate membrane trafficking, control protein and lipid flux toward 
the cell surface and contribute to lipid metabolism (D'Angelo et al, 2008). 
PI(5)P is perhaps the least characterized phosphoinositide. PI(5)P is generated in vitro 
from direct phosphorylation of PI at D5 by two kinases PIP5K (PI(4)P 5-kinase) and 
PIKfyve. The ability of these kinases to generate PI(5)P from PI in vivo is still uncertain 
(Grainger et al, 2012). Instead, PI(5)P can be generated from dephosphorylation of 
PI(4,5)P2 by PI(4,5)P2 4-phosphatase and of PI(3,5)P2 by myotubularins. PI(5)P is found 
constitutively in several cell types and the majority of PI(5)P exists in the plasma 
membrane as well as intracellular membrane compartments such as the ER and Golgi 
(Sarkes & Rameh, 2010). Nuclei also have a PI(5)P pool, and this pool is responsive to 
the cellular stress (Jones et al, 2006). Although few protein effectors of PI(5)P have been 
identified, studies showed this molecule plays roles in nuclear protein function regulation, 
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gene expression, glucose metabolism, and also possibly in membrane trafficking 
(Grainger et al, 2012). 
1.3.2 Phosphatidylinositol bisphosphates: PI(3,5)P2, PI(4,5)P2 and PI(3,4)P2  
PI(4,5)P2 is also one of the most abundant phosphoinositides in cells (Lemmon, 2008). It 
is generated by phosphorylation of PI(4)P and PI(5)P by phosphatidylinositol phosphate 
kinases (PIPKs). It can be dephosphorylated to PI(4)P by PI 5-phosphatase and to PI(5)P 
by PI 4-phosphatase (Sasaki et al, 2009). As addressed before, PI(4,5)P2 can be degraded 
to IP3 and DAG by PLC enzymes. PI(4,5)P2 is mostly found at the plasma membrane and 
participates in nearly all cellular processes involving the cell surface (Di Paolo & De 
Camilli, 2006). First, it is considered as an intermediate of second messenger generation 
that propagates and amplifies the signaling (Di Paolo & De Camilli, 2006). PI(4,5)P2 is 
cleaved by PLC upon stimulation to generate IP3 and DAG. IP3 is responsible for calcium 
signaling, and DAG can activate protein kinase C (PKC), which accounts for much 
cellular signaling by phosphorylating diverse proteins (Nishizuka, 1988). In parallel, 
PI(4,5)P2 can be phosphorylated at D3 to produce PI(3,4,5)P3, which generates a key 
component of another important signaling pathway (PI3K signaling pathway, see 
discussion below). Besides being a precursor, PI(4,5)P2 itself also mediates plasma 
membrane-cytoskeleton interactions with PI(3,4,5)P3 and small GTPases, to control cell 
shape, motility and other processes (Di Paolo & De Camilli, 2006). It is directly involved 
in exocytosis and all forms of endocytosis. Some of the proteins required for these 
processes have the ability to bind PI(4,5)P2 (Mayinger, 2012). The PI(4,5)P2 signal can 
be turned off through dephosphorylation of  PI(4,5)P2 by PI 5-phosphatase, and this 
process is important for a functional endocytic pathway (Mayinger, 2012).  
 11 
 
PI(3,5)P2 is generated by phosphorylation of PI(3)P by type III phosphatidylinositol 
phosphate kinase (PIPKIII) initially known as PIKfyve in mammals (Sasaki et al, 2009). 
It can be dephosphorylated to PI(3)P by type IV 5-phosphatase and sac family Sac3. It 
can also be dephosphorylated to PI(5)P by myotubularins (Sasaki et al, 2009). In higher 
eukaryotes, PI(3,5)P2 exists in endolysosomes, and it is important for endolysosomes 
functions, including  endolysosome morphology, acidification and trafficking (Ho et al, 
2012). It also regulates membrane transport, autophagy, and other cellular processes, 
although the identities of some of the protein effectors involved in these processes are not 
very clear (Ho et al, 2012). 
PI(3,4)P2 can be generated from PI(4)P phosphorylation by class II PI3K, although this 
class of enzyme mainly accounts for generation  of PI(3)P from PI. Dephosphorylation of 
PI(3,4)P2 is accomplished by type II 4-phosphatase (INPP4) to produce PI(3)P (Sasaki et 
al, 2009).  PI(3,4)P2 appears to be  part of the PI 3-kinase signaling pathway, and the 
specific signaling role of PI(3,4)P2 remains unassigned (Leslie et al, 2008). Akt, a 
component of PI3K signaling pathway, binds to PI(3,4)P2 by its pleckstrin homology (PH) 
domain (Franke et al, 1997). PI(3,4)P2 also plays a distinct role in Akt phosphorylation 
and activity (Ma et al, 2008). There are also some proteins that contain PH domains that 
specifically bind to PI(3,4)P2. Examples are TAPP (tandem pleckstrin-homology domain-
containing protein) (Dowler et al, 2000) and lamellipodin (Krause et al, 2004). The two 
phosphatases that dephosphorylate PI(3,4)P2 also have some functional significance. 
INPP4A suppresses excitotoxic cell death in neurons (Sasaki et al, 2010) and INPP4B is 
proposed as a potential tumor suppressor (Agoulnik et al, 2011). These observations 
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imply that PI(3,4)P2 may have distinct roles in cellular function besides acting in PI3K 
signaling. 
1.3.3 PI(3,4,5)P3 and the PI 3-kinase (PI3K) signaling pathway 
Before identification of PI(3,4,5)P3, PI 3-kinase (PI3K) was first found to be associated 
with oncogene products and platelet-derived growth factor (PDGF) receptors. It was  
later identified as a kinase that phosphorylates phosphoinositides at the D3 position of the 
inositol ring to generate PI(3)P from PI (Whitman et al, 1988).  The same year, 
PI(3,4,5)P3 was identified as a novel phosphoinositide in activated neutrophiles 
(Traynorkaplan et al, 1988). In 1989, PI(3,4,5)P3 was reported to be generated from 
PI(4,5)P2 by PI3K in anti-phosphotyrosine immunoprecipitants of PDGF stimulated 
vascular smooth muscle cells. This novel phosphoinositide was proposed as the signaling 
molecule that propagates PDGF signal into the cells (Auger et al, 1989). Today, 
numerous studies on PIP3 and the PI3K signaling pathway demonstrate this signaling 
regulates many cellular processes including cell growth, proliferation, migration, 
differentiation, survival, chemotaxis, and metabolism (Di Paolo & De Camilli, 2006) 
(Figure 1.4). 
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Figure 1.4 PI3K/ Akt signaling pathway 
The level of PI(3,4,5)P3 in resting cells is negligible, but it can be increased dramatically 
and transiently due to the activation of PI3K by growth factor stimulation (Di Paolo & De 
Camilli, 2006). There are three classes of PI 3-kinase, with Class I PI3K phosphorylating 
PI(4,5)P2 to PI(3,4,5)P3 preferentially (Hawkins et al, 2006). Once ligands, such as 
growth factors, bind to the cell surface receptors, for example receptor tyrosine kinase 
(RTK) or G-protein coupled receptor (GPCR), PI3K is recruited to the inner leaflet of 
plasma membrane and activated by binding to phosphorylated tyrosine on RTK or Gβγ 
subunits of GPCR downstream G proteins. PI3K can also be recruited to the membrane 
by activated GTPase, Ras family members (Hawkins et al, 2006; Vanhaesebroeck et al, 
2010; Vanhaesebroeck et al, 2012). Upon translocation to the membrane and activation, 
PI3K phosphorylates PI(4,5)P2 to generate PI(3,4,5)P3. PIP3 mediates downstream 
signaling by binding to proteins containing domains that bind PIP3 specifically. One of 
the key downstream effectors of PI(3,4,5)P3 is Akt (also known as protein kinase B or 
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PKB) (Bunney & Katan, 2010; Hers et al, 2011). This protein contains a pleckstrin 
homology (PH) domain, a common domain found in most PIP3 binding proteins. Upon 
binding to PIP3, Akt is recruited to the plasma membrane where it undergoes a 
conformational change. After phosphorylation on Thr308 by co-recruited PDK1 (3-
phosphoinositide-dependent protein kinase 1) and on Ser473 by mTORC2 (mammalian 
target of rapamycin complex 2), Akt is activated and dissociates from the plasma 
membrane into the cytosol as well as traffics to the nucleus. In those locations, Akt 
phosphorylates its substrates, including but not limited to FOXO (forkhead box O), 
GSK3 (glycogen synthase kinase 3), Bad (B cell lymphoma 2 (BCL-2) antagonist of cell 
death), and the E3 ubiquitin-protein ligase MDM2. These phosphorylations affect 
downstream signaling molecules, leading to the regulation of many cellular process such 
as proliferation, cell survival, metabolism and angiogenesis (Hers et al, 2011; Manning & 
Cantley, 2007). 
PI(3,4,5)P3 can be dephosphorylated by PI 3-phosphatase or PI 5-phosphatase, but these 
two dephosphorylation steps lead to different fates. PTEN (phosphatase and tensin 
homolog deleted on chromosome ten) dephosphorylates PI(3,4,5)P3 at the D3 position 
and turns off the signal (see discussion below), while SHIP1 and SHIP2 (SH2 domain-
containing inositol 5-phosphatase 1 and 2) dephosphorylate PIP3 to generate PI(3,4)P2, 
another second messenger that can regulate cell signaling and lengthen the duration of 
PIP3 signaling (Bunney & Katan, 2010; Di Paolo & De Camilli, 2006). 
Dysregulation of the PI3K /Akt signaling pathway is linked to many diseases, including 
cancer, metabolic dysfunction, cardiovascular diseases and mental diseases (Franke, 
2008). Due to its importance, PI3K is now considered as a drug target for disease 
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treatment. Many PI3K inhibitors have been generated and some of them are already in 
clinic trials with promising results (Vanhaesebroeck et al, 2012). 
1.4 PTEN 
Back in 1997, two groups reported the identification of a gene located on chromosome 
10q23, the mutation of which was found in most advanced cancers. This gene was 
proposed as a tumor suppressor and one of the groups named it as Phosphatase and 
Tensin homolog deleted on chromosome Ten, PTEN, due to the presence of a protein 
tyrosine phosphatase (PTP) signature motif and protein sequence homology to tensin 
(Myers et al, 1997; Steck et al, 1997). From then on, numerous studies on the role of this 
gene and its encoded protein, PTEN, revealed the importance of this protein as the 
gatekeeper of the PI 3-kinase signaling pathway. In cells where PTEN function is lost, 
excessive PI(3,4,5)P3 recruits and activates Akt and other downstream signaling 
molecules at higher levels, leading to abnormal cell growth and proliferation which in 
turn causes many diseases (Song et al, 2012). 
The deletion, insertion and/or mutation of the PTEN gene are often found in a wide 
variety of tumor cells including endometrial cancer, glioblastoma, prostate cancer, breast 
cancer and lung tumor (Salmena et al, 2008).  Germline mutations of the PTEN gene are 
also present in patients having PTEN hamartoma toumor syndromes (PHTs), including 
Bannayan–Riley–Ruvalcaba syndrome (BRRS), Cowden syndrome, Proteus syndrome 
(PS), and Proteus-like syndrome (PSL), with which patients may have developmental 
disorders, neurological deficits, and have an increased risk of developing breast and other 
cancers (Salmena et al, 2008; Song et al, 2012). Studies also found that overexpression of 
PTEN in tumor cells which have lost PTEN expression suppresses cell growth and 
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tumorigenicity (Leslie & Downes, 2004). Besides serving as a tumor suppressor, PTEN 
has many roles in other cellular processes, such as cell metabolism, cell polarity, stem 
cell self-renewing activity and neuronal injury (Chang et al, 2007; Song et al, 2012). 
Most of the functions of PTEN are linked to its ability to dephosphorylate 
phosphoinositides. Since PTEN has such clinical significance, there has been intense 
study of this enzyme in many laboratories; the function and regulation of PTEN has also 
been highly reviewed (Gericke et al, 2006; Leslie et al, 2008; Leslie & Downes, 2004; 
Maehama et al, 2001; Shi et al, 2012; Song et al, 2012). 
1.4.1 Substrate specificity 
PTEN was first identified as a dual-specificity phosphatase (it can dephosphorylate 
phosphotyrosine and phosphoserine or phosphothreonine) based on the observation that it 
contained the signature motif of the protein tyrosine phosphatase (PTP) superfamily of 
enzymes (Li et al, 1997; Myers et al, 1997). Initial enzymatic activity studies of 
recombinant PTEN showed it could dephosphorylate proteins and peptides commonly 
used as PTP substrates, but the activity toward these phosphorylated Ser/Thr/Tyr 
substrates was very low. PTEN also had a strong preference for extremely acidic peptide 
substrates (Myers et al, 1997). Later on, PTEN was found to dephosphorylate the D3 
position of the inositol ring of PIPs, with highest activity observed toward PI(3,4,5)P3 and 
lower activity toward PI(3,4)P2 and PI(3)P in vitro. PTEN could also dephosphorylate 
I(1,3,4,5)P4, the water soluble head group of PI(3,4,5)P3, at the D3 position of the inositol 
ring (Maehama & Dixon, 1998). However the activity toward lipid substrates was 
significantly higher than that toward water soluble inositol polyphosphates (Myers et al, 
1998). PTEN’s function as a lipid PIP3 phosphatase to suppress PI3K/Akt signaling in 
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vivo was also demonstrated (Myers et al, 1998; Stambolic et al, 1998). As summarized in 
Table 1.2 (Maehama et al, 2001), the specific activity of PTEN toward PI(3,4,5)P3 is 50-
1500 fold higher than other substrates, suggesting this lipid is the physiological substrate 
of PTEN. Our group also reported the apparent Km and Vmax value of PTEN toward short 
chain diC8PI(3)P were 0.2±0.07 mM and 14±1 nmol/mg/min, consistent with the results 
of other groups (Wang et al, 2008). 
Table 1.2 PTEN phosphatase activity toward different substrates (adapted from 
Meahama, et al. 2001, N.D. not determined). Unless indicated the PIPx were 
obtained from natural sources so they have unsaturated acyl chains. 
Substrate Km (μM) Specific activity (min-1) 
pNPP (p-nitrophenyl phosphate) 25600 0.77 
I(1,3,4)P3 N.D. 0.078 
I(1,3,4,5)P4 98.9 0.30 
PI(3)P N.D. 2.0 
PI(3,4)P2 N.D. 2.6 
PI(3,4,5)P3 <50 120 
1.4.2 PTEN structure 
The PTEN gene encodes a 403-amino-acid long protein that belongs to the dual-
specificity protein phosphatase and PI 3-phosphatase family (EC 3.1.3.16, 3.1.3.48, 
3.1.3.67). The crystal structure of PTEN was solved in 1999 by cocrystallization of 
tartrate with a truncated form of protein (Lee et al, 1999). The structure is composed of 
the N-terminal catalytic phosphatase domain and a C-terminal lipid-binding C2 domain 
(Figure 1.5). The phosphatase domain has a five-stranded β sheet in the center with two 
and four α helices packed on each side. Its structure is similar to dual-specificity 
phosphatase VHR (vaccinia H1-related phosphatase, also known as DUSP3, the dual 
specificity protein phosphatase 3) with several residues inserted in some loops. One of 
the insertions is an 11-residue insertion in the pβ2-α1 loop from residue 42 to 52. The 
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phosphatase domain of PTEN contains the PTP signature motif HCXXGXXR (residues 
123-130), which comprises the “P loop” located at the bottom of the active site pocket. 
Cys124 in this P loop acts as the nucleophile to attack D3 phosphate. The “WPD” loop 
(residues 91-94) and the “TI” loop (pα5-α6) form the wall of the active site (Figure 1.6). 
Due to a 4-residue insertion in the “TI” loop, the active site pocket of PTEN is wider 
when compared to that of VHR and PTP1B (protein tyrosine phosphatase 1B) and deeper 
than VHR. The larger width of the active site pocket can accommodate the larger size of 
the phosphorylated inositol ring of the substrate, PI(3,4,5)P3. The positive charges on two 
unique residues, Lys125 and Lys128, in the signature motif are consistent with 
interacting with the negative charges of the PI(3,4,5)P3 substrate. A tartrate molecule was 
found bound in the active site pocket (Figure 1.6). I(1,3,4,5)P4, the head group of 
physiological substrate PI(3,4,5)P3, can be superimposed on the tartrate. In this in silico 
complex, the substrate D3 phosphate was superimposed on one carboxylate group of 
tartrate, forming hydrogen bonds with Cys124 and Arg130 on the P loop. The D4 
phosphate was superimposed on the other carboxylate group, forming hydrogen bonds 
with residues in both the WPD and TI loops. The phosphate at the D5 position of IP4 in 
this superposition structure resides next to Lys128 and His93. The interaction between 
the D5 phosphate and those two basic residues was demonstrated by mutation. The 
proteins K128M and H93A had reduced activity toward PI(3,4,5)P3 but comparable 
activity toward PI(3,4)P2 and PI(3)P (Lee et al, 1999). 
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Figure 1.5 Ribbon diagram showing the crystal structure of PTEN. The phosphatase 
domain is colored in cyan, C2 domain in red, and P loop is colored in yellow. (PDB 
1D5R) 
 
Figure 1.6 Structure of the PTEN active site. A tartrate molecule is colored in yellow 
with oxygen atoms in red. The hydrogen bonds formed by tartrate with protein 
active site are shown as dashed lines (Lee et al, 1999) 
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The structure of the C-terminal domain adopts a type II C2 fold topology, a β sandwich 
consisting of two antiparallel β sheets with two α helices intervening between. This 
domain is similar to the C2 domains of PKCδ, PLCδ1, and cPLA2 (cytosolic 
phospholipase A2). Unlike the PLCδ1 and cPLA2 C2 domains, the PTEN C2 domain 
does not bind Ca2+ and so is Ca2+ independent. It has only one of the three loops (termed 
the CBR3 loop) that are needed for calcium binding. The PTEN C2 domain has been 
shown to bind to phospholipid vesicles in vitro (Lee et al, 1999). There are two basic 
patches on the CBR3 and the adjacent Cα2 helix of C2 domain, proposed as the 
important membrane-binding elements of PTEN. Mutation at these two basic patches 
made the protein lose its tumor suppressor function (Lee et al, 1999). 
 
Figure 1.7 Representation of PTEN sequence showing key residues. Phosphatase 
and C2 domains are indicated as boxes. The sequence of the N-terminal cationic 
binding patch (NBP) is shown with the conserved residues in bold. Two cysteines in 
the phosphatase domain that can be oxidized are also shown. The C-terminal tail 
contains multiple phosphorylation sites; the last three residues are assigned as a 
PDZ binding domain. 
Along with these two globular domains, the PTEN protein has an N-terminal loop 
containing a PI(4,5)P2 binding consensus sequence (N-terminal PI(4,5)P2 binding patch 
or NBP) (Maehama et al, 2001), a 50-amino acid C-terminal tail containing Ser and Thr 
residues that could be phosphorylated, and a PSD-95/Dlg/ZO-1 homology (PDZ) binding 
domain at the C-terminal end (Figure 1.7). All these elements are not included in the 
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protein crystal structure, but are shown to play important roles in PTEN function (see 
discussion below). 
1.4.3  PTEN membrane binding and the role of the N-terminal loop 
Most PTEN molecules are found in cytosol. However, the substrate of PTEN, PI(3,4,5)P3, 
resides in the inner leaflet of plasma membrane. In order to catalyze dephosphorylation of 
the substrate, PTEN has to bind to the membrane. This membrane binding event is 
critical for PTEN function. Initial studies showed that both PTEN full length protein and 
GST-fused C2 domain alone had some affinity for phosphatidylcholine (PC) 
multilamellar vesicles. Mutations in the CBR3 and Cα2 regions to remove most of 
positive charges as well as hydrophobic residues reduced the binding affinity for vesicles 
and reduced the growth suppression effect in U87-MG glioblastoma cells (Lee et al, 
1999). These results indicated the importance of the C2 domain in mediating PTEN 
membrane binding. Later, binding of PTEN to immobilized vesicles was explored by 
surface plasma resonance analysis, and the results showed that both phosphatase and C2 
domains are important for lipid binding (Das et al, 2003). PTEN full length protein and 
C2 domain had low affinity for neutral PC vesicles, but the lipid binding affinity was 
increased by incorporating anionic lipids such as phosphatidylserine (PS) into the 
vesicles. For phosphatase domain contribution to vesicle binding, surface Lys and Arg 
clusters (R11/K13/R14/R15 and R161/K163/K164) provide nonspecific electrostatic 
interactions with the negatively charged lipids. Deletion of this domain increased the 
vesicle dissociation constant (Kd). A kinetic study of PTEN with unilamellar vesicles 
revealed that PTEN is an interfacial enzyme whose activity is dependent on both the mole 
fraction of the substrate in the vesicles and the bulk concentration of the lipid vesicles 
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(McConnachie et al, 2003). A single molecule study of PTEN binding to membranes in 
live cells showed that the binding is highly dynamic with a dwell time less than 400 ms 
but long enough for PIP3 dephosphorylation (Vazquez et al, 2006). 
Incorporation of the anionic lipid PI(4,5)P2, the dephosphorylation product of PI(3,4,5)P3, 
into the lipid vesicles, enhanced protein activity (McConnachie et al, 2003). When the 
substrate PI(3,4,5)P3 was in PIP3/PC vesicles (starting from a mole fraction of 0.0001 
with a bulk concentration  10μM), adding 100-fold greater PI(4,5)P2 (mole fraction 0.01 
in the vesicles) enhanced protein activity 5-fold, while incorporation of 0.05 mole 
fraction PS enhanced activity only slightly. In contrast, with PI(4,5)P2 present, PTEN 
activity toward water soluble I(1,3,4,5)P4 substrates was inhibited. So the mechanism for 
how PI(4,5)P2 enhanced protein activity was suggested as interfacial activation. The 
excess of anionic lipids in the vesicles enhanced protein proximity to substrates and thus 
activated the protein (McConnachie et al, 2003).  
The PI(4,5)P2 activation of PTEN was also reported in a phospholipid monomer system 
(Campbell et al, 2003). Dioctanoyl-PI(3,4,5)P3 (diC8PI(3,4,5)P3) was used as the 
substrate at the concentration of 45 μM, below the critical micelle concentration (CMC) 
of diC8PI (stated as 60μM, but it depends critically on the ionic strength and is usually 
about 5- to 10-fold higher). Adding half (22.5 μM) or equal (45 μM) amounts of 
diC8PI(4,5)P2 compared to substrate enhanced protein activity. This kinetic activation 
was more obvious when using PI(3,4)P2 as the substrate. The results suggested a positive 
feedback of dephosphorylation of PIP3 since PI(4,5)P2 is the dephosphorylation product. 
PI(5)P also promoted PIP3 dephosphorylation, while PI(4)P did not. DiC4PI(4,5)P2 could 
not activate PTEN. The PI(4,5)P2 activation effect also occurred when all the substrates 
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and activator molecules were monomers (at least in the absence of protein), suggesting 
that a membrane interface is not a necessary factor for activation. The PTEN N-terminus 
has a PI(4,5)P2 binding consensus sequence K/R-X-X-X-X-K/R-X-K/R-K/R. Mutation 
studies at this binding motif showed that K13A and R14A exhibited much less activity in 
the presence and absence of PI(4,5)P2. The authors then proposed that PTEN binds to 
PI(4,5)P2 specifically with this N-terminal motif and a critical conformational change is 
induced that enhances catalytic activity. 
The study looking at tumor-derived point mutations in this potential N-terminal PIP2 
binding patch (NBP), and notably K13E, led to a somewhat different conclusion (Walker 
et al, 2004). In vitro studies with this mutant PTEN showed it had similar activity toward 
PI(3,4,5)P3 and I(1,3,4,5)P4, but PTEN K13E lost activation by PI(4,5)P2 and PS. 
Furthermore, PI(4,5)P2 could not inhibit PTEN-K13E activity toward I(1,3,4,5)P4, while 
this molecule could inhibit wild type PTEN activity toward IP4. Due to the different 
effects of PI(4,5)P2 on PTEN activity toward PIP3 and IP4, and the reversed behavior of 
PTEN-K13E, the authors argued that the role of PI(4,5)P2 is to enhance protein 
recruitment on lipid vesicles and orient the protein active site for interaction with 
substrate, rather than to act as a purely allosteric activator. The role of this N-terminal 
loop in PTEN function would appear to be quite important. PTEN-K13E no longer 
suppresses Akt phosphorylation or prevents cell proliferation in pten-null U87MG cells. 
However, the physiological binding partner of this N-terminal loop is uncertain, since PS 
could also activate PTEN and it is more abundant than PI(4,5)P2 in the plasma membrane 
(Walker et al, 2004). 
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Another in vitro investigation of the N-terminal PI(4,5)P2 binding patch was done using 
florescence spectroscopy (Redfern et al, 2008). The fluorophore was incorporated into 
the PC vesicles containing anionic lipids (PI(4,5)P2 and/or PS). When PTEN binds to 
these vesicles, its intrinsic fluorescence (due to Trp residues) is quenched. This technique 
can be used to monitor vesicle binding. Incorporation of 5 mol% PI(4,5)P2 into PC 
vesicles enhanced protein binding by lowering the apparent Kd from near 600 μM to 163 
μM. Adding higher amount of PS (10 mol%) also enhanced binding 3-fold. PI(4,5)P2 and 
PS were found to work synergistically so that the highest affinity binding (the lowest Kd, 
42 μM) was observed when using vesicles contained both PIP2 and PS (5 mol% PI(4,5)P2 
/5 mol% PS / PC). The binding affinity was even higher than with 10 mol% PIP2 
containing vesicles. Deletion of the first 15 residues or a point mutation at Lys13 (K13E) 
weakened the binding to PIP2 containing vesicles. The peptide derived from PTEN 
residues 1-21 also showed preferential binding to vesicles with PIP2. These results 
suggest that binding of PIP2 with the N-terminal region is specific. Evidence for a protein 
conformational change was investigated using infrared spectroscopy (IR). The α-helix 
content of PTEN increased when it bound to PI(4,5)P2, while binding to PS increased 
protein β-sheet content slightly. These authors suggested that PTEN binding to PI(4,5)P2 
is specific and uses the N-terminal binding motif. They also argue that there is a 
conformational change in the phosphatase domain upon PI(4,5)P2 binding since this 
domain mostly consists of α-helices. However, in this study, validation of PTEN 
specifically binding to PI(4,5)P2 via the NBP was only demonstrated indirectly by the 
different behavior of mutated proteins. PTEN1-21 showed preferential binding to PI(4,5)P2 
but there is no way to demonstrate this peptide has the same behavior as full-length 
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protein. There was also no detailed information about any conformational change upon 
vesicle binding.  
Other studies looking at this potential N-terminal PIP2 binding patch (NBP) also showed 
the importance of this binding motif in PTEN function. A study of chemotaxis in 
Dictyostelium discoideum showed PTEN is important for this process of moving toward 
chemoattractants (Iijima & Devreotes, 2002; Iijima et al, 2004). Cells lacking PTEN 
activity lost polarity and directional sensing. In D. discoideum, PTEN is associated with 
the plasma membrane at the rear of the cell when the extracellular stimuli were detected, 
and this membrane association is important for cell chemotaxis. PTEN membrane 
binding is independent of its phosphatase activity, since the catalytically dead C124S and 
G129E both bound to membranes. However, deletion of first 15 residues of PTEN, 
containing the whole NBP, abrogated PTEN membrane binding and proper function, and 
this truncated version of PTEN had no activity toward PI(3,4,5)P3 but higher activity 
toward I(1,3,4,5)P4 (Iijima et al, 2004). This led to a model for PTEN regulation. In the 
cytosol, the N-terminal PIP2 binding motif masks the PTEN catalytic domain, but when 
the protein is bound to a membrane this constraint is relieved and protein regains catalytic 
function (Iijima et al, 2004). However, this chemotaxis study only demonstrated the 
importance of this binding motif in membrane association; it was not related to PI(4,5)P2 
activation. The importance of this PIP2 binding motif in PTEN membrane binding and 
proper function was also confirmed by using single-molecule total internal reflection 
fluorescence microscopy (TIRF) to study PTEN membrane binding dynamics in HEK293 
cells. Deletion of the first 10 residues, part of the NBP, eliminated PTEN binding to the 
plasma membrane and prevented it from rescuing function in pten- cells (Vazquez et al, 
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2006). However, again, PI(4,5)P2 was not involved. The first report of the necessity of 
PI(4,5)P2 at the plasma membrane for PTEN binding was in 2009 (Rahdar et al, 2009). 
The report showed that in HeLa cells, if the PI(4,5)P2 was depleted from the inner leaflet 
of the membrane, a dephosphorylated dead version of PTEN (PTENC124S, A4) fused to 
YFP (yellow fluorescent protein) (PTENC124S, A4-YFP) was re-localized to the cytosol, 
indicating the membrane binding site for PTEN disappeared. This result clearly 
demonstrated that PI(4,5)P2 is required for PTEN binding to membrane, but the work did 
not answer whether or not deletion or mutation at the NBP eliminated this particular 
version of PTEN association with the membrane, although combined with the other 
results discussed above this is highly probable. 
To date there is no definitive evidence that an individual PI(4,5)P2 molecule binds to the 
N-terminal binding motif of PTEN. There is more evidence supporting a PI(4,5)P2 
activation mechanism that is due to the PI(4,5)P2 binding to the NBP and inducing the 
conformational change, but the details of this mechanism are still missing. 
To complicate matters, phosphorylation of the C-terminal tail and interaction with PDZ 
domain-containing proteins also regulate PTEN membrane binding events (see discussion 
below). Taken together, PTEN uses all of its different domains and motifs to regulate its 
binding to membranes (Figure 1.8). 
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Figure 1.8 Regulation of PTEN binding to membranes. In the cytosol, 
phosphorylated PTEN is in a ‘closed’ conformation, and the N-terminal PI(4,5)P2 
binding patch masks the active site. After dephosphorylation, PTEN is in an ‘open’ 
conformation, and the NBP is released from the phosphatase domain. NBP interacts 
with PI(4,5)P2 to activate protein. PDZ binding domain (shown as grey box) also 
interacts with PDZ domain containing proteins on the membrane. PTEN binds to 
membranes and dephosphorylates PI(3,4,5)P3 (Iijima et al, 2004; Rahdar et al, 2009; 
Vazquez et al, 2000). 
1.4.4 PTEN C-tail, regulation by phosphorylation 
PTEN has a 53-amino-acid long unstructured flexible tail, from residue 351 to the C-
terminus, which was not included in the crystal structure. Several Ser and Thr residues on 
this C-tail have been reported to be phosphorylated. To date, up to 9 residues on the C-
tail, Ser361, Ser362, Thr363, Thr366, Ser370, Ser380, Thr382, Thr383 and Ser385 have 
been reported as phosphorylation sites (Cordier et al, 2012; Gericke et al, 2006; Leslie et 
al, 2008). The effect of phosphorylation of the C-tail on PTEN function was studied 
extensively, especially for the Ser380-Ser385 cluster. Dephosphorylation mimics, where 
alanine was substituted for the Ser residues in the Ser380-Ser385 cluster (PTENA4 or 
S380A/T382A/T383A/S385A), had higher phosphatase activity but decreased stability. 
Phosphorylation at these sites inhibited protein function and prevented PTEN binding to 
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protein complexes via its PDZ binding domain (Vazquez et al, 2001; Vazquez et al, 
2000). A two-conformation model was proposed whereby phosphorylation at the C-tail 
makes the protein adopt a ‘closed’ conformation in which its PDZ binding domain is 
masked, and dephosphorylation biases the protein to adopt a more active but less stable 
‘open’ conformation (Vazquez et al, 2001; Vazquez et al, 2000). Many studies support 
this closed/open model. For example, the phosphorylation mimic, substituting a 
glutamate at phosphorylation sites (PTEN S380E/T382E/T383E) lowers the protein 
affinity for PS containing vesicles (Das et al, 2003). PTENA4 was shown to have 
enhanced membrane association, and phosphorylation reduced protein membrane binding 
(Vazquez et al, 2006). The peptide containing part of C-tail (residues 368-390) with 
glutamate mutations mimicking the phosphorylation was able to inhibit the PTEN 
phosphatase activity toward PIP3 (Odriozola et al, 2007). A detailed study of this 
closed/open model provided more evidence (Rahdar et al, 2009). Truncated PTEN which 
had no C-tail (PTEN1-351) had higher membrane binding than full length protein, and co-
expression of PTEN C-tail (PTEN352-403) in U87 cells prevented PTEN1-351 binding to 
membranes, while co-expression of the C-tail containing dephosphorylation mimicking 
alanine mutations (PTEN352-403(A4)) did not. Coimmunoprecipitation of PTEN1-351 with 
PTEN352-403 happened regardless of whether PTEN 1-351 and PTEN352-403 were expressed 
together or separately in HEK293T cells; the ‘dephosphorylated’ C-tail (PTEN352-403(A4) 
or phosphatase treatment) did not coimmunoprecipitate with PTEN1-351. All these 
findings demonstrated phosphorylated PTEN C-tail has specific interactions with the 
other part of the protein, and this interaction was phosphorylation dependent. 
Interestingly, part of the NBP (residues 11-15), active site integrity and accessibility, a 
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positively charged cluster on the phosphatase domain (R161, K163, K164), and the 
CBR3 loop in the C2 domain were all important for the interaction with phosphorylated 
C-tail. This work strongly supported the closed/open model of PTEN, and provided an 
explanation for the fact that most PTEN was cytoplasmic although the protein is 
constitutively active (Ross & Gericke, 2009) (Figure 1.8).  
Several kinases are found to be responsible for PTEN phosphorylation. Casein kinase 2 
(CK2) phosphorylates the protein at Ser370, Ser380, Thr382, Thr383 and Ser385 (Miller 
et al, 2002; Torres & Pulido, 2001), and glycogen synthase kinase-3 β (GSK3β) accounts 
for Ser362 and Thr366 phosphorylation (Al-Khouri et al, 2005; Miller et al, 2002). A 
very recent study of PTEN phosphorylation was done using high-resolution NMR 
spectroscopy (Cordier et al, 2012). The results showed that the phosphorylation by CK2 
and GSK3β were relatively independent but each phosphorylation process proceeded in a 
defined order. Late phosphorylation of Ser361 and Thr363 by CK2 was first reported; 
this occurred after phosphorylation of Ser362 by GSK3β. 
Along with Ser380-Ser385 cluster, the role of phosphorylation on other sites has been 
studied, although some results are controversial (Song et al, 2012). For example, 
phosphorylation on Thr366 by GSK3β was reported to destabilize PTEN (Maccario et al, 
2007), while phosphorylation by Polo-like kinase 3 (Plk3) on the same residue increased 
PTEN stability (Xu et al, 2010). Aside from phosphorylation on the C-tail, some residues 
on the C2 domain were also reported as the phosphorylation sites, and their roles are 
under investigation (Shi et al, 2012; Song et al, 2012). 
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1.4.5 Regulation of PTEN by other post-translational modification 
PTEN can be oxidized and inactivated in vitro by H2O2. Upon oxidation, Cys124, the 
active site cysteine, forms a disulfide bond with Cys71, which is near the active site (the 
distance between the two Cys is 5.9 Å). This oxidation is reversible and PTEN can be 
reduced by thioredoxin (Lee et al, 2002). This fact suggested PTEN can be regulated by 
reactive oxygen species (ROS) in cells. Indeed, studies reported the inactivation of PTEN 
and regulation of the PI3K/Akt pathway by H2O2 and endogenous ROS in macrophages 
(Kwon et al, 2004; Leslie et al, 2003). Furthermore, the oxidation of PTEN can also be 
regulated. Peroxidase peroxiredoxin 1 (Prdx1) can protect PTEN from oxidation-induced 
inactivation by directly binding to PTEN (Cao et al, 2009), and thioredoxin-interacting 
protein (Txnip) keeps PTEN in a reduced form by maintaining the thioredoxin NADPH-
dependent disulfide reduction activity (Hui et al, 2008).  
PTEN can also be regulated by ubiquitylation. NEDD4 (neural precursor cell expressed, 
developmental downregulated-4), a E3 ligase, can polyubiquitylate PTEN to mediate its 
cellular level through proteasomal degradation (Wang et al, 2007). Besides NEDD4, two 
other E3 ligases were also proposed as mediators for PTEN polyubiquitylation (Maddika 
et al, 2011; Van Themsche et al, 2009). It has been suggested that the regulation of PTEN 
by polyubiqutylation occurs in a context-dependent manner to achieve specific functions 
(Shi et al, 2012). Interestingly, PTEN can be monoubiquitylated at Lys13 and Lys289, 
and this monoubiquitylation dictates the nuclear import of PTEN (Trotman et al, 2007). 
In the nucleus, PTEN plays important roles in controlling cell cycle progression, 
maintaining chromosomal stability and promoting tumor suppression (Shi et al, 2012; 
Song et al, 2012). 
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1.4.6 PDZ binding domain and regulation of PTEN by protein-protein interactions 
The last three residues of PTEN are assigned to a PDZ binding domain, or PDZ domain-
interaction motif, which could allow PTEN to interact with PDZ domain containing 
proteins (Figure 1.8). PTEN was shown to bind the MAGI-2 (membrane associated 
guanylate kinase inverted-2) PDZ domain 2 via its C-terminal PDZ binding domain (Wu 
et al, 2000). MAGI-2 exists at the membrane of epithelial cells where PTEN was 
colocalized by this protein-protein interaction. This interaction enhanced the tumor 
suppression function of PTEN (Wu et al, 2000). PTEN also binds to the PDZ domain 
containing protein NHERF (Na+/H+ exchanger regulatory factor) and this binding 
recruits PTEN to protein complexes on the membrane to suppress PI3K activation 
(Takahashi et al, 2006).  
Besides interacting with other proteins through PDZ binding domain, other regions of 
PTEN, such as C2 domain and C-tail, also participate in protein-protein interactions. This 
protein-protein interaction can affect PTEN activity and stability differently. Some 
interactions can even have opposite effects on activity in response to different stimuli 
(Leslie et al, 2008; Shi et al, 2012). This calls for further investigations of the PTEN-
protein interactions. Given the many processes in which PTEN participates, more protein 
binding partners will certainly be detected in the future. 
1.4.7 Role of PTEN protein phosphatase activity and its function beyond PI3K/Akt 
signaling pathway 
Along with acting as a lipid phosphatase, PTEN is also a dual-specific protein 
phosphatase. Studies of PTEN mutations have identified some mutant proteins which 
only have one of the phosphatase activities. Mutation of Gly129 to Glu (G129E) 
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abrogated lipid phosphatase activity but preserved protein phosphatase activity (Myers et 
al, 1998), while Y138L has intact lipid phosphatase activity but undetectable protein 
phosphatase activity (Davidson et al, 2010). These results provided a strategy for 
investigating the function of PTEN lipid and protein phosphatase activities separately. 
Although inactive as a lipid phosphatase, PTEN G129E had the same effect as wild type 
PTEN in inhibiting glioblastoma cell invasion and migration. This effect was linked to 
PTEN function as phosphotyrosine phosphatase that dephosphorylates focal adhesion 
kinase (FAK) (Tamura et al, 1999). PTEN also inhibited human glioma cell migration, 
and this function was dependent on its protein phosphatase activity and 
dephosphorylation of Thr383. This finding also suggested that one of the physiological 
substrates for PTEN protein phosphatase activity could be PTEN itself  (Raftopoulou et 
al, 2004). A very recent study of PTEN function using neuronal spine density as the read-
out showed the presence of PTEN or PTEN-G129E reduced neuronal spine density in 
cultured hippocampal slices, while catalytically dead mutant C124S and protein 
phosphatase-deficient mutant Y138L did not reduce neuronal spine density (Zhang et al, 
2012). Furthermore, the ability to decrease spine density only required the 
dephosphorylation of the PTEN C-tail and the presence of PDZ binding domain, 
suggesting phosphorylation on the C-tail also regulated PTEN binding to PDZ domain 
containing proteins. The observations that the phosphorylated peptide which has the C-
tail sequence could be dephosphorylated by PTEN in vitro and that PTEN 
autophosphorylation could be observed in HEK293 cells were also reported (Zhang et al, 
2012). These results provided evidence that PTEN protein phosphatase is critical for 
autodephosphorylation to control cellular processes independent of the PI3K/Akt 
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signaling pathway. Although studies on the function of PTEN in the PI3K/Akt pathway 
have made considerable progress, less is known about the role of PTEN in PI3K/Akt-
independent pathways. A thorough understanding of PTEN should provide insights for 
developing novel therapies for cancers and other diseases that modulate particular 
activities and regulation strategies of PTEN. 
1.5 Inositol-containing molecules in Bacteria and Archaea 
Although primarily associated with eukaryotes, inositol-containing molecules are found 
in many archaea but seldom found in bacteria (Michell, 2011). The one group of bacteria 
noted for containing inositol lipids are mycobacteria (and other actinobacteria). The 
majority of bacteria do not incorporate inositol lipids into their membranes. In contrast, 
many members of the archaeal domain synthesize inositol containing lipids in their 
membranes; they also synthesize and accumulate small, water-soluble molecules derived 
from inositol (Michell, 2011). 
1.5.1 Inositol and its derivatives in bacteria 
In actinobacteria, inositol can be synthesized de novo following the same biosynthetic 
pathway used in eukaryotes. The two genes encoding inositol phosphate synthase (MIPS) 
and inositol monophosphatase (IMPase) are found in all actinobacteria (Morita et al, 
2011). Myo-inositol can also be transported into the cells from the environment (Newton 
et al, 2006). In actinobacteria, the majority of the inositol serves as the precursor for 
synthesizing PI and its derivatives and mycothiol, a redox-active analogue of glutathione 
in these organisms (Morita et al, 2011). 
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Similar to eukaryotes, de novo synthesis of PI occurs by the exchange of the CMP moiety 
of CDP-DAG with inositol. This reaction is catalyzed by PI synthase (Salman et al, 1999).  
PI was demonstrated to be an essential phospholipid for mycobacteria survival since 
disruption of its gene in Mycobacterium smegmatis caused the organism to lose cell 
viability (Jackson et al, 2000). PI also serves as the lipid anchor of complex glycosylated 
derivatives (Morita et al, 2011). PI can be mannosylated to form PI mannoside (PIM), 
and PIM can be further mannosylated and arabinosylated to form lipomannan (LM) and 
lipoarabinomannan (LAM) (Morita et al, 2011) (Figure 1.9). All these inositol containing 
lipids are important for mycobacteria growth and the ability to infect their targets (Fratti 
et al, 2003; Geijtenbeek et al, 2003).  
Mycothiol (MSH or AcCys-GlcN-Ins) is synthesized from inositol (in this case D-I3P, 
which is the same as L-I1P). After the generation of D-I-3-P, an activated GlcNAc (N-
acetyl-D-glucosamine) is linked to the hydroxyl group at D1 position of the inositol ring, 
then the glycosylated inositol is further linked to N-acetylated cysteine to form mycothiol 
(Newton et al, 2008) (Figure 1.9). Mycothiol is a substitute for glutathione in 
mycobacteria and plays important roles in maintaining the reducing environment in the 
cells; it is also important in detoxification of alkaline reagents, reactive oxygen species 
and antibiotics (Newton et al, 2008). 
PI(3)P has recently been identified in mycobacteria, although the role of this inositol 
phospholipid is still under debate. One group suggested PI(3)P is the intermediate prior to 
the synthesis of PI. PI(3)P, produced by condensing L-I-1-P with CDP-DAG, can be 
dephosphorylated to produce PI (Morii et al, 2010). Others proposed that it is produced 
upon cell stress and can be a mediator of cellular signaling (Morita et al, 2010). 
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Figure 1.9 Inositol and inositol-containing molecules in actinobacteria (Morita et al, 
2011; Newton et al, 2008) 
1.5.2 Inositol-containing molecules in archaea 
Inositols occur in at least two different kinds of molecules in archaea (Michell, 2011). 
The first group includes the inositol phospholipids, although most of them have different 
structures than inositol-containing phospholipids in eukaryotes. The second group is 
based on the water soluble molecule di-myo-inositol-1, 1’-phosphate (DIP). DIP and 
several of its derivatives are used to protect cells against harsh environments (increased 
salinity or temperature). 
 36 
 
The structures of phospholipids found in archaea are different from those in eukaryotes 
and bacteria (Koga & Morii, 2007; Lombard et al, 2012; Michell, 2011) (Figure 1.10). 
The phosphate group in eukaryotic phospholipids is linked at sn-3 position of the glycerol 
backbone, while in archaea, the phosphate is attached at sn-1 position of the glycerol. 
This feature makes the glycerolphosphate backbone of lipids in archaea the enantiomer of 
that found in eukaryotes. Another noticeable difference is that the bonds linking the 
hydrophobic hydrocarbon tails to the glycerol backbone are ethers in archaea instead of 
esters seen in eukaryotes. The hydrocarbon tails of archaeal lipids are branched based on 
an isoprenoid structure instead of the straight chain fatty acid in eukaryotes and bacteria 
(or the bacterial lipids with a single cyclohexyl or isopropyl group at the end of the acyl 
chain). These striking features of archaeal phospholipids compared to lipids in eukaryotes 
gives archaeal lipids different physical properties and are partly responsible for the 
survival of archaea in extreme environments (Koga & Morii, 2007; Lombard et al, 2012; 
Michell, 2011). However, the head groups of lipids found in all three domains are mostly 
the same, including myo-inositol. Inositols are also linked to the phosphate group of 
glycerol at D1 position to form the phospholipids (Koga & Morii, 2007). The 
biosynthesis of myo-inositol in archaea is the same as that in eukaryotes and bacteria. D-
I3P (L-I1P) is first generated from D-G6P by MIPS, then dephosphorylated by IMPase to 
form myo-inositol (Michell, 2011). The biosynthetic pathway for the primary inositol 
phospholipid in archaea, archaetidylinositol (ArcIns), has been recently reported. Instead 
of directly linking inositol with CDP-archaetol, these organisms link phosphorylated 
inositol D-I3P to CDP-archaetol to form phosphorylated ArcIns. That phosphorylated 
molecule is then dephosphorylated to form the archaetidylinositol (Morii et al, 2009).  
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Inositol can also be incorporated into a series of water-soluble small molecules, with the 
prominent one di-myo-inositol-1, 1’-phosphate or DIP. DIP is accumulated as a 
compatible solute in thermophiles / hyperthermophiles and aids in protecting cells against 
increased temperature. 
 
Figure 1.10 Structure of inositol phospholipid in eukaryotes (phosphatidylinositol) 
and in archaea (archaetidylinositol) (Michell, 2011). 
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Figure 1.11 DIP and its derivatives found in (hyper)thermophilic bacteria and 
archaea (Lamosa et al, 2006; Martins et al, 1996; Rodrigues et al, 2009) 
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1.5.3 DIP and its derivatives 
Thermophiles and hyperthermophiles are groups of organisms that thrive at high 
temperatures. The organisms with an optimal growth temperature between 65°C and 
80°C are termed thermophiles; the optimal growth temperature of hyperthermophiles is 
above 80°C (Santos & da Costa, 2002). Although some bacteria are thermophiles/ 
hyperthermophiles, most hyperthermophiles are archaea (Empadinhas & da Costa, 2006; 
Santos & da Costa, 2002). In order to survive at high temperatures as well as adjust to 
altered water activity caused by fluctuations in salt concentrations, thermophiles and 
hyperthermophiles have had to develop some adaptive strategies. Proteins in 
thermophiles and hyperthermophiles have higher thermal stability than their homologues 
in mesophilic organisms by making subtle changes in their structures (Luke et al, 2007). 
However, this may not be sufficient for all proteins in thermo-/hyperthermophiles 
subjected to thermal stress. These organisms also accumulate small molecular weight 
molecules, by de novo synthesis or by uptake from the environment, to maintain the cell 
turgor pressure and protect enzyme activity. These small molecules are termed osmolytes 
or compatible solutes since they are thought to be benign (not very reactive) in the 
cytoplasm (Burg & Ferraris, 2008; Empadinhas & da Costa, 2006; Khan et al, 2010; 
Roberts, 2004; Yancey, 2005). Osmolytes almost always have a thermoprotective effect 
as well as contributing to osmotic balance. DIP is one of the more unusual compatible 
solutes identified in a variety of thermophiles and hyperthermophiles. 
DIP was first identified as an intracellular counter ion of K+ in Pyrococcus woesei and 
was shown to protect  glyceraldehyde-3-phosphate dehydrogenase from heat inactivation 
effectively at high temperatures (Scholz et al, 1992). DIP is also accumulated by 
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Methanococcus igneus (later rename as Methanotorris igneus). In this methanogen, DIP 
is accumulated as a compatible solute, and its accumulation is dependent on the 
temperature. DIP accumulation has also been reported in hyperthermophilic archaea 
including Archeaglobus fulgidus (Goncalves et al, 2003; Martins et al, 1997), Pyrococcus 
furious (Martins & Santos, 1995), order Thermococcus (Lamosa et al, 1998) and 
Pyrolobus fumarii (Goncalves et al, 2008), and in hyperthermophilic bacteria including 
Thermotoga maritima (Ramakrishnan et al, 1997) and order Thermotogales (Martins et al, 
1996). DIP also exists in the thermophilic actinobacterium Rubrobacter xylanophilus 
(Empadinhas et al, 2007). In all these organisms, there is a strong correlation between the 
accumulation of DIP and growth at supraoptimal temperatures. This correlation clearly 
indicates DIP has a role in thermoprotection. 
DIP is an unusual phosphodiester. Originally it was identified as a chiral molecule, di-
myo-inositol-1,1’-phosphate or L,L-DIP (Figure 1.11), by synthesis of the molecule and 
comparing the synthetic material to isolated DIP from P. woesei (Scholz et al, 1992). The 
optical rotation of DIP purified from P. woesei was reported as [α]D20 = 2.39°, 
comparable with that of synthesized L,L-DIP. Initial studies of DIP biosynthesis in M. 
igneus proposed a pathway based on this identification (Chen et al, 1998). However, 
based on the HMQC NMR result, another stereoisomer of DIP was found in Thermotoga 
neapolitana cell extract, and this stereoisomer was thought to be di-myo-inositol-1,3-
phosphate or L,D-DIP (Martins et al, 1996) (Figure 1.11). Currently, it is thought that all 
these organisms synthesize L,D-DIP as a natural product. This was based on results with 
a key enzyme, CTP:inositol-1-phosphate cytidylyltransferase (IPCT) (see discussion 
below). 
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The first biosynthetic pathway of DIP was proposed in 1998 based on the activities of 
enzymes in cell extracts of M. igneus (Chen et al, 1998). The pathway has four steps: (1) 
G6P is converted to L-I1P (equivalent to D-I3P) by myo-inositol phosphate synthase 
(MIPS); (2) L-I1P is dephosphorylated by inositol monophosphatase (IMPase) to produce 
inositol; (3) inositol is activated by attaching it to CDP through CTP:I-1-P 
cytidylyltransferase (IPCT) to produce CDP-inositol; (4) the CMP part in CDP-inositol 
was exchanged with inositol through nucleophilic attack to generate DIP by DIP 
synthases (DIPS) (Figure 1.12). However, direct detection of the production of CDP-
inositol failed, although the enzymes in cell extract can catalyze the DIP generation 
reaction with synthetic CDP-inositol and inositol. Four enzymes are involved in the 
biosynthesis of DIP from G6P, MIPS, IMPase, IPCT and DIPS. Since MIPS and IMPase 
account for the generation not only DIP, but also other inositol-containing molecules, the 
identification of IPS and IMPase in hyperthermophiles is easier, and there has been 
extensive characterization of these two hyperthermophilic enzymes (Chen et al, 2000; 
Stieglitz et al, 2002). However, for many years there was no identification of genes 
encoding IPCT and DIPS.  
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Figure 1.12 Proposed DIP synthesis pathway (Chen et al, 1998) 
The DIP biosynthetic pathway was revised by the finding a phosphorylated form of DIP 
(P-DIP) in some organisms (Borges et al, 2006) and characterization of enzymes IPCT 
and DIPS (Rodionov et al, 2007). The genes encoding these two enzymes were identified 
by comparative genomics and were found in all the organisms that synthesized DIP. 
These two genes were found clustered on the chromosome with the gene encoding MIPS 
(Rodionov et al, 2007). The activity of IPCT from T. maritima was shown to 
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preferentially catalyze the transferase reaction with CTP and L-I1P as the substrates to 
produce CDP-inositol. The MIPS activity was tested using the cell lysate. In the absence 
of the IMPase, a novel product, phosphorylated DIP (P-DIP) was identified by NMR. 
These findings suggested a revised DIP biosynthesis pathway (Figure 1.13). Instead of 
direct condensation of CDP-inositol with free inositol to form DIP, a phosphorylated DIP 
(P-DIP) was first formed by condensing CDP-inositol with L-I1P catalyzed by PDIPS. 
After this, the P-DIP was dephosphorylated by a phosphatase to generate DIP. In vitro P-
DIP can be dephosphorylated by adding purified IMPase enzymes. Due to the specificity 
of IPCT activity toward L-I1P, DIP generated by this pathway was L,D-DIP. This revised 
pathway was further confirmed by the study of the protein encoded by fused IPCT and 
DIPS genes (ipct/dipps) from A. fulgidus and other hyperthermophiles, which showed the 
same substrate specificity (Rodrigues et al, 2007). By using 13C labeled L-I-1-P, it was 
demonstrated that only D,L-DIP was produced.  
Besides DIP, other inositol containing compounds are also identified in archaea as 
compatible solutes. For example, 1-glyceryl-1-myo-inosityl phosphate (GIP) (Figure 1.11) 
was found to be a compatible solute in A. fulgidus when the organism encounters both 
osmotic and heat stress (Lamosa et al, 2006). GIP was also identified as the major 
osmolyte in the hyperthermophilic bacterium Aquifex pyrophilus (Lamosa et al, 2006). 
The identification of mannosylated DIP in hyperthermophiles was also reported. T. 
neapolitana accumulates di-2-O-β-mannosyl-di-myo-inositol phosphate (DMDIP) 
(Figure 1.11) as well DIP as compatible solutes when growing at supraoptimal 
temperatures (Martins et al, 1996). DMDIP is also found in A. pyrophilus (Lamosa et al, 
2006). The monomannosylated DIP (mannosyl-di-myo-inositol phosphate, MDIP) 
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(Figure 1.11) was also identified as one of the compatible solutes accumulated by T. 
maritima (Rodrigues et al, 2009).  
 
Figure 1.13 Revised DIP biosynthetic pathway (Rodionov et al, 2007; Rodrigues et al, 
2007) 
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1.6 Inositol monophosphatase 
Inositol monophosphatase (IMPase, EC 3.1.3.25) catalyzes dephosphorylation of inositol 
monophosphate to generate inositol. It plays important roles in inositol generation and 
recycling. Since all inositols, no matter in eukaryotes or prokaryotes, are generated by the 
same de novo synthetic pathway, IMPase and its encoding gene imp are found in 
organisms throughout the three domains of life. However, prokaryotic IMPase proteins, 
especially those from hyperthermophilic organisms have different properties and 
structural features compared to their eukaryotic counterparts. The understanding of these 
differences also contributes to our understanding of how hyperthermophilic proteins are 
adapted to high temperatures.  
From a structural view, hyperthermophilic proteins increase their thermal stability by 
increasing the intramolecular interactions that hold the native conformations together  at 
high temperature (Razvi & Scholtz, 2006). This can generally be achieved by lowering 
the volume of cavities or increasing compactness of the protein, increasing the number of 
ion pairs, increasing secondary structure content with corresponding decrease in irregular 
regions, truncating solvent-exposed loops, and changing the amino acid composition by 
increasing prolines and reducing thermally labile amino acids such as Met and Gln 
(Sterner & Liebl, 2001; Szilagyi & Zavodszky, 2000). However, mechanisms a particular 
protein uses to adapt to higher temperatures can be very diverse (Feller, 2010).  
1.6.1 Eukaryotic IMPase 
Several structures of human IMPase and other eukaryotic IMPase with different ligands 
have been solved by crystallography (Arai et al, 2007; Bone et al, 1994a; Bone et al, 
1994b; Bone et al, 1992; Ganzhorn & Rondeau, 1997; Singh et al, 2012). Most 
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eukaryotic IMPase proteins are dimeric and have a similar core structure with tetrameric 
fructose-1,6-bisphosphatase (FBPase) (Figure 1.14), although these two proteins have 
low sequence similarity (Atack et al, 1995; York et al, 1994). The crystal structures of the 
eukaryotic IMPase show that the proteins contain two or three metal ions. Since this 
protein is Mg2+ dependent and no phospho-enzyme intermediate was found during 
dephosphorylation, it was suggested that a water molecule instead of protein side chain 
acts as the nucleophile to dephosphorylate the substrate (Bone et al, 1994b; Bone et al, 
1992). Although three metal ions are found in the crystal structures, some studies have 
suggested a two-metal ion mechanism, in which only two Mg2+ are important in catalysis 
(Pollack et al, 1994; Wang & Hirao, 2013). Two metals at site 1 and 2 can facilitate the 
deprotonation of water molecule to become nucleophilic and facilitate the release of the 
product to finish the catalytic cycle (Bone et al, 1994a). 
Human IMPase can be inhibited by lithium. The Ki of Li+ to human IMPase is only 0.3 
mM (McAllister et al, 1992). Li+ inhibits the protein in an uncompetitive fashion 
(Hallcher & Sherman, 1980), and it is believed that Li+ occupies the metal binding site 2 
to trap the phosphate group from leaving the protein active site and thus inhibits enzyme 
activity (Atack et al, 1995; Haimovich et al, 2012). IMPase is likely to be the target of Li 
therapy in the treatment of bipolar disorder, where it is suggested that lithium inhibits 
IMPase activity to deplete the inositol production, so as to lower the generation of PI and 
related second messengers to attenuate the response to extracellular stimuli (Atack et al, 
1995; Harwood, 2005). 
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Figure 1.14 Monomer structure of human IMPase (left) with pig kidney FBPase 
(right). Human IMPase (PDB 1IMC) protein is shown in grey cartoon, 2 Mn2+ are 
shown in blue, 1 PO43- ion is shown in orange with oxygen atoms in red. Pig kidney 
FBPase (PDB 1CNQ) protein is shown in grey carton, 3 Zn2+ are shown in green, 1 
PO43-  is shown as in IMPase structure, 1 F6P molecule is shown in cyan, with 
oxygen atoms in red and phosphorus in orange. 
1.6.2 Hyperthermophilic IMPase 
Several IMPase enzymes from hyperthermophiles are well characterized with high 
resolution crystal structures (Johnson et al, 2001; Stieglitz et al, 2002; Stieglitz et al, 
2007). Compared to eukaryotic IMPase, there are several striking features of 
hyperthermophilic IMPase proteins. First, the hyperthermophilic IMPase enzymes are 
dual-specific phosphatases. They can dephosphorylate fructose-1,6-bisphosphate (FBP) 
as well as inositol-1-phosphate. This is in contrast to the IMPase enzymes from 
eukaryotes and other bacteria where dephosphorylation of those two substrates is 
catalyzed by two separate enzymes, IMPase and FBPase (Stec et al, 2000). Second, they 
are Li+ insensitive. Unlike the eukaryotic IMPase which can be inhibited by Li+ with the 
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IC50 less than 1 mM, the IC50 of Li+ for hyperthermophilic IMPase enzymes is more than 
100 mM (Chen & Roberts, 1998; Stieglitz et al, 2002). Third, consistent with their 
existence in hyperthermophiles, the IMPase protein from these organisms have higher 
thermal stability. The Tm (mid-point of the thermal denaturation transition) of A. fulgidus 
IMPase (AF2372) is around 88°C (Wang et al, 2006). Methanocaldococcus jannaschii 
IMPase (MJ0109) has higher thermal stability with Tm of 95 °C (Chen & Roberts, 1998) 
and T. maritima IMPase (TM1415) is still active at 100°C (Chen & Roberts, 1999). Last, 
the dephosphorylation mechanism of the dual-specific hyperthermophilc IMPase is likely 
to require three-metal ions, similar to FBPase catalysis but not the human IMPase 
(Johnson et al, 2001) (Figure 1.15). The mobile loop in MJ0109, which is critical for 
protein activity, is slightly longer (2 residue insertion) than that in human IMPase. It 
adopts a conformation more similar to the corresponding loop in pig kidney FBPase that 
would facilitate binding of the third metal ion. Although there is only one residue, Asp38, 
that has direct contact with the third metal ions (and this metal ion binds relatively 
weakly at metal binding site 3), the third metal ion together with metal at site 2 provides 
the right environment for activation of the nucleophilic water molecule and formation and 
release of products. 
The kinetics parameters of IMPase and other related enzyme from different organisms are 
summarized in Table 1.3, The differences between the dual-specificity IMPase enzymes 
from hyperthermophiles and the IMPases of other bacteria and eukaryotes are obvious.  
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Figure 1.15 Proposed IMPase three-metal ion assisted catalytic mechanism (adapted 
from Johnson et al, 2001). 
Table 1.3 Kinetics parameters for IMPase and FBPase enzymes from different 
organisms (Chen & Roberts, 1999; Matsuhisa et al, 1995; McAllister et al, 1992; 
Stec et al, 2000; Stieglitz et al, 2002; Zhang et al, 1996) 
Protein I-1-P FBP Li+ IC50 
(mM)  Km (mM) kcat (s-1) Km (mM) kcat (s-1) 
AF2372a 0.11 2.5 0.08 2.7 290 
MJ0109a 0.091 4.2 0.038 7.0 250 
TM1415b 0.013 207  268 100 
E coli SuhBc 0.07 6.5  <0.005 0.35 
Human IMPasec 0.075 17.2   0.3 
Pig kidney FBPased  0.02 0.0014 21 1-3e 
Assays were carried out at (a) 85°C, (b) 95°C, (c) 37°C, (d) 30°C, (e) 24°C. 
There is no unique way the hyperthermophilic IMPases have altered structure to adapt to 
high temperatures. However, a comparison of MJ0109 with human IMPase and pig 
kidney FBPase does point out some changes (Johnson et al, 2001). The amino acid 
sequence of MJ0109 has less Met, Ser and no His and Gln, consistent with the above 
mentioned general change of amino acid content upon adaptation to high temperature. 
Compared to human IMPase, MJ0109 has a smaller volume and smaller solvent 
accessible area, indicating the protein has become more compact. Although the pattern of 
changes in loops is complex in MJ0109 compared to human IMPase, in general the loops 
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in MJ0109 are shorter. One changed loop (residues 67-76) forms a β-strand rather than 
the flexible conformation seen for the corresponding loop in human IMPase. The dimer 
interface of MJ0109 is smaller than that of human IMPase, suggesting dimer stability is 
not directly linked to the thermal stability of the whole protein. However, there are more 
charged contacts between the two monomers in the archaeal IMPase interface. All these 
features are consistent with general observations for thermostable proteins. Again this 
demonstrates that proteins adopt several strategies instead of a single one to increase their 
thermal stability (Petsko, 2001). 
1.6.3 A. fulgidus IMPase (AF2372) 
Like other hyperthermophilic IMPase proteins, AF2372 is also a dual-specific 
phosphatase. It can dephosphorylate inositol phosphate, both D-I-1-P and L-I-1-P, with 
similar kcat values. However, the Km for D-I-1-P is 10-fold lower than that for L-I-1-P, 
indicating formation of a different hydrogen bond network when these two substrates 
bind (Morgan et al, 2004). It can also dephosphorylate FBP, but has no activity toward G-
6-P or F-6-P (fructose 6-phosphate) (Stieglitz et al, 2002). Along with I-1-P and FBP, 
AF2372 can also dephosphorylate NADP+ and NADPH with comparable kinetics 
parameters (Fukuda et al, 2007). Li+ barely inhibits AF2372 activity. The Li+ IC50 values 
for enzyme activities toward I-1-P, FBP, NADP and NADPH range from 50 to 300 mM, 
almost 1000-fold higher than for Li+ inhibition of the human IMPase (Fukuda et al, 2007; 
Stieglitz et al, 2002). The activity of AF2372 is dependent on the presence of Mg2+. The 
apparent Kd for Mg2+ or Mn2+ is 15-30 mM (depends on substrate concentration since the 
phosphate esters can bind divalent cations). Ca2+ inhibits both the IMPase and FBPase 
activities (Stieglitz et al, 2002). 
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Like other IMPase enzymes, AF2372 protein is a homodimer with each monomer 
consisting of alternating layers of α-β-α-β-α structure (Figure 1.16). The layers of α-
helices and β-sheets are connected by loops with variable length (Stieglitz et al, 2002). 
Compared to the MJ0109 structure, AF2372 has slightly longer N-terminal helices and a 
deletion of a small helix that is part of the dimer interface in MJ0109. These features 
cause a looser dimeric organization of AF2372 and may be responsible for the relatively 
lower thermal stability of AF2372 than MJ0109. 
 
Figure 1.16 Crystal structure of AF2372 (PDB 1LBY). The protein is shown in grey, 
In each monomers, 3 Mn2+ ions are shown in blue; 1 F6P molecule is shown in cyan, 
with oxygen atoms in red and phosphorus in orange; 1 PO43- ions is shown in orange 
with oxygen in red. 
Studies of the conformation of the mobile loop revealed some interesting features in the 
IMPase superfamily of proteins. The mobile loop in AF2372, MJ0109 and pig kidney 
FBPase have a similar closed conformation, while human IMPase has the mobile loop 
with a more open conformation. Similar with what was reported for MJ0109 structures, 
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this mobile loop in the apo form of AF2372 is unstructured. However, when metal ions 
and ligands are bound, this loop became ordered and moves toward the metal ions 
(Figure 1.17). Just like in MJ0109, movement of this mobile loop facilitates metal ion 
binding and water nucleophile formation. The mobility of the mobile loop is critical for 
product release to prepare the protein for the next catalytic cycle. The same 
conformational change of the mobile loop is also observed in FBPase (Choe et al, 1998). 
The mobility of this critical mobile loop is also related to Li+ sensitivity. A mutation in 
the MJ0109 mobile loop, D38A, yielded a protein that was inhibited by Li+ with an IC50 
of 12 mM. This mutant protein had significantly lower affinity for Mg2+, indicating the 
role of that Asp in metal ions binding (Li et al, 2010). 
A unique feature of AF2372 is that enzyme activity can be regulated by oxidation 
(Stieglitz et al, 2003). It was shown that protein activity can be eliminated by oxidation 
with O2 for 6 h or incubation with oxidized thioredoxin for 28 h. The oxidation could be 
reversed by adding a reducing agent, such as DTT. The mutant protein C150S lost the 
sensitivity to oxidation. The distance between the S atoms of Cys150 and Cys186 in 
AF2372 is only 4Å, so it is believed that upon oxidation, a disulfide bond could form 
between these two cysteines. Regulation of IMPase activity by cysteine oxidation and 
disulfide formation is postulated to be the result of altering the affinity of protein for 
metal ions.  
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Figure 1.17 Monomer structures of AF2372 apo form (left, PDB 1LBW) and ligand/ 
metal bound form (right, PDB 1LBY). The mobile loops (residues 32 to 43) in both 
forms are colored in red. In the ligand/metal bound form, 3 Mn2+ ions are colored in 
blue, 1 F6P molecule is colored in cyan with oxygen in red and phosphorus in 
orange, 1 PO43- ion is colored in orange. 
A kinetic study of the temperature dependence of Km of AF2372 for inositol phosphate 
revealed the unique regulation of this protein by temperature (Wang et al, 2006). The 
decrease of Km for I-1-P from 55°C to 75°C is only 2.5-fold, while the Km at 85°C 
decreased 8 to 10-fold compared to that at 75°C. This dramatic decrease of Km was only 
observed when using inositol phosphate as the substrate, and it only happened in AF2372 
not in MJ0109 or TM1415. A hydrogen bonding network at the active site was suggested 
to account for this Km temperature dependence. Higher temperatures might alter the 
mobility of a loop at the interface which in turn changes this hydrogen bonding network 
to increase the substrate affinity. The temperature dependence of AF2372 activity toward 
inositol phosphate also correlates with accumulation of DIP at higher temperatures. 
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However, when I started my research there was no study of DIP thermoprotection of this 
particular protein. 
1.7 Brief outline of this thesis 
The studies addressed in this thesis are focused on two proteins:  human PTEN and A. 
fulgidus IMPase (AF2372). Work with PTEN started with a collaboration with Prof. 
Goran Krilov and his student Qin Wang. They carried out a molecular dynamics 
simulation of a series of short-chain phosphatidylinositols (and deoxy-PIs) binding to the 
PTEN phosphatase domain. They identified a hydrophobic site around Arg47 on PTEN 
that appeared critical for ligand binding to the active site. This model was supported by 
testing PTEN activity using lipid substrates with different aggregation states. Mutation at 
Arg47 revealed the importance of this residue in protein activity.  The second area of 
PTEN work centered on studying the interaction of PTEN with lipid molecules using 
NMR spectroscopy. Different binding modes of activator molecule PI(4,5)P2 and 
substrate analog lipids were identified by fixed field NMR. Field cycling NMR showed 
different binding sites for both the activator and substrate analog molecules on the PTEN 
phosphatase domain that were spatially near each other. This result clearly proves there is 
a discrete binding site for activator molecules that is separate from the active site, 
although under some conditions the activator molecule can bind to the protein active site. 
An NMR study of the PTEN mutant K13E modified the conventional interpretation of 
this particular mutant by providing evidence for the interaction of K13E with PI(4,5)P2 
and other lipid molecules. The last part of the thesis presents a study on the 
thermoprotection mechanism of DIP as well as other compatible solutes using AF2372 as 
the model protein. DIP and diglycerophosphate (DGP) showed high thermoprotection of 
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AF2372 while glutamate ions are less effective. In collaboration with protein 
crystallographers (Drs. Bog Stec and Rebecca Goldstein), we identified specific binding 
sites on AF2372 for glutamate anions. Mutation of the glutamate binding sites showed 
they were not necessary for glutamate thermoprotection. However, the residues of these 
sites were very important for overall protein thermal stability. A proposed mechanism for 
compatible solutes protecting AF2372 from thermal denaturation is suggested whereby 
the compatible solutes bind to either the active site or a specific binding site for glutamate 
on the protein (that is not detected at low or room temperature and that may be weakly 
associated) to change the mobility of the active site or the mobile loop, and preserve the 
protein activity at high temperature.  
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Chapter 2  
 
Materials and Methods 
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2.1 Chemicals 
2.1.1 Molecular biology reagents 
Quikchange site directed mutagenesis kit, E. coli XL1-Blue competent cells, and E. coli 
BL21-CondonPlus (DE3)-RIL competent cells were purchased from Stratagene. E. coli 
NovaBlue competent cells and the pET-23b(+) vector were from Novagen. GoTaq PCR 
Core system kit for cloning was from Promega. The oligonucleotide primers were 
ordered from Operon. QIAprep spin miniprep kit, QIAquick PCR purification kit and 
QIAquick gel extraction kit were from Qiagen. NdeI, XhoI, T4 DNA ligase, Antarctic 
phosphatase and1Kb DNA ladder were from New England Biolabs. Protein standards for 
SDS-PAGE were from Bio-Rad. LB broth was from Fisher. Lys C endoproteinase was 
from Wako. PTEN-pET-28a plasmid was the gift of Prof. Wonhwa Cho at University of 
Illinois, Chicago.  
2.1.2 Chemicals 
Isopropyl-β-D-thiogalactopyranoside (IPTG), ampicillin, and chloramphenicol are from 
American Bioanalytical. Sodium dodecyl sulfate (SDS) and 30% acrylamide/bis 
acrylamide solution were from Bio-Rad. The spin-labeling reagent, 2,2,5,5-tetramethyl-l-
oxyl-3-methyl methanethiosulfonate (MTSL), was from Toronto Research Chemicals. D-
myo-inositol-1-phosphate (D-I-1-P) was from Cayman Chemicals. Kanamycin sulfate, 
Triton X-100, D2O, Trizma base, boric acid, EDTA, DTT, β-mercaptoethanol, MgCl2, 
KCl, NaCl, KH2PO4, p-nitro-phenyl phosphate (pNPP), fructose-1,6-bisphosphate (FBP), 
sodium glutamate (Na-Glu), potassium glutamate (K-Glu), sodium aspartate (Na-Asp), 
potassium aspartate (K-Asp), proline, betaine and other chemicals were from Sigma-
Aldrich. Sodium L,L- and D,L-di-myo-inositol-1, 1’-phosphate (DIP) were gifts from Dr. 
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Christina Longo and Dr. Scott Miller at Yale University.  Diglycerol phosphate (DGP) 
was synthesized by Jessica Chao in our laboratory.  
2.1.3 Resins and columns 
Ni-NTA agarose resin was from Qiagen. Q sepharose Fast Flow (QFF) ion exchange 
resin was from GE Health Care Life Science. The micro bio-spin 6 columns were 
purchased from Bio-rad. The PepClean C-18 spin column was from Thermo Scientific. 
2.1.4 Phospholipids 
The dioctanoylphosphatidylinositol derivatives (diC8PI, diC8PI(3,4)P2, diC8PI(4,5)P2, 
diC8PI(3)P) and dipalmitoyl phosphatidylinositol 3-phosphate (diC16PI(3)P) were 
purchased from Echelon. The dihexanoyl phosphatidylinositol compounds (diC6PI and 
diC6PI(4,5)P2) were obtained from Cayman Chemicals. Long-chain phospholipids, 
including brain phosphatidylinositol-4’,5’-bisphosphate (PI(4,5)P2), 1,2-dioleoyl-sn-
glycero-3-phospho-(1'-myo-inositol-3',4'-bisphosphate) (DOPI(3,4)P2), 1,2-dioleoyl-sn-
glycero-3-phospho-(1'-myo-inositol-4',5'-bisphosphate) (DOPI(4,5)P2), 1-palmitoyl-2-
oleoyl-sn-glycero-phosphocholine (POPC) and 1,2-diheptanoyl-sn-glycero-3-
phosphocholine (diC7PC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(5-
dimethylamino-1-naphthalene-sulfonyl) (Dansyl-PE) were obtained from Avanti Polar 
Lipids. The 3-deoxy-dioctanoylphosphatidylinositol derivatives were gifts of Dr. Yingju 
Xu and Dr. Scott Miller, Yale University.  
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2.2 Methods 
2.2.1 Mutagenesis  
All mutagenesis was done using the QuikChange site-directed mutagenesis kit. This 
method utilized double strand DNA plasmid as the template. Primers containing the 
desired mutation (point mutation, insertion or deletion) were extended during PCR 
amplification by PfuTurbo DNA polymerase. This DNA polymerase has high fidelity 
assuring the replication, but does not change the mutation site. After amplification, the 
parental plasmid containing methylated adenine was digested by Dpn I endonuclease to 
leave the newly synthesized mutation containing plasmids present (Nelson & McClelland, 
1992). The primer pairs containing the mutation were designed to have 25-45 bases and 
good annealing to the template plasmid. The CG content should be at least 40% and the 
melting temperate is optimally above 78°C. Table 2.1and Table 2.2 showed the primers 
used for generating designated PTEN and A. fulgidus IMPase mutants. Typically 50 ng of 
plasmid was mixed with 125 ng sense and antisense primers in 200 μl PCR tubes with 
dNTP (deoxyribonucleotide mix) and reaction buffer added following the manufacturer’s 
protocol. 1 μl of PfuTurbo DNA polymerase was added. The PCR cycling parameters 
used heating to 95°C for 30 s for single strand generation, cooling to 55°C for 1 min to 
allow the DNA and primers to anneal, then heating to 68°C for either 13 min (for PTEN) 
or 8 min (for A. fulgidus IMPase) for elongation. After 16 cycles, the product was cooled 
to 4°C. Then 1 μl DpnI was added to digest the parental plasmid at 37°C for 1 h. The 
digested product was transformed into E. coli XL1-blue competent cells for plasmid 
propagation and preparation. All mutants were confirmed by the DNA sequencing 
(Genewiz, NJ). 
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Table 2.1 Primers used for PTEN mutagenesis - the nucleotides changed are in bold 
type and underlined. 
Protein mutant Primers 
K13E 5'-GAGATCGTTAGCAGAAACGAAAGGAGATATCAAGAGG-3' 
 5'-CCTCTTGATATCTCCTTTCGTTTCTGCTAACGATCTC-3' 
R47G 5'-GACTTGAAGGCGTATACGGGAACAATATTGATG-3' 
 5'-CATCAATATTGTTCCCGTATACGCCTTCAAGTC-3' 
R47W 5'-GACTTGAAGGCGTATACTGGAACAATATTGATG-3' 
 5'-CATCATCAATATTGTTCCAGTATACGCCTTCAA-3' 
R47K 5'-GACTTGAAGGCGTATACAAGAACAATATTGATGATGTAG-3' 
 5'-CTACATCATCAATATTGTCTTGTATACGCCTTCAAGTC-3' 
R47L 5'-GACTTGAAGGCG TATACCTGAACAATATTGATGATGTAG-3' 
 5'-CTACATCATCAATATTGTTCAGGTATACGCCTTCAAGTC-3' 
C124S 5'-GCAGCAATTCACAGTAAAGCTGGAAAG-3' 
 5'-CTTTCCAGCTTTACTGTGAATTGCTGC-3' 
 
Table 2.2 Primers used for A. fulgidus IMPase mutagenesis - the nucleotides 
changed are in bold type and underlined. 
Protein mutants Primers 
R11A 5'-ATGCGCTGAGAATTTCGGCGGAGATTGCAGGAGAGG-3' 
 5'-CCTCTCCTGCAATCTCCGCCGAAATTCTCAGCGCAT-3' 
R18A 5'-GATTGCAGGAGAGGTCGCAAAGGCCATTGCGTC-3' 
 5'-GACGCAATGGCCTTTGCGACCTCTCCTGCAATC-3' 
R29A 5'-CAATGCCCTTGAGGGAGGCAGTAAAGGACGTGGG-3' 
 5'-CCCACGTCCTTTACTGCCTCCCTCAAGGGCATTG-3' 
R92Q 5'-GGAACCTTCAATGCTACGCAAGGGATTCCAGTTTATTC-3' 
 5'-GAATAAACTGGAATCCCTTGCGTAGCATTGAAGGTTCC-3' 
K164E 5'-CAGGAAGTTTCCCTTTGAGAGGATGAGGATTTTTG-3' 
 5'-CAAAAATCCTCATCCTCTCAAAGGGAAACTTCCTG-3' 
L57A 5'-CTGCGCTTGAAATTGCGAGAAAGGAGAGGGTTACGG-3' 
 5'-CCGTAACCCTCTCCTTTCTCGCAATTTCAAGCGCAG-3' 
V142A 5'-GGAGAGGATTGAGGCGAGCGATGCTGAG-3' 
 5'-CTCAGCATCGCTCGCCTCAATCCTCTCC-3' 
L148A 5'-GTGAGCGATGCTGAGGAGGCTTACTGCAACGCCATAATC-3' 
 5'-GATTATGGCGTTGCAGTAAGCCTCCTCAGCATCGCTCAC-3' 
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2.2.2 Cloning  
The pten gene was amplified by PCR using the GoTaq PCR Core system kit (Promega). 
200 ng PTEN-pET-28a(+) plasmid was used as the template. The sequence of the primers 
is shown in Table 2.3. 50 pmol of each primer, 2.5 mM MgCl2, DNA template and dNTP 
(deoxyribonucleotide mix) were mixed in reaction buffer following the manufacturer’s 
protocol. Subsequently, 1.25 µl GoTaq DNA polymerase was added. PCR temperature 
cycling used 95°C for 2 min for initial production of single-stranded DNA, then 30 cycles 
of heating at 95°C for 1 min for denaturation, 55°C for 1 min for annealing template 
DNA with primer, and 72°C for 3 min for chain elongation. After PCR, the mixture was 
cooled to 4°C. The PCR products were visualized by electrophoresis on a 1% agarose gel 
with 1 μg/ml ethidium bromide and purified using a gel extraction kit. Purified PCR 
products and pET-23b(+) vector were doubly digested overnight at 37°C with NdeI and 
XhoI DNA endonuclease. The digested vectors were treated with Antarctic phosphatase 
to remove the 5’ phosphate to prevent self-ligation, then purified with a gel extraction kit. 
Digested PCR products were purified using a PCR purification kit. Digested and purified 
vector and PCR products were mixed at a ratio of 1:6, and 1 μl T4 DNA ligase was added. 
The ligation reaction was incubated overnight at 16°C. After ligation, the product was 
transformed into E. coli Novablue competent cells for plasmid propagation. Positive 
cloning plasmid was confirmed by DNA sequencing.  
Table 2.3 Primers used for cloning pten gene into pET-23b(+) vectors. The NdeI and 
XhoI restriction sites are underlined. 
 Primers 
Forward  5'-GCAAGTTCCATATGACAGCCATCATCAAAGAGATCG-3' 
Reverse 5'-CTTGATGACTCGAGGACTTTTGTAATTTGTGTATGCTG-3' 
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2.2.3 Transformation 
1 μl of the DpnI digested plasmids obtained from mutagenesis was mixed with 100 or 
200 μl E. coli XL1-blue competent cells, or 10 μl cloning product were mixed with 100 
μl NovaBlue competent cells and incubated on ice for 30 min. After incubation, the cells 
were heated to 42°C for 45 s for XL1-blue or 30 s for NovaBlue competent cells. After 
heat shock, the cell mixture was placed on ice for 2 min, and 500 μl LB media were 
added. The cell mixture was incubated on the rollerdrum for 1 h at 37°C. Then 200 μl 
cells were spread on LB-agar plates containing appropriate antibiotics. After growing 
overnight at 37°C, the plates with E. coli colonies were stored at 4°C.  
2.2.4 Plasmid DNA extraction 
A single colony from the plate of transformed XL1-blue competent cells (or NovaBlue 
competent cells for cloning) was picked and grown overnight in 5 ml LB media with 
proper antibiotics. DNA plasmid was extracted from the cells using QIAprep spin 
Miniprep Kit (Qiagen) following the manufacturer’s protocol. The final concentration of 
DNA was measured by the UV absorbance at 260 nm using an extinction coefficient of 
0.020 (μg/ml)-1 cm-1. 
2.2.5 Protein overexpression 
All the plasmids containing the designated genes are based on pET vectors. In the pET 
vector expression system, gene expression is controlled by the T7 promoter (Rosenberg 
et al, 1987; Studier et al, 1990). E. coli BL21 competent cells were used for protein 
overexpression. In the uninduced state, the target gene expression is silent due to the lack 
of T7 RNA polymerase. Addition of IPTG, which binds to the lacUV5 promoter, releases 
the T7 RNA polymerase for expression. After induction, T7 RNA polymerase initiates 
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the transcription of the target gene. Since T7 RNA polymerase is more active than RNA 
polymerase in E coli, most of the cells express the target gene, 1 μl plasmid obtained 
from the miniprep was mixed with 100 μl E. coli BL21 condonplus(DE3)-RIL competent 
cells for transformation. After heat shock at 42°C for 30 s, the cells were incubated for 1 
h at 37°C. The cells (200 μl) were spread on LB-Agar plates and grown overnight as 
single colonies. One of these single colonies was grown overnight in 5 ml LB media with 
appropriate antibiotics. This 5 ml culture was transferred to a flask containing 2 L LB 
media and grown at 37°C until the O.D. at 600 nm was between 0.6 and 0.8 (for PTEN 
the O.D.600nm was around 0.9). IPTG at 0.1 mM (for PTEN) or 0.8 mM (for IMPase) was 
added to induce protein overexpression. After 20 h incubation at 16°C, the cells were 
harvested by centrifugation and stored at -20°C. 
2.2.6 Protein purification 
2.2.6.1 PTEN purification 
The frozen cells from 2 L culture were resuspended in 45 ml lysis buffer (50 mM Tris, 
300 mM NaCl, 10 mM imidazole, 10 mM β-mecaptoethanol, pH 8, stored at 4°C) and 
incubated on ice for 30 min. The cells were lysed using 15×20 s sonication cycles. After 
centrifugation at 15,000 rpm for 35 min, the cell debris was removed and the supernatant 
was loaded at 0.5 ml/min and 4°C onto a column with 7.5 ml Ni-NTA agarose slurry pre-
equilibrated with 100 ml lysis buffer. After loading, the column was washed with 150 ml 
lysis buffer at 1.5 ml/min and 350 ml wash buffer (50 mM Tris, 300 mM NaCl, 20 mM 
imidazole, 10 mM β-mecaptoethanol, pH 8, pre-cooled to 4°C) at 2 ml/min to remove 
any contaminating proteins bound on the resin. After the wash step, the protein was 
eluted with a gradient formed from 75 ml each of 20 and 250 mM imidazole in 50 mM 
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Tris, 300 mM NaCl and 10 mM β-mecaptoethanol. The purity of the eluted fractions was 
monitored by SDS-PAGE and fractions >90% pure were pooled and dialyzed overnight 
at 4oC against 4 L of 50 mM Tris, 1 mM DTT, pH 8. After dialysis, the protein was 
concentrated to ~4 mg/ml. The protein concentration was measured by UV absorbance at 
280 nm with ε = 45,270 M-1 cm-1. Protein aliquots were flash frozen in liquid nitrogen 
and stored at -80°C. Once the protein was thawed, it was kept at 4°C and used within 3 
days.  
For purifying the C-terminal His-Tag PTEN protein, a gel filtration column was used 
after initial purification with the Ni-NTA affinity column. The protein was eluted in 50 
mM Tris pH 8, 100 mM NaCl and 10 mM β-mecaptoethanol buffer. After gel filtration, 
the fractions containing the protein (monitored by SDS-PAGE) were collected. The 
protein was dialyzed against 100 mM Tris, 1 mM DTT, pH 8, and stored at -80°C.  
2.2.6.2 Archaeoglobus fulgidus inositol monophosphatase  (IMPase) purification 
Cell pellets from 2 L culture were resuspended into 30 ml buffer A (50 mM Tris, 1 mM 
EDTA), sonicated with 10×30 s pulses, and centrifuged for 30 min at 15,000 rpm to 
remove insoluble cell debris. After centrifugation, the supernatant was heated (85°C for 
wild type, 65°C for R11A/R18A and R11A/R18A/R92Q/K164E, and 75°C for other 
mutants) for 30 min to denature most of the E. coli protein. Denatured E. coli proteins 
were removed by centrifugation at 15,000 rpm for 45 min. The supernatant was dialyzed 
against 4 L buffer A overnight. The dialyzed cell lysates were loaded at 1.5 ml/min onto 
the QFF resin column (~40ml) equilibrated with 200 ml buffer A. After loading, the 
column was washed with 40 ml buffer A, and the protein was eluted with a gradient of 0 
to 0.6 M KCl in buffer A. The fractions containing >90% pure protein (determined by 
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SDS-PAGE) were collected and dialyzed twice against 4 L buffer A to remove salts. 
After dialysis, the protein was concentrated to ~10 mg/ml, and stored at 4°C. The protein 
concentration was measured by Lowry assay (Lowry et al, 1951). 
2.2.7 Large unilamellar vesicles (LUVs) and small unilamerllar vesicles (SUVs) 
preparation 
Desired amounts of lipids in chloroform were mixed together in a 20 ml scintillation 
glass vial. The organic solvent was removed under a stream of nitrogen and the lipids 
were dried by lyophilization overnight. The dry lipid film was suspended in 50 mM Tris, 
pH 8.0, and vortexed. The multilamellar vesicles that formed spontaneously were 
extruded through a 0.1 μm polycarbonate membrane 25 times to form LUVs (1000 Å 
average diameter). For SUVs, the resuspended solution of the lipids was put on ice and 
sonicated with 30 s on and 30 s off cycles until the solution was clear; these have an 
average diameter 250-300 Å. 
2.2.8 Phosphatase assays  
Enzyme activities of PTEN and IMPase were determined by measuring the concentration 
of the inorganic phosphate (Pi) using a colorimetric malachite green assay (Itaya & Ui, 
1966). 0.05% (w/v) malachite green oxalate in water was mixed with 4.2% ammonium 
molybdate in 6 M HCl at a ratio of 3:1 and incubated for 30 min prior to use. KH2PO4 
was used as the standard: 2, 5, 10, 15 and 20 μl of 1 mM KH2PO4 were mixed with 50 or 
200 μl 50 mM Tris, pH 8.0. The malachite green reagent (1 ml) was added to each 
sample, and the absorbance at 660 nm was recorded. Absorbance versus Pi provided a 
standard curve for calculating the amount of Pi produced by enzyme dephosphorylation 
of different substrates (Figure 2.1). 
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Figure 2.1 Standard curve of phosphatase assay. The absorbance of different 
amounts of inorganic phosphate (Pi) in total 50 μl (♦) and 200 μl () 50mM Tris 
buffer (pH 8.0) was measured. The data were fitted in a liner equation and the 
correlation coefficient was shown. 
2.2.8.1 PTEN activity 
These assays were carried out in 50 mM Tris, pH 8.0, with 2 mM EDTA, 10 mM DTT, 
and substrates. For each reaction sample, PTEN was incubated with substrate for 20 or 40 
min at 37°C, then 1 ml malachite green reagent was added and the absorbance at 660 nm 
was recorded. The amount of enzyme added to each sample was chosen to obtain 5 to 20% 
substrate hydrolysis. In a ‘monomer’ assay system, 0.5 mM diC8PI(3)P or 0.1 mM 
diC8PI(3,4)P2 was used (the critical micelle concentration, or CMC, for each compound 
is > 0.5 mM). DiC8PI(4,5)P2 and diC7PC concentrations in the assays were one half or 
equal to that of the substrate. The ratio of Triton X-100 to short chain substrates was 4:1. 
A mixed micelle system was also used with long-chain phosphoinositides. DOPI(3,4)P2 
with or without DOPI(4,5)P2 was dissolved in Triton X-100 with a total phospholipid to 
detergent ratio of 1:4. For assays using vesicles, 5 mM total of DOPI(3,4)P2/POPC (5:95) 
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or DOPI(3,4)P2/DOPI(4,5)P2/POPC (5:5:90) LUVs were made. Enzyme assays used 1 
mM (total phospholipid) LUVs as the substrate. 
The effect of deoxy-diC8PI analogs on PTEN activity was tested using 0.1 mM 
dipalmitoyl-PI(3)P (D-diC16PI(3)P) as the substrate presented in either Triton X-100 
micelles or in LUVs with POPC. For the mixed micelle assay, the substrate was mixed 
with Triton X-100 at a molar ratio of 1:4 D-diC16PI(3)P/Triton X-100 dissolved in 100 
mM Tris-HCl, pH 8.0. For the vesicle system, POPC was mixed with D-diC16PI(3)P at a 
molar ratio of 9:1 to form LUVs with 1 mM total phospholipid as the substrate. Both 
types of assays were carried out in 200 μL buffer (100 mM Tris-HCl, pH 8.0, 2 mM 
EDTA, 10 mM DTT) at 37°C for 20-40 min incubation with the enzyme. Most of the 
assays were done at least in duplicate. The effect of deoxy-diC8PI derivatives was 
measured by mixing the desired concentration of deoxy-diC8PI derivatives (0.1 mM, 0.5 
mM and 1 mM) with the substrates and measuring the amount of Pi produced as 
described above.  
2.2.8.2 A. fulgidus IMPase activity and compatible solute thermoprotection effect 
The activity of recombinant A. fulgidus IMPase was measured at 85°C. Typically, 0.2 μg 
of protein was added to 0.5 mM D-I-1-P in 50 μl of 50 mM Tris, 1 mM EDTA, 5 mM 
MgCl2, pH 8.0. The mixture was heated at 85°C for 5 min then placed on ice to cool to 
room temperature. 1 ml of malachite green reagent was added and the absorbance at 660 
nm was measured.  
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2.2.8.2.1 DIP and compatible solutes thermoprotection at 95°C 
Recombinant A. fulgidus IMPase, in 50 mM Tris HCl, pH 8.0, was placed in 200 μl PCR 
tubes to which different compatible solutes (DIP, KCl, NaCl, K+-glutamate or Na+-
glutamate) were added. The total volume was 50 μl, and the final concentration of protein 
was 52 μg/ml. Each solution was heated at 95°C in the PCR amplifier (GeneAmp PCR 
System 9700, PE Applied Biosystems). After 15 min, the samples were removed and 
placed on ice prior to measuring residual catalytic activity. The activity of the protein 
after heating with or without the compatible solutes was measured by adding aliquots of 
the protein from each sample to the substrate buffer. The residual activity was calculated 
by comparing the specific activity from each assay to what was observed with proteins 
without heating inactivation in the absence of any thermoprotective agents. 
2.2.8.2.2 Compatible solute thermoprotection at 90°C 
IMPase (9.6 μg) was mixed with 0, 0.05, 0.1, 0.3 and 0.5 M compatible solutes (KCl, K-
Glu, Na-Glu, K-Asp, Na-Asp, proline and betaine) in 50 mM Tris, pH 8.0, and heated at 
90°C in the PCR amplifier for 30 min. An aliquot of the heated mixture was removed for 
measurement of the residual activity compared to untreated enzyme. As another control, 
the same amount of the each solute was mixed with the untreated enzyme to account for 
any effect of the solute on enzyme activity. The amount of enzyme added was adjusted to 
generate 5% to 20% substrate hydrolysis. 
The thermoprotection of IMPase by dicarboxylate salts was also tested. IMPase (7.6 μg) 
was mixed with 0.3 M of tartrate, succinate, methylsuccinate, maleate, fumarate and 
isocitrate (in sodium form) in 50 mM Tris, pH 8.0, and heated at 90°C for 30 min. The 
residual activity was measured at 85°C with 0.5 mM D-I-1-P as the substrate. 
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2.2.8.2.3 DGP thermoprotection of IMPase  
In the synthesis of DGP, there is some contaminating Pi that was not completely removed. 
While irrelevant if DGP is used at mM concentrations, it makes the background in the Pi 
assay too high to detect signal if high concentrations of DGP are used. Therefore, a 
different assay and substrate were used. Cleavage of pNPP by IMPase generates PI and 
p-nitrophenol, which has a strong yellow absorbance at 405 nm. Assay mixtures 
consisted of  2 μg of IMPase and 0.5 mM pNPP in 50 mM Tris, 1 mM EDTA, 5 mM 
MgCl2, pH 8.0. The reaction was carried out at 85°C for 5 min. The reaction mixture was 
then placed on ice, and 1 ml of 3 M NaOH was added to quench the reaction. Absorbance 
at 405 nm was recorded to calculate the amount of p-nitrophenol produced using 
ε=1.78x104 M-1 cm-1. 
For inactivation of the protein, 19.2 μg of IMPase was mixed with 10 or 100 mM DGP in 
50 mM Tris, pH 8.0, and heated in PCR tubes at 90°C for 30 min. The residual activity 
was measured by adding the aliquots of the heated protein into pNPP substrate buffer and 
measuring the activity as described above. The control protein activity was measured by 
mixing the same amount of DGP solution with the protein without heating.  
2.2.8.2.4 IMPase mutant thermoprotection by compatible solutes 
The enzyme activity of specifically mutated proteins and the residual activity after 
heating these variants were measured as for recombinant IMPase but with minor changes 
to account for altered thermostability. The activity and extent of thermoprotection of 
R11A/R18A and the quad-mutant were measured at 55oC with 0.5 mM FBP as the 
substrate. For thermal denaturation, R11A/R18A was heated for 30 min at 73°C, and the 
quad-mutant was heated for 30 min at 71°C. The activity and residual activity after 
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heating of R18A and R29A were measured at 75°C with 0.5 mM D-I-1-P as the substrate. 
R18A was heated for 26 min at 87°C, while R29A was incubated at 85°C for 30 min. The 
activities of R92Q and R92Q/K164E were measured at 65°C with 0.5 mM D-I-1-P as the 
substrate; for thermal denaturation, R92Q was heated at 80°C for 26 min and 
R92Q/K164E was heated at 77°C for 25 min. 
2.2.9 Fixed field 31P NMR spectroscopy 
The binding of PTEN to phospholipids was investigated by measuring the phospholipid 
phosphodiester peak linewidth change in the presence of the PTEN protein.  31P NMR 
spectra of phospholipids were obtained at 242.7 MHz on a Varian 600 MHz VNMRS 
system at 25°C. Short-chain phospholipid solutions (diC8PI, diC8PIPx, diC7PC) in 100 
mM Tris, 2 mM EDTA, pH 8.0, were placed in 5 mm Shigemi tubes. PTEN, wild type or 
mutated protein, was added to the lipid mixture to a final concentration of 0.5 mg/ml 
(10.1 µM). The peak width at half height (Δν1/2) was measured, and the linewidth 
difference ΔΔν1/2 was calculated by subtraction of the linewidth for lipid alone from the 
linewidth when protein was present (ΔΔν1/2 = Δν1/2, lipid, protein - Δν1/2, lipid). 31P spectra were 
acquired for every lipid concentration at least in duplicate to obtain an average change in 
linewidth caused by addition of the protein.  
2.2.10 High-resolution field cycling NMR 
Field cycling NMR was used to study the spin-labeled PTEN protein proximity to bound 
phospholipid headgroups, and the binding of 13C labeled Glu to spin-labeled IMPase. 
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2.2.10.1 PTEN 31P field cycling NMR  
2.2.10.1.1 Spin-labeling PTEN  
Prior to labeling of PTEN cysteine groups, the protein (4 mg/ml protein solution in 100 
mM Tris, pH 8.0) was incubated for 30 min with 10 mM DTT to reduce any disulfide 
bonds that had formed. The protein was then exchanged into 20 mM Tris, pH 7.5, and 
excess DTT was removed using a micro bio-spin 6 column. MTSL, from a 20 mg/ml 
stock in acetone, was added to the protein solution at a ratio of protein: MTSL = 1:4 
based on the PTEN concentration prior to the spin column (on which about half the 
protein is typically lost). The incubation time, 1 h for PTEN and 1.5 h for K13E, was 
chosen so that >90% of the PTEN activity was lost. Unreacted MTSL was removed by 
two spin columns which also served to exchange the protein back into 100 mM Tris, pH 
8.0.  
Unmodified cysteine residues were measured using DTNB (Ellman, 1959), by comparing 
the spin-labeled preparation to unlabeled PTEN. Each protein (10 µg) was incubated with 
500 µmol DTNB in 50 mM Tris, pH 8 (total volume 200 µl) for 15 min. The absorbance 
at 412 nm was used to calculate the free cysteine concentration (ε=13,600 M-1 cm-1). The 
labeling ratio was calculated by [Cys]free, PTEN-SL / [Cys]free, PTEN-WT ×10, since PTEN has a 
total of 10 Cys residues, 
2.2.10.1.2 Mass spectrometry (MS) detection of modification sites of spin-labeled PTEN 
MS was used to monitor the extent of MTSL modification of the 10 cysteines on PTEN. 
The protein (10 µg), before or after spin-labeling, in 50 mM Tris, pH 8.5, was incubated 
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in 8 M urea for 30 min. The sample was then diluted 8-fold with 50 mM Tris, pH 8.5, and 
mixed with LysC endoproteinase (Wako) added in a ratio of 1:50 (w/w) LysC / PTEN. 
After overnight digestion at 37oC, the peptide mixture was desalted on a C18 spin column, 
dried in a speedvac concentrator (Thermo Scientific) and resuspended in 10 µL Buffer A 
(95% water, 5% acetonitrile, 0.1% formic acid). LC-MS/MS analysis was performed on 
an LTQ-Orbitrap Discovery mass spectrometer (Thermo Fisher) coupled to an Agilent 
1200 series HPLC system. The LysC digest was pressure loaded onto a 100 µm fused 
silica column (100 µm fused silica with a 5 µm tip) packed with 10 cm of Aqua C18 
reverse phase resin (Phenomenex). The peptides were then eluted from the column using 
a 120 minute gradient of 5–100% buffer B in buffer A (buffer A: 95% water, 5% 
acetonitrile, 0.1% formic acid; buffer B: 20% water, 80% acetonitrile, 0.1% formic acid), 
and injected into the mass spectrometer. The flow rate through the column was set to 
~0.25 µl/min and the spray voltage was set to 2.75 kV. One full MS scan (FTMS) (400–
1,800 MW) was followed by 7 data dependent scans (ITMS) of the nth most intense ions 
with dynamic exclusion enabled. The tandem MS data were searched using the 
SEQUEST algorithm (Yates et al, 1995) using a concatenated target/decoy variant of the 
human International Protein Index database. A differential modification of +185.0874 on 
cysteine was specified to account for the MTSL modification. SEQUEST output files 
were filtered using DTASelect 2.0 (Tabb et al, 2002). Discriminant analyses were 
performed to achieve a peptide false-positive rate below 5%. (Mass spectrometry and 
peptide identification were kindly done by Prof. Eranthie Weerapana, Boston College). 
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2.2.10.1.3 High resolution field cycling 31P NMR  
31P field-cycling spin-lattice relaxation rate (R1) measurements were made at 20oC on a 
Varian Unityplus 500 spectrometer using a standard 10-mm Varian probe in a custom-built 
device that moves the sample, from the sample probe location to a higher position within, 
or just above, the magnet, where the magnetic field is between 0.04 and 11.7 T. Lower 
fields are accessed by shuttling the sample to the middle of a permanent magnet 
(mounted on the top of the magnet dewar) that can be tuned down to 0.002 T (Roberts & 
Redfield, 2004a). Concentrations of the phosphorus-containing ligands were usually 3 
mM for phosphoinositides, 5 mM for diC7PC, and 5 mM for inositol phosphates. Spin-
labeled protein concentration was usually 0.1 mg/ml (2.0 µM) for diC8PI samples and 
0.25 mg/ml (4.9 µM) for other ligands. The sample buffer was 100 mM Tris, pH 8.0, 
with 2 mM EDTA. Controls used the same concentration of phospholipids but with 0.1 or 
0.25 mg/ml PTEN without spin-labeling. The contribution of unlabeled protein binding to 
the field dependence of different phospholipids was used to calculate the change in 
relaxation rate due to the spin-labeled protein: ΔR1 = R1, spin-label – R1, control. The data were 
fit to the following equation: 
 ΔR1 = ΔRP-e (0) / (1+ωp2τP-e2) + c 
where ΔRP-e (0) is the low-field limit of ΔR1. ωp is the angular frequency of 31P, τP-e is the 
correlation time of the dipolar relaxation of 31P by nearby nitroxide unpaired electrons. 
The ‘c’ term represents a limiting CSA contribution due to the paramagnetic interaction. 
If the protein contains a single spin-label, the average distance rP-e between abound 
phospholipid phosphorus and the unpaired electron of the spin-labeled proteins can be 
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extracted from the parameters ΔRP-e (0) and τP-e along with the concentration of the 
protein and phospholipid, [PTEN-SL] and [PL]: 
 rP-e6 = ([PTEN-SL]/ [PL]) (S2 τP-e)[0.3μ2(h/2π)2γP2 γe2]/ ΔRP-e (0) 
However, when more than one cysteine bears a spin-label the relaxation will be an 
average of the different label positions. Although exact distances are not easy to extract, 
it is possible to compare the effectiveness of the multiply-labeled protein in relaxing the 
31P of different molecules. If the lipids occupy discrete and different sites, then one 
should see differences in the ratio (τP-e/ΔRP-e(0)) × [PTEN-SL]/[PL]. 
2.2.10.2 A. fulgidus IMPase field cycling 13C NMR   
2.2.10.2.1 Spin-labeling IMPase 
Recombinant IMPase (or R92Q/K164E protein) at 10 mg/ml was incubated with 1 mM 
DTT for 30 min to reduce any disulfide bonds. Excess DTT was removed and the protein 
was buffer exchanged into 25 mM Tris, pH 7.5, using a micro bio-spin 6 column (Bio-
Rad). The protein was mixed with the 10 mg/ml MTSL stock, at a molar ratio of 1:10 
protein/MTSL and incubated at room temperature for 2 h. After incubation, free MTSL 
was removed by 2 successive spin columns, which also served to exchange the buffer to 
50 mM Tris, pH 8.0. The protein concentration after spin-labeling was measured by 
Lowry assay. 
2.2.10.2.2 High resolution field cycling 13C NMR 
10 mM or 25 mM 13C-Glu or 13C-Ala (pH 8.0) was mixed with 3 mg/ml of spin labeled 
IMPase. The 13C field cycling NMR spin-lattice relaxation rate (R1) measurements were 
carried out at 25°C and 45°C on a Varian Unityplus 500 spectrometer with the sample 
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shuttling mechanism and accessible magnetic fields as described above for 31P field 
cycling. R1 measurements at high compatible solute concentrations used 25 mM of 13C-
Glu with non-isotopically enriched Glu to yield a total solute concentration of 40 and 75 
mM; the spin-labeled protein concentration was 3 mg/ml. The contribution of unlabeled 
protein binding to the field dependence of different salts was measured but was usually 
minimal, except at the lowest concentration of 13C-Glu used (where binding is very low 
and the enhancement of the relaxation rate is small). Here, the relaxation rate due to the 
spin-labeled protein is ΔR1 = R1, spin-label – R1, control. The data were fit to the following 
equation: 
 ΔR1 = ΔRC-e (0) / (1+ωC2τC-e2) + a 
where ΔRC-e (0) is the low-field limit of ΔR1. ωp is the angular frequency of 13C, τC-e is 
the correlation time of the dipolar relaxation of 13C by nearby nitroxide unpaired 
electrons. Again, the ‘a’ term represents a limiting CSA contribution due to the 
paramagnetic interaction. 
2.2.11 Circular dichroism  
CD spectra of proteins were recorded in a 1 cm path length quartz cuvette with 0.04 
mg/ml protein in 10 mM borate buffer, pH 8.0, using an Aviv 420 circular dichroism 
spectrometer (Biomedical Inc.). Protein ellipticity was scanned from 290 to 180 nm with 
the solution at 25°C. The thermal melting (or denaturation) temperature (Tm) of proteins 
was monitored by measuring the ellipticity at 222 nm (where only helices contribute to 
the ellipticity) as the sample temperature was increased from 30°C to 99°C. The Tm is the 
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temperature at which the derivative of ellipticity with temperature is a maximum (Figure 
2.2 provides an example of a denaturation curve for IMPase R92Q/K164E).  
 
Figure 2.2 0.04 mg/ml A. fulgidus IMPase R92Q/K164E ellipticity change (solid line) 
at 222 nm upon heating measured with circular dichroism (CD) spectrometry. The 
derivative of ellipticity is calculated (dash line). The temperature at which the 
derivate is maximal is the Tm. 
2.2.12 Fluorescence spectroscopy 
Binding of PTEN to the LUVs was measured by Förster resonance energy transfer 
(FRET) fluorescence spectroscopy. 2% Dansyl-PE containing vesicles were used as the 
acceptor and Trp residues in PTEN were the donor. The fluorescence spectra of 1.5 or 3 
μM PTEN protein in 100 mM Tris, pH 8 containing 2 mM EDTA, 10 mM DTT and 150 
mM NaCl were recorded using a Fluorolog R-3 spectrofluorometer. The protein was 
excited at 290 nm, and the fluorescence spectra were recorded between 300 and 400 nm. 
A maximum intensity around 340 nm was recorded. Next 2% Dansyl-PE containing 
vesicles were added into the protein solution to cover the concentration range from 0 to 2 
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mM total lipid; the total lipid concentration was incremented in 0.2 mM steps. The 
vesicles used were 88:2:10 POPC/Dansyl-PE/PL (where PL = POPC, DOPS, DOPA, soy 
PI or brain PI(4,5)P2), 25:2:73 DOPS/Dansyl-PE/ POPC, and 10:5:2:83 DOPS/ PI(4,5)P2/ 
Dansyl-PE/POPC. The fluorescence intensity change upon the addition of Dansyl-PE 
containing vesicles was corrected by subtracting the intensity change caused by titrating 
in vesicles without the fluorophore; a small dilution correction was also used. The 
apparent dissociation constant (Kd) was calculated by fitting the fluorescence intensity 
data into the equation: fbound= c×[phospholipid]/(Kd + [phospholipid]) where 
[phospholipid]is the total concentration of the phospholipids in the vesicles, fbound is the 
fraction bound. It is calculated from ΔIcorr/I0 where ΔIcorr is the corrected intensity change 
and I0 is the initial intensity before the lipid added. However, the maximum FRET change 
in donor fluorescence is not necessarily known so the ‘fbound’ estimated this way is not a 
true fraction of protein bound but proportional to it. In the fitting, c is a constant that is 
proportional to the maximum protein bound. 
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Chapter 3  
 
Exploring phospholipid binding sites  
on PTEN 
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3.1 Introduction 
Deoxy-diC8PI derivatives with one or more hydroxyl groups on the inositol head group 
removed are analogs of PTEN substrate, diC8PI(3)P. The structures of these synthetic PI 
compounds, synthesized by Yingju Xu in the laboratory of Prof Scott Miller when he was 
at Boston College, are shown in Figure 3.1. The effect of these PI derivatives on PTEN 
enzymatic activity was tested (Wang et al, 2008); all these deoxy-PI derivatives were 
inhibitory to PTEN when substrate diC8PI(3)P was used at 0.5 mM. However, there were 
some interesting trends in the inhibition effects. Generally, the D-series of deoxy-PI 
derivatives were more potent than their L-series counterparts, and D-3-deoxy-diC8PI was 
the most potent inhibitor. Removing another hydroxyl group from the inositol ring in D-
3-deoxy-diC8PI generated a less potent inhibitor, while this behavior was reversed in L-
series compounds. L-3,5-dideoxy-diC8PI was a considerably more potent PTEN inhibitor 
than L-3-deoxy-diC8PI (Wang et al, 2008). All of the deoxy-PI derivatives had similar 
critical micelle concentration (CMC) values around 0.5 mM. Thus, micelle formation 
could not explain the specificity of inhibition. The attempt to explain these kinetic results 
using the known crystal structure of PTEN also failed. The crystal structure of PTEN had 
a tartrate molecule in the active site (Lee et al, 1999). An I(1,3,4,5)P4 molecule, the head 
group of the substrate PI(3,4,5)P3, could be superimposed on the tartrate molecule. 
However, the lack of acyl chains (or even the glycerol backbone) made it difficult to 
understand how the lipid glycerol and acyl chains might interact with the protein. Head 
group hydrogen bonding to the protein and hydrophobic interaction between the acyl 
chain(s) and the protein could be the key to explaining how the deoxy-PI derivatives 
affected PTEN activity so differently.  
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Figure 3.1 The structures of the substrate dioctanoylphosphatidylinositol-3-
phosphate (diC8PI(3)P) and the six 3-deoxy-dioctanoylphosphatidylinositol (3-
deoxy-diC8PI) inhibitors. 
In order to provide an explanation of the inhibitor pattern for the deoxy-PI molecules, 
molecular dynamics (MD) simulation, quantum mechanical and free energy calculations 
were used to study the PTEN phosphatase domain interacting with deoxy-diC8PI 
derivatives and substrate diC8PI(3)P. The simulations and calculations were done by Dr. 
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Qin Wang in the laboratory of Prof. Goran Krilov (Wang et al, 2010). From the MD 
simulations, different binding modes were identified between the D- and L- series deoxy-
diC8PI derivatives and PTEN. The head group of all the six deoxy-PI derivatives and the 
substrate diC8PI(3)P bound into the active site, forming hydrogen bonds and salt bridge 
with the protein. Interestingly, the hydrogen bonding decreased as the inhibition potency 
increased. The poorest inhibitor, L-diC8PI, actually had the most favorable hydrogen 
bonding interaction between lipid head group and the protein (Figure 3.2). The most 
obvious difference was the orientation of the acyl tails of the D- and L- series lipids due 
to the different inositol chirality (Figure 3.3). In general, the acyl chains of D- series 
compounds had more contact with PTEN compared to their enantiomer. The one 
exception was L-3,5-dideoxy-diC8PI, which had more protein-tail interactions than its D-
inositol enantiomer. A hydrophobic cleft formed by the loop pβ2-α1 (residues 42-52) on 
the phosphatase domain was identified; the acyl chain of D-3-deoxy-diC8PI had the 
strongest hydrophobic contact with this region of the protein. The interaction between the 
pβ2-α1 loop and the acyl chain was also observed in the energy minimized structure of 
substrate D-diC8PI(3)P binding to PTEN. L-3,5-dideoxy-diC8PI also had a large number 
of acyl tail-protein contacts, but these contacts were from the residues on the opposite 
side of the active site instead of the pβ2-α1 hydrophobic cleft. L-3,5-dideoxy-diC8PI was 
almost as potent an inhibitor as D-3-deoxy-diC8PI, which had a smaller number of 
hydrogen bonds of the head group to PTEN. For D-3-deoxy-diC8PI to be the most potent 
PTEN inhibitor, the loss in hydrogen bonding interactions was compensated by a greater 
hydrophobic contact of the acyl chain with the protein. 
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Figure 3.2 Median structures of the PTEN phosphatase domain complexes with 
compounds 2 (D-3-deoxy-diC8PI), 3 (L-3,5-dideoxy-diC8PI) and 5 (L-diC8PI), and 
the substrate S (D-diC8PI(3)P), obtained by clustering configurations collected from 
a 2 ns MD simulation. The lipids (green) and adjacent protein residues are shown as 
sticks and the protein backbone as ribbons. Important lipid-protein hydrogen bonds 
are shown as dark blue dashed lines. Note the difference in tail orientation between 
the D-series (2 and S) and L-series (3 and 5) PI derivatives (Wang et al, 2010). 
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Figure 3.3 Representative snapshots of the conformations of compound 2 (left, D-3-
deoxy-diC8PI) and compound 5 (right, L-3,5-dideoxy-diC8PI) bound to the active 
site of the PTEN phosphatase domain from a 2 ns MD simulation. The lipids are 
shown as sticks, while the accessible protein surface is shown in tan. The difference 
of the lipid tail flexibility in the two complexes is clearly visible (Wang et al, 2010). 
The MD simulations explained the inhibition trend of PTEN by monomeric deoxy-diC8PI 
derivatives. A key feature of the simulations was that there is a different balance of 
hydrophilic and hydrophobic interactions for the different deoxy-PI compounds binding 
to PTEN. My contribution to this work was to test the importance of the hydrophobic 
pocket formed by the pβ2-α1 loop for interactions with the substrates and soluble 
dioctanoyl-PI inhibitors. Enzyme kinetics were measured using long chain dipalmitoyl-
PI(3)P as the substrate and solubilizing it with the detergent Triton X-100 in mixed 
micelles or with 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC) presented in large 
unilamellar vesicles (LUVs). In both these substrate aggregates, the hydrophobic chains 
were not, on average, located at the surface, and not likely to be accessible to PTEN. The 
prediction was that the inhibition potency of the different diC8PI molecules would vary 
so that only the interactions of the polar headgroup would dominate PTEN inhibition. 
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Mutations of key residues in the hydrophobic pocket were also generated in order to 
investigate the importance of this pocket in processing substrate 
3.2 Results 
3.2.1 Effect of deoxy-PI derivatives in substrate micelles on PTEN activity 
Previously the effect of the deoxy-diC8PI compounds was assayed with substrate 
diC8PI(3)P at 0.5 mM (Wang et al, 2008). At this concentration, substrates existed as 
mostly monomers with some small micelles. The inhibition efficiency of the deoxy-PI 
derivatives could change if the substrate was present as mostly micelles, since the 
substrate acyl chains would not be accessible for interaction with PTEN. In the mixed 
micelle assay system (0.1 mM dipalmitoyl-PI(3)P and 0.4 mM TX-100), the large excess 
of detergent may have two effects. It can enhance solubilization of the deoxy-diC8PI 
compounds in micelles, particularly as the inhibitor CMC is approached. However, at low 
concentrations where the inhibitor is likely to exist as a monomer, the detergent 
molecules (Triton X-100 has a CMC ~0.2 mM) may bind to the protein in the 
hydrophobic regions suggested by the simulations to harbor the deoxy-PI acyl chains. In 
either of these cases, the remaining driving force for the short-chain PI derivatives 
binding to PTEN would be the polar interactions of the inositol ring. As shown in Figure 
3.4A, the deoxy-PI compounds tested had little inhibition of PTEN hydrolysis of 0.1 mM 
dipalmitoyl-PI(3)P, even at concentrations above the CMC of most of the diC8PI 
compounds. Only L-diC8PI appeared to be a significant inhibitor. In the structures 
obtained in the simulations, L-diC8PI also appeared to form the strongest hydrogen 
bonding network with residues in the PTEN active site (Wang et al, 2010). The best 
inhibitor in assays with monomeric substrate D-diC8PI(3)P was D-3-deoxy-diC8PI. 
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However, this compound had the least interactions of the inositol ring with PTEN. It is 
not an inhibitor in the mixed micelle assay system, consistent with hydrophobic 
interactions as the dominant force in the binding of D-3-deoxy-diC8PI to PTEN. 
3.2.2 Effect of deoxy-PI derivatives on PTEN activity towards substrate in vesicles 
In contrast to the mixed micelles, PI/PC vesicles are unlikely to present any acyl chain 
moieties for interaction with PTEN. As long as the diC8PI compound is below its CMC, 
it is likely to exist as mostly monomer (Wang et al, 2008). Thus, the most potent inhibitor 
should be D-3-deoxy-diC8PI as seen with the original assays using D-diC8PI(3)P as the 
substrate (Wang et al, 2008). This is, in fact, what is observed (Figure 3.4). However, at 
the inhibitor CMC and higher concentrations, all the short-chain compounds will be 
mixed with the vesicles and all are likely to compete with substrate for binding to PTEN. 
As observed, at 0.5 mM or higher concentration of diC8PI compound, all the molecules 
are inhibitory in this vesicle assay system.  
Comparison of the inhibition efficiency of D-3-deoxy-diC8PI in micelle and vesicle assay 
systems can provide more information about what binds to PTEN. At 0.1 mM, D-3-
deoxy-diC8PI caused 40% inhibition of PTEN (60% residual activity left) activity in the 
PI/PC vesicle assay system, but no inhibition by this molecule was detected in the 
PI/Triton X-100 micelle system. This significant difference in the inhibitory potency of 
D-3-deoxy-diC8PI provided evidence that Triton molecules can bind into the novel 
hydrophobic pocket identified by the simulations. Since potency of D-3-deoxy-diC8PI 
depends on binding of its acyl chains to the hydrophobic site, occupation of this site by 
the detergent (which should have no affinity for the inositol binding site) should reduce 
inhibition by that deoxy-PI compound. This information was very useful since it provided 
 86 
 
a way to investigate the role of the hydrophobic pocket by studying how detergents alter 
PTEN kinetics with different substrates and inhibitors.  
 
Figure 3.4 Effect of different concentrations of diC8PI compounds on PTEN-
catalyzed hydrolysis of 0.1 mM dipalmitoyl-PI(3)P in (A) 0.4 mM Triton X-100 
micelles or (B) unilamellar vesicles with 0.9 mM POPC: ●, D-3-deoxy-diC8PI; ○, L-
3-deoxy-diC8PI; ■, D-diC8PI; □, L-diC8PI; ∆, L-3,5-dideoxy-diC8PI. 
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3.2.3 Mutations in hydrophobic site: kinetics of Arg47 mutants 
One of the unexpected features of the MD simulations was the hydrophobic site formed 
by the loop containing Arg47. This region was suggested to be a major part of stabilizing 
the binding of D-diC8PI derivatives and not the L-enantiomers. We chose to mutate 
Arg47 to probe the importance of this residue for enzyme activity. It has two features that 
may be relevant to PTEN activity: (i) a positive charge, and (ii) a large and hydrophobic 
side chain, at least until the guanidino group, which appeared to be involved in 
interacting with the octanoyl- chains of the inhibitors (and the substrate). Characterization 
of the kinetics of the mutant proteins in different substrate assay systems should reveal 
the importance of this site for substrate and D-enantiomer ligand binding. 
Arg47 was mutated to four different residues: R47G, R47K, R47L and R47W. The 
proteins expressed moderately well (at least to the extent of wild type PTEN). CD spectra 
of the mutants as well as the wild type protein were recorded and compared (Figure 3.5). 
There was no significant difference in the secondary structures of the mutant and wild 
type proteins. D-diC8PI(3)P, at 0.5 mM where the molecule alone is mostly monomeric, 
was first used as the substrate to test the effect of the mutation on protein activity. As 
shown in Table 3.1, whether Arg47 is replaced with a glycine, a lysine or a hydrophobic 
residue, the enzyme specific activity towards D-diC8PI(3)P decreased significantly. 
R47W was the worst enzyme (3000-fold lower specific activity), presumably because of 
the bulky and inflexible nature of the tryptophan side chain. The low activity for the 
R47K enzyme was particularly surprising, since the lysine side chain has both the 
hydrophobic chain (although now larger) and positive charge of the arginine side chain. 
There were no differences in the far UV CD spectra indicating that the bulk of the mutant 
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protein is as folded as normal recombinant PTEN. We cannot easily increase substrate 
concentration since the aggregation of D-diC8PI(3)P is likely to complicate kinetics. 
However, these results clearly showed that the interaction of the side chains from this 
loop region really do contribute to correct substrate binding and catalysis. 
 
Figure 3.5 CD spectra of 0.04 mg/ml wild type PTEN (solid line) and PTEN R47K 
(dashed lind) in 1 ml 0.01 M borate, pH8.0. 
Table 3.1 Relative activity of Arg47 mutants compared to wild type PTEN 
 diC8PI(3)P 
0.5 mMa 
diC16PI(3)P/ 
TX100 (1:4)b 
diC16PI(3)P/ 
POPC (1:9)c 
diC8PI(3,4)P2 
0.1 mMd 
DOPI(3,4)P2/ 
POPC (1:19)e 
R47G 0.040 0.049 0.063 0.019 0.23 
R47W 0.010 0.015 0.052 N.D. N.D. 
R47L 0.014 0.041 0.24 N.D. N.D. 
R47K 0.006 0.018 0.28 0.12 0.29 
i) The specific activities of wild type PTEN toward each substrate are (a) 14.2±0.4, (b) 11.5±0.7, 
(c) 0.27±0.03, (d) 45±4 and (e) 0.59±0.02 nmol/mg/min. 
ii) The concentrations of diC16PI(3)P in (b) is 0.1 mM. 
iii) The total phospholipid concentrations in (c) and (e) are both 1 mM. 
iv) Most of the mutants activities were measured in duplicates with errors less than 20%. 
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The activities of the Arg47 mutants towards diC16PI(3)P in detergent micelles and 
diC16PI(3)P in mixed vesicles with POPC vesicles were also measured (Table 3.1). Again, 
all of the mutants had lower activity than wild type PTEN. R47W always exhibited the 
lowest activity, consistent with what was observed in the diC8PI(3)P monomer assay 
system, suggesting the bulky side chain interferes with proper substrate binding. 
Interestingly, in the vesicle assay system, R47K and R47L had better activities than the 
other two mutants (Table 3.1), indicating a middle sized residue with some hydrophobic 
character is important for occupation of this hydrophobic pocket, possibly by maintaining 
the local structure of this pocket.  
The phosphatase activities of R47G and R47K toward PI(3,4)P2 were also tested both 
with monomer diC8PI(3,4)P2 and with vesicles of DOPI(3,4)P2/PC (Table 3.1). Similar to 
what we observed with diC8PI(3)P as the substrate, these two mutant PTENs had lower 
activity than wild type protein towards a multiply phosphorylated substrate. R47K had 
similar activity to that of R47G towards the PI(3,4)P2/PC vesicles but had higher activity 
toward diC8PI(3,4)P2 monomers. Given that the head group of PI(3,4)P2 has two 
phosphates that would form more hydrogen bonds when binding into the active site, the 
higher activity of R47K than R47G in diC8PI(3,4)P2 monomer assay systems suggested 
that the lysine side chain at residue 47 also provided some hydrophobic interaction for 
substrate binding.  
As a further test of the relevance of this hydrophobic site to PTEN activity, we examined 
the potency of L-3,5-dideoxy-diC8PI as an inhibitor of R47G. In the simulations, this 
fairly potent L-isomer does not exploit the region around Arg47 for anchoring its acyl 
chains (Wang et al, 2010). Adding 0.1 mM L-3,5-dideoxy-diC8PI to substrate diC8PI(3)P 
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(0.5 mM) reduced the specific activity of wild type PTEN to 0.73 of the value in the 
absence of the L-dideoxy-compound, confirming what was observed previously (Wang et 
al, 2008). The same assay conditions with R47G PTEN led to a more pronounced 
inhibition – the residual activity of R47G was 0.34±0.04 that in the absence of inhibitor. 
We can compare this extent of inhibition for R47G PTEN with the published curve for 
PTEN (Wang et al, 2008), where 0.5 mM L-3,5-dideoxy-diC8PI was needed to reduce 
enzyme activity to one third of the value for substrate alone. Thus, as predicted by the 
molecular dynamics, the L-isomer is a more potent inhibitor of PTEN when interactions 
of Arg47 with the D-isomer substrate are precluded, presumably because its acyl chains 
bind to a different site on the protein. 
3.3 Discussion 
An analysis of MD simulations explained the experimental results for changes in potency 
of deoxy-PI derivatives inhibiting PTEN and provided evidence for a hydrophobic pocket 
near (adjacent to) the active site of PTEN. This hydrophobic pocket was shown both by 
computer calculation and experiment to be important for phospholipid substrate 
hydrolysis and inhibitor binding. The findings from the MD simulations suggest that the 
lipophilic tails play a critical role in modulating the activity of the ligands. Kinetic data 
showing variations in activity across the deoxy-diC8PI derivatives in assay systems with 
the substrate presented in detergent micelles or vesicles support this interpretation. The 
hydrophobically driven tail protein association of the inhibitors would likely be masked 
by detergent monomers occupying the hydrophobic site on the protein. This explanation 
was confirmed by the fact that the weakest inhibitor in the monomer assay system (which 
happened to have the most headgroup interactions in the active site) became most potent 
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in a PI(3)P/Triton X-100 assay system. In contrast, the binding of the soluble inhibitor 
molecules to PTEN assayed in a vesicle system should be similar to what is seen with 
soluble substrates as long as the inhibitor is monomer. However, once it is above the 
CMC, it will insert into vesicles and directly compete with substrate and at slightly higher 
concentrations may convert vesicles to mixed micelles. This was observed for all the 
deoxy-PI derivatives when added to PTEN assays at concentrations above their CMC. 
The fact that L-series compounds with strong hydrogen bonding interactions are actually 
poor inhibitors suggested the strongly hydrophobic nature of acyl chain/protein 
interactions provide a significant contribution to the binding free energy. 
Arg47 in the hydrophobic pocket was found to be conserved in PTEN proteins among 
different species (Figure 3.6A). Also, this residue is conserved in some related human 
proteins (Figure 3.6B) including tensin, auxilin and PTEN-like proteins, TPTE 
(transmembrane phosphatase with tensin homolog) (Chen et al, 1999) and TPIP (TPTE 
and PTEN homologous inositol lipid phosphatase) (Walker et al, 2001). TPIP is a 
phosphoinositide 3-phosphatase, while TPTE does not dephosphorylate 
phosphoinositides. However, TPTE was found to be associated with the plasma 
membrane (Walker et al, 2001). Tensin binds to cytoplasmic tails of integrin via its PTB 
(phosphotyrosine binding) domain to link actin filaments to integrin (Lo, 2004). The 
PTEN-like domain in tensin 2 has the active site cysteine (similar to Cys124 in PTEN), 
and tensin 2 can regulate Akt signaling negatively (Hafizi et al, 2005). Auxilin is the 
cofactor of Hsc70 (heat shock cognate 70) and mediates the clathrin uncoating in 
clathrin-mediated endocytosis (Lemmon, 2001). The PTEN-like region in auxilin and its 
ubiquitous form GAK (cyclin G-associated kinase) binds to phosphoinositides (PI(3)P, 
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PI(4)P, PI(5)P and PI(3,4)P2) to recruit the auxilin to the clathrin-coated vesicles (Lee et 
al, 2006; Massol et al, 2006). So the conservation of R47 reflects the importance of this 
residue in maintaining the structure of PTEN and PTEN homologues for 
phosphoinositide binding.  The R47G mutation was detected from a patient with Cowden 
Syndrome (Marsh et al, 2001), also indicating the biological relevance of R47 in PTEN 
function. 
(A) 
Human 38 PA-ERLEGVYRNNIDDVVRFLDSKH-KNHYKIYNLCAERHYDTAKFNCR 
Mouse 38 PA-ERLEGVYRNNIDDVVRFLDSKH-KNHYKIYNLCAERHYDTAKFNCR 
Rat 38 PA-ERLEGVYRNNIDDVVRFLDSKH-KNHYKIYNLCAERHYDTAKFNCR 
D. melanogaster 45 PAPDKLEGLFRNRLEDVFKLLEENH-AQHYKIYNLCSERSYDVAKFRGR 
X. laevis 38 PA-ERLEGVYRNNIDDVVRFLDSKH-KNHYKIYNLCAERHYDTNKFSCR 
D.discoideum 38 PS-EKVEGVFRNPMKDVQRFLDQYH-KDHFKVYNLCSERVYDHSKFYGR 
C. elegans 82 PA-TGIEANFRNSKVQTQQFLTRRHGKGNVKVFNLRGGYYYDADNFDGN 
(B) 
PTEN 38 PA-ERLEGVYRNNIDDVVRFLDSKH-KNHYKIYNLCAERHYDTAKFNCR 
TPIP 123 PS-SGRQSFYRNPIEEVVRFLDKKH-RNHYRVYNLCSERAYDPKHFHNR 
TPTE 252 PS-SGRQSFYRNPIKEVVRFLDKKH-RNHYRVYNLCSERAYDPKHFHNR 
Auxilin 66 PL-DNVDIGFRNQVDDIRSFLDSRH-LDHYTVYNL-SPKSYRTAKFHSR 
Tensin 2 146 PA-RPDEQRHRGHLRELAHVLQSKH-RDKYLLFNLSEKRH-DLTRLNPK 
Figure 3.6 Protein sequence alignment of human PTEN (NP_000305) with (A) 
PTEN from mouse (NP_032986), rat (NP_113794), Drosophila melanogaster 
(NP_477423), Xenopus laevis (NP_001083831), Dictyostelium discoideum (XP_637576) 
and Caenorhabditis elegans (AAD21620.1), and with (B) human PTEN-like protein 
TPIP (NP_001135440), TPTE (NP_954870), tensin 2 (NP_733610) and auxilin 
(NP_001243794). The conserved arginine residues are in bold and shadowed. The 
number of the starting residue is also labeled. 
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R47G had the highest relative activity toward PI(3,4)P2 vesicles than with other 
substrates, presumably because in this case hydrogen bonding between the head group 
and the PTEN active site pocket dominated substrate binding. Two phosphates on the 
substrate headgroup provide stronger electrostatic contacts with the protein. An 
interesting observation was that R47K was relatively more active when using vesicles as 
the substrate. This suggested that the positive charge on the residue at the 47th position 
may help the protein bind to the membrane, possibly by nonspecific electrostatic 
interactions with negatively charged phospholipids in the vesicle. Besides providing 
hydrophobic interactions, Arg47 also contributes electrostatic interactions critical for 
substrate binding.  
To summarize, we demonstrated the existence of a hydrophobic site adjacent to the active 
site, first identified by MD simulation, that was important for substrate (and inhibitor) 
binding. This hydrophobic site works synergistically with the active site, presumably to 
provide correct orientation of the substrate. Mutation at this hydrophobic site impaired 
substrate binding and thus lowered the protein activity. 
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Chapter 4  
 
Binding of PI(4,5)P2 to an allosteric site  
in PTEN?  
NMR studies of PTEN/phospholipids 
interactions 
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4.1 Introduction 
The first evidence for PI(4,5)P2 activation of PTEN towards its substrates presented in 
vesicles was reported in 2003 (McConnachie et al, 2003). This research group explained 
the activation mechanism by postulating that substrate access was enhanced by 
incorporating the very anionic PI(4,5)P2 into substrate vesicles. This explanation was 
revised by the observation that PI(4,5)P2 monomers (dioctanoyl chains for the 
phosphoinositides) could also activate the protein when mixed with substrate monomers 
(Campbell et al, 2003). The PTEN N-terminus contains the conserved PI(4,5)P2 binding 
patch (NBP) K/R-X4-K/R-X-K/R-K/R (Maehama et al, 2001), and PI(4,5)P2 could bind 
at this site to induce the conformational change that leads to activation of the protein 
(Campbell et al, 2003). This allosteric mechanism was supported by the reports that 
mutation or deletion of this NBP eliminated the PI(4,5)P2 activation and caused a loss of 
PTEN function (Walker et al, 2004; Vazquez et al, 2006; Rahdar etal, 2009).  
PTEN can dephosphorylate PI(3,4,5)P3, PI(4,5)P2 and PI(3)P in vitro (Maehama et al, 
2001), although relative rates decrease with decreasing phosphorylation of the inositol 
ring. PI(4,5)P2 is the product of PI(3,4,5)P3 dephosphorylation. Previously, we 
demonstrated that diC8PI, the product of diC8PI(3)P hydrolysis, can inhibit the protein 
with a Ki that was 2-3 fold less than the Km for diC8PI(3)P (Wang et al, 2008). Given the 
similar structure and the same negative charge of PI(4,5)P2 and PI(3,4)P2, we assumed 
that under some conditions PI(4,5)P2 could also bind in the active site. This raises a 
question as to whether there is a discrete PI(4,5)P2 binding site other than active site.  
In order to demonstrate a distinct PI(4,5)P2 binding site, several methods, including 
FRET (Redfern et al, 2008) and surface plasma resonance (Das et al, 2003), have been 
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used to investigate PTEN or its C2 domain binding to phospholipid vesicles. However, 
these methods are based on the overall partitioning of the protein onto the phospholipid 
surfaces. Location of an individual lipid on the protein is harder to define and usually 
relies on mutants that show altered behavior. 
Besides using protein kinetics to access the binding behavior of PI(4,5)P2 and other 
phospholipids to PTEN, we used NMR methods to investigate the PTEN protein binding 
to phospholipids. In fixed field NMR studies, the NMR linewidth at half height (∆ν1/2) is 
proportional to the spin-spin relaxation rate of the nucleus. When a small phosphorylated 
molecule, in this case a short-chain phospholipid, forms a larger complex, i.e. binds 
reversibly to protein, the relaxation rate of the 31P should be the weighted average of the 
relaxation rate of the small free molecule and the larger relaxation rate of the bound 
lipid/protein complex. Thus, by measuring changes in the 31P linewidth with protein 
added, information on the binding process can be obtained. If the relaxation is mainly 
dipolar, information of potential distances of the 31P to nearby 1H may be obtained. 
However, for the phosphorus nucleus in phosphate esters, the relaxation mechanism at 
magnetic fields above 2 T is dominated by chemical shift anisotropy (CSA). CSA reflects 
electron asymmetry around a nucleus and this mode of relaxation increases with the 
square of the magnetic field, so at the high magnetic field of conventional NMR 
spectrometers, any linewidth changes are difficult to interpret. Nonetheless, changes in 
linewidth at fixed high magnetic field provide an empirical characterization of 
protein/ligand interactions. 
An alternate approach to obtaining and interpreting 31P relaxation is to use high 
resolution field cycling methods (Roberts & Redfield, 2004a; Roberts & Redfield, 2004b). 
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This method excites the phosphorus nuclei at the high magnetic field and then shuttles the 
sample up the bore of the magnet to a defined lower magnetic field for relaxation, in this 
case spin-lattice relaxation (R1). After an interaction time the sample is shuttled back 
down into the probe for read-out of the extent of relaxation. This allows one to measure 
the relaxation rate of the 31P as a function of magnetic field. The field dependence profile 
of R1 can be used to describe the different modes of relaxation mechanisms and the 
correlation times associated with them (Roberts & Redfield, 2004a). At low magnetic 
fields (< 2T), 31P relaxation is mainly from dipolar interactions – 31P with nearby 1H – 
and these can be intra- or intermolecular. If the phosphorylated ligand is exchanging 
between a free and protein-bound state, R1 is related to the ratio of the 31P nuclei bound 
state to free state, and the proximity of 31P to the proton dipoles that relax it (Pu et al, 
2009b; Pu et al, 2010). If a much larger dipole, such as an unpaired electron is near 31P, 
R1 is further enhanced and overwhelms 31P-1H interactions if the 31P and spin-label are 
within 20 Å. Relaxation theory applied to the field dependence profile then allows one to 
estimate rP-e, the averaged distance between the 31P and the unpaired electron when the 
phosphorylated molecule is bound to the protein. This methodology was first used to 
localize the site for a PC binding to a bacterial PI-specific phospholipase C (Pu et al, 
2010).  
This methodology has been applied to PTEN to address (i) is there a PI(4,5)P2 site that is 
discrete from where substrate binds, and (ii) where is this PIP2 site with respect to the 
active site. Cysteines in the protein were labeled with the nitroxide spin label reagent S-
(2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl methanesulfonothioate (MTSL) 
and the relaxation enhancement of the 31P nuclei of different short-chain 
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phosphoinositides was measured. This relaxation enhancement depends on the proximity 
of the phosphorus to the unpaired electron attached to the protein, thus the extent of the 
relaxation enhancement is a measure of the distance between the phospholipid and the 
protein. 
4.2 Results 
4.2.1 PI(4,5)P2 effects on recombinant wild type PTEN enzymatic activity 
The effect of the PI(4,5)P2 on PTEN specific activity was assessed using both monomer 
and vesicle substrate systems. First, as expected, with 0.1 mM diC8PI(3,4)P2 as the 
substrate, 0.05 mM diC8PI(4,5)P2 increased recombinant PTEN activity 6-fold (Figure 
4.1 A), comparable to what has been reported previously (Campbell et al, 2003). 
Increasing the diC8PI(4,5)P2 to 0.1 mM has little additional effect; the observed 
activation was 7-fold. In these two conditions, both substrate diC8PI(3,4)P2 and activator 
diC8PI(4,5)P2 exist as monomers in solutions, at least in the absence of protein, 
suggesting that a membrane interface is not necessary for kinetic activation. 
DiC8PI(3)P as a substrate shows somewhat different behavior (Figure 4.1A). The CMC 
of diC8PI(3)P was reported as 0.7±0.2 mM (Wang et al, 2008), which means under the 
assay condition, both substrate and activator would be mostly monomers although 
perhaps with some micelles, again at least in the absence of protein. With 0.5 mM 
diC8PI(3)P as the substrate, 0.25 mM diC8PI(4,5)P2 reduced PTEN activity to 70% and 
0.5 mM diC8PI(4,5)P2 reduced activity to 40% of the rate in the absence of the ‘activating’ 
lipid. Here diC8PI(4,5)P2 is acting as an inhibitor, presumably by binding to the active 
site. This suggests that the effect of PI(4,5)P2 depends on the identity and physical state 
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of the substrate and its ability to bind to the protein. If we assume that the inhibition is 
because the PIP2 binds to the active site, we can use the Km for diC8PI(3)P to estimate a 
Ki of 0.1 mM for diC8PI(4,5)P2.Thus, the diC8PI(4,5)P2 PTEN product has a considerably 
higher affinity for the active substrate than the diC8PI(3)P PTEN substrate. 
The dioctanoyl lipids have CMCs around 0.5-1 mM and PTEN could lower the CMC, 
differently for each lipid. To try and circumvent this potential complication, we also 
examined the effect of diC6PI(4,5)P2 on PTEN hydrolysis of diC6PI(3,4)P2 and 
diC8PI(3,4)P2. Resultant activities showed that acyl-chain length is another factor 
modulating the magnitude of PI(4,5)P2 activation (Figure 4.1B). The shorter molecule, 
diC6PI(4,5)P2, was less effective as an activator than diC8PI(4,5)P2, both for substrates 
diC6PI(3,4)P2 and diC8PI(3,4)P2, indicating the binding of the PI(4,5)P2 to the protein is 
not just an electrostatic interaction between the anionic charge on the head group of 
PI(4,5)P2 and cationic charge on protein surface when the monomeric molecules are used. 
The higher activation observed for systems poised around the CMC suggests that the 
kinetic activation is enhanced with the formation of an interface. 
The effect of inositol-1,4,5-trisphophate (I(1,4,5)P3), the head group of PI(4,5)P2, was  
also tested for its effect on PTEN activity. No kinetic activation was seen with either 
diC8PI(3,4)P2 or diC8PI(3)P, but rather a slight decrease in enzyme activity. PTEN 
exhibited 80% residual activity when 0.5 mM I(1,4,5)P3 was mixed with 0.5 mM 
diC8PI(3)P as the substrate. These results also confirm the interaction between PI(4,5)P2 
and protein is stronger when the acyl chains are present and contains more than just 
electrostatic interactions. 
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Figure 4.1 (A) Effect of PI(4,5)P2 on PTEN hydrolysis of  different substrates. The 
relative specific activities for PTEN towards 0.1 mM diC8PI(3,4)P2, DOPI(3,4)P2/ 
POPC (0.05 mM/0.95 mM) LUVs, DOPI(3,4)P2/POPC (0.1 mM/0.9 mM) LUVs, and 
0.5 mM diC8PI(3)P with PI(4,5)P2 are shown, with substrate:PIP2 = 0.5 () or 1.0 
(\\\\). (B) Effect of varying the chain length of substrate and activator. Substrates 
include 0.1 mM diC6PI(3,4)P2 or 0.1 mM diC8PI(3,4)P2 with dihexanoyl- or 
dioctanoyl-PI(4,5)P2 added, and substrate:PIP2 = 0.5 () or 1.0 (\\\). (C) Effect of 
PIP2 and Triton X-100 on PTEN hydrolysis of different substrates. Substrates 
include diC8PI(3,4)P2/TX-100 (0.1 mM/0.4 mM), DOPI(3,4)P2/TX-100 (0.1 mM/0.4 
mM), and diC8PI(3)P/TX-100 (0.5 mM/2 mM). The PIP2 concentration was half () 
or the same (\\\) as that of the substrate. (D) DiC7PC inhibition of PTEN activity 
toward diC8PI(3)P (, □) and diC8PI(3,4)P2 (●, ○) in the absence (filled symbols) or 
presence (open symbls) of Triton X-100 present with substrate: TX-100=1:4. 
0
2
4
6
8
10
R
el
at
iv
e 
Ac
tiv
ity
diC
8
PI(3,4)P
2
   DOPI(3,4)P
2
/    DOPI(3,4)P
2
/  diC
8
PI(3)P
                         PC (1:19)           PC (1:9)
  
A
0
2
4
6
8
10
PI(4,5)P
2
/ PI(3,4)P
2
diC
6
/diC
6
        diC
6
/diC
8
          diC
8
/diC
8
       diC
8
/ diC
6
B
0
2
4
6
8
10
diC
8
PI(3,4)P
2
/TX    DOPI(3,4)P
2
/TX    diC
8
PI(3)P/TX
          (1:4)                     (1:4)                    (1:4)
C
R
el
at
iv
e 
Ac
tiv
ity
0
0.2
0.4
0.6
0.8
1
0 0.1 0.2 0.3 0.4 0.5
+ diC
7
PC (mM)
D
 101 
 
The long chain lipid DOPI(3,4)P2 was also examined as a substrate (5 or 10 mol % of 
total lipid) presented in PC large unilamellar vesicles (Figure 4.1A). The addition of brain 
PI(4,5)P2 equivalent to the substrate mole fraction in the vesicles could activate the 
enzyme 3-fold for a sample with 1 mM total lipids and 5 mol % PI(3,4)P2. However, if 
the LUVs had a higher percent of DOPI(3,4)P2 (10 mol% DOPI(3,4)P2) adding the same 
amount of brain PI(4,5)P2 (10 mol% brain PI(4,5)P2) inhibited the enzyme to 40% 
residual activity. This indicates that the PIP2 activator molecule has a higher affinity for a 
site not in the active site but at sufficiently high concentrations in the vesicle, the 
molecule can bind to the catalytic site as well (again not surprising since it is a product of 
PI(3,4,5)P3 hydrolysis). 
Along with examining PIP2 activation of PTEN in PI(3,4)P2 / PC vesicles, the PI(4,5)P2 
effect was also examined when long chain lipid DOPI(3,4)P2 and DOPI(4,5)P2 were 
solubilized in Triton X-100 micelles. Addition of the same amount of DOPI(4,5)P2 /TX-
100 micelles to substrate DOPI(3,4)P2/TX-100 micelles (0.1 mM of each lipid) reduced 
PTEN activity to 63% of that with just substrate DOPI(3,4)P2/TX-100 micelles (Figure 
4.1C). Doubling the DOPI(4,5)P2/TX-100 concentration increased the inhibition from 63% 
to 52%. Triton X-100 is a non-ionic detergent that we have shown previously can reduce 
the inhibition potency of short-chain deoxy-PI derivatives by either binding into a 
hydrophobic site adjacent to the active site (the ‘adjacent hydrophobic site’ or AHS), or 
forming micelles that reduce the on/off rates of the PI derivative from accessing PTEN 
binding sites (Wang et al, 2010). The inhibition observed in the DOPI(3,4)P2/ 
DOPI(4,5)P2/TX-100 micelles indicated at high concentration, the head group of 
PI(4,5)P2 had some affinity for the active site, and this molecule could act as an inhibitor.  
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Along with its effect in long chain phospholipids dispersed in micelles, the effect of TX-
100 on PTEN kinetics was also examined with short chain substrate and activator (Figure 
4.1C). Adding TX-100 (1:4 = substrate: TX-100) could enhance the inhibition by 
diC8PI(4,5)P2 when using diC8PI(3)P as the substrate. PTEN activity was significantly 
inhibited to 5% residual activity (i.e., when compared to substrate with Triton X-100 but 
no diC8PI(4,5)P2). However, Triton had no effect on the PIP2 activation in the 
diC8PI(3,4)P2/diC8PI(4,5)P2 assay system, PI(4,5)P2 activation was still observed with 
Triton X-100 present. It also suggests that the matrix in which diC8PI(3)P is presented is 
critical for observing PIP2 activation as opposed to inhibition. This is another indication 
that there are two discrete sites for substrate and PIP2 binding.  
PC is often used as the matrix lipid in preparing vesicles. However, in monomer/micelle 
assay systems, short-chain PC is a very effective inhibitor of PTEN (Figure 4.1D). 
Comparable concentrations of Triton X-100 have no significant effect on PTEN activity. 
With 0.5 mM diC8PI(3)P as the substrate, the addition of 0.25 mM diC7PC (well below 
its CMC of 1.5 mM) reduced the enzyme activity to ~60% of the control. For 
diC8PI(3,4)P2 (0.1 mM) as well, added diC7PC reduces PTEN activity but not to the level 
of what occurs with diC8PI(3)P (80% residual activity). Interestingly, adding the nonionic 
detergent Triton X-100 into the mixture reduces the diC7PC inhibition of PTEN, 
suggesting the PC molecules may interact with the protein AHS and in so doing alter 
access to the active site. Triton, in contrast, appears to bind almost exclusively to the 
AHS; it has little affinity for the active site. 
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4.2.2 Fixed field 31P NMR study of phospholipids binding to recombinant PTEN  
Changes in the 31P linewidths (ΔΔν1/2) of ligands induced by the presence of the protein 
were used to characterize lipid binding to PTEN at 14.02 T (Table 4.1). Concentrations of 
the ligands were 0.25 or 0.5 mM, at or below the CMC of all the phospholipids, and the 
ratio of phospholipid to protein was usually either 24.7:1 or 49.4:1. The 
dihexanoylphospholipids exhibited minimal changes in linewidth (<2.5 Hz), consistent 
with their lack of much kinetic activation of PTEN (and their poor substrate properties). 
Both diC6PI and diC6PI(4,5)P2 exhibited only a 1-2 Hz increase in linewidth. In contrast, 
the dioctanoylphosphoinositides showed significantly larger linewidths in the presence of 
PTEN: (i) D-diC8PI and L-3,5-dideoxy-diC8PI, as well as diC7PC, all of which bind to the 
active site (Wang et al, 2008; Wang et al, 2010), exhibit a 25-30 Hz increase in linewidth 
under the experimental conditions used;  (ii) non-substrate diC8PI(4)P and diC8PI(5)P 
molecules have intermediate linewidths, 12-17 Hz; and (iii) diC8PI(4,5)P2 shows much 
smaller line broadening in the presence of PTEN (~ 5 Hz increase). 
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Table 4.1 NMR linewidth changes for the phospholipid phosphodiester resonance 
upon the addition of recombinant PTEN and variants.. The concentrations of PTEN, 
spin-labeled PTEN wild type (PTEN-SL), K13E, R47K, and R47G were 10 µM. 
ΔΔν½ PDE (Hz) 
PI (mM) PTEN PTEN-
SL 
K13E R47K R47G 
diC6PI 
0.25 1.9±0.1     
0.50 1.2±0.1     
diC6PI(4,5)P2 
0.25 2.3±0.2     
0.50 1.8±0.1     
diC8PI 
0.25 24.7±1.2 34.8±1.4    
0.50 38.6±14.4  41.8±7.4 36.9±4.5 32.6±5.3 
diC8PI/TX-100 (2 mM) 0.50 11.5±2.8  6.3±0.5 11.2±3.1 8.8±0.9 
diC8PI(4)P 0.25 11.6±0.5     
diC8PI(5)P 0.25 17.3±1.3     
diC8PI(4,5)P2 
0.25 4.7±0.3 6.1±0.4 6.9±0.7 6.7±1.3 6.6±0.9 
0.50 3.8±1.2 3.7±0.3    
L-3,5-dd-diC8PI 0.50 26.7±0.7 25.3±1.0    
L-3,5-dd-diC8PI / 
diC8PI(4,5)P2 
0.25 30.5±0.8 37.8±1.6    
0.25 5.7±0.2 6.3±1.5    
diC7PC 1.0 28.3±4.3   37.0±2.0 36.0±7.2 
diC7PC/TX-100 (4 mM) 1.0 3.3±0.2   4.3±0.7 4.5±0.2 
Interpreting these linewidth changes is difficult because 31P at this field strength has 
contributions from CSA as well as dipolar interactions that are also coupled with 
exchange of molecules onto a protein binding site, and perhaps formation of small 
micelle aggregates with protein. Interesting, if Triton X-100 is added to the sample with 
diC8PI, the linewidth is significantly reduced. Since that nonionic detergent is not an 
inhibitor (Wang et al, 2008), this suggests that either the diC8PI/PTEN complex may be 
large or perhaps that the exchange of ligand on and off the protein is in an intermediate 
regime and that the Triton, by virtue of providing a micelle reservoir may accelerate such 
exchange. L-3,5-dideoxy-diC8PI and diC7PC, which are also inhibitors of PTEN activity 
(Wang et al, 2008), also exhibited large line widths in the presence of a small amount of 
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protein (Table 4.1). This suggests that if a molecule binds to the active site, the change in 
ligand 31P linewidth will be fairly large. As in the diC8PI/TX-100 system, adding Triton 
to diC7PC samples reduced line broadening to a large extent, from 30-40 Hz change to 
less than 5 Hz change with that detergent present. This could be explained by competitive 
binding between diC7PC and Triton X-100 in the AHS, (although the diC7PC also binds 
at least partially in the active site since it is inhibitory) consistent with what was observed 
in the enzyme kinetics where addition of Triton X-100 reduced the inhibition caused by 
diC7PC.  
PTEN was also incubated with both diC8PI(4,5)P2 and L-3,5-dideoxy-diC8PI. The 
phosphodiester peaks of these two lipids have slightly different chemical shifts and 
linewidth changes in the two can be measured separately. A large increase in linewidth 
was detected for the deoxy-PI bound in the active site. The 5 Hz increase observed for the 
diC8PI(4,5)P2 phosphodiester is comparable to its behavior in the absence of an active 
site ligand. Two other phosphoinositides were examined: diC8PI(4)P and diC8PI(5)P. 
Both exhibit linewidths intermediate between diC8PI and diC8PI(4,5)P2 upon the addition 
of protein. The PTEN-induced increase in linewidth for diC8PI(4)P was smaller than that 
for diC8PI(5)P, suggesting there is a particular orientation for non-substrate 
phosphoinositides binding to PTEN. 
While these fixed field 31P linewidths might perhaps provide a fingerprint for active site 
(large linewidth change), adjacent hydrophobic site (large change but greatly reduced by 
the addition of Triton X-100), and activator site binding (small linewidth change), there is 
no information on where such sites might be and if they are indeed spatially distinct. 
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4.2.3 Kinetics and fixed field 31P NMR study of PTEN mutants binding to phospholipids 
Lys13 has been suggested as a key residue for PIP2 activation in PTEN (Walker et al, 
2004; Redfern et al, 2008). Conversion of this cationic side chain to an anionic one 
should definitely alter electrostatic interactions of protein and ligand. K13E was less 
active than wild type PTEN  towards diC8PI(3)P or diC8PI(3,4)P monomers (less than 10% 
of wild type PTEN activity), and towards DOPI(3,4)P2 in PC vesicles (25% of the activity 
of wild type PTEN). K13E could not be activated either by diC8PI(4,5)P2 or long-chain 
DOPI(4,5)P2 (Figure 4.2). The enzyme kinetics suggest the activator site has been lost 
with this mutation. However, they do not address binding. It is possible that the PIP2 
could bind to the protein but communication of that binding with the active site has been 
altered, hence the loss of kinetic activation. 
Arg47 was previously shown to be a key residue in the hydrophobic site adjacent to the 
active site (Wang et al, 2010). Mutation of Arg47 to replace the cationic side chain with 
lysine generated an enzyme, R47K, that could still be activated by PIP2, although the 
activity was low (5%-30% of wild type depending on the substrate used). When the 
charge was removed, as for R47G, PIP2 activation was significantly reduced. 
DiC8PI(4,5)P2 monomer activated the protein less than 2-fold with diC8PI(3,4)P2 as the 
substrate, while PIP2 activation was not detected when vesicle substrates were used 
(Figure 4.2). This kinetic result suggests that the PIP2 binding site is near the AHS, and 
the positive charge on Arg47 is important for PIP2 activation, possibly by interacting with 
the negatively charged activator molecule. It is also possible that the loop containing 
Arg47 is involved in the conformational change induced by activator binding, since Gly 
should alter the flexibility of the loop while Lys is more like the normal Arg. 
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Figure 4.2 Effect of PI(4,5)P2 on the activity of recombinant PTEN and variants 
K13E, R47K and R47G in monomer and vesicle assay systems. The ratio of the 
specific activity with PIP2 added to the activity in its absence is shown for WT and 
the three mutant proteins. In the monomer substrate mixture 
diC8PI(3,4)P2/diC8P(4,5)P2 is either 0.1 mM/0mM (), 0.1 mM/0.05 mM (|///|)  or 0.1 
mM/0.1 mM (|\\\|). Vesicles were composed of DOPI(3,4)P2/POPC (0.05 mM/0.95 
mM) in the absence (□) or presence (#) of 0.05 mM DOPI(4,5)P2. 
Line broadening of 31P resonances in the presence of K13E and R47 mutants was also 
measured (Table 4.1). DiC8PI in the presence of these three mutant enzymes still showed 
a large increase in linewidth with a much smaller linewidth increase (6-7 Hz) for 
diC8PI(4,5)P2. DiC7PC was also broadened in a similar fashion to diC8PI for the R47G or 
R47K mutants; when Triton X-100 was added, the increase in linewidth caused by PTEN 
was reduced, suggesting that Triton X-100 binding to the AHS can still displace the 
zwitterionic phospholipid for the adjacent hydrophobic site. DiC8PI(4,5)P2 linewidths in 
the presence of K13E, R47K or R47G were very similar to the effect of wild type PTEN, 
again suggesting this lipid binds to the protein, but not at the active site. The loss of 
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activity and PIP2 activation for these mutant enzymes does not appear to be caused by a 
lack of PIP2 binding to PTEN.  
4.2.4 High resolution field cycling 31P NMR study of short chain phospholipids binding 
to PTEN and its mutants  
4.2.4.1 Spin-labeling PTEN 
Modifying a protein to introduce a spin-label is a useful method to look for proximity of 
ligands to discrete places. The large electron dipole can dominate dipolar relaxation of 
nearby nuclei leading to a paramagnetic relaxation enhancement (PRE) that is distance 
dependent. PTEN, however, is not an easy target since it has 10 cysteines, 5 on the 
phosphatase domain, and 5 on the C2 domain. Under our spin-labeling conditions (which 
used loss of enzyme activity to ensure modification of Cys124), 8 of the 10 cysteines 
were modified by the spin-label reagent (Figure 4.3). This labeling was confirmed by MS 
(the result shown in Table 4.2), which showed that 9 out of 10 Cys were labeled, 
including the active site nucleophile Cys124 and nearby Cys71. The spin-labeled PTEN 
samples usually had a small amount (<20%) residual activity towards diC8PI(3)P. In the 
MS analyses of peptides, the peptide containing the unmodified Cys124 could be 
detected (Table 4.2). 
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Figure 4.3 Structure of PTEN showing the thiols of the cysteine residues modified by 
the spin-labeling reagent as sticks. The phosphatase domain, in grey, has a tartrate 
molecule in space-filling representation, while the C2 domain is cyan. Cys71 is 
colored in green, Cys124 in blue and other modified cysteines in orange with S 
atoms in yellow. The C-terminal loop which is not in the crystal structure is shown 
in dashed curve. The distances of cysteine S atoms to C(1) and C(4) of tartrate are 
indicated for the closest Cys in the phosphatase domains. 
The phosphoinositide binding sites on PTEN we are examining are all on phosphatase 
domain. The spin labels on the C2 domain are fairly far from the active site. In the PTEN 
crystal structure, the distances of the C2 domain cysteine sulfur atoms to tartrate carbons 
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are > 20 Å. To a first approximation spin-labels on at those sites should not contribute 
significantly to the relaxation of bound phospholipids. Spin labels attached to Cys83 and 
Cys105, located in the phosphatase domain, are far from the suggested membrane 
binding interface (Lee et al, 1999) and protein active site (Figure 4.3) and should be only 
minor contributors to 31P dipolar relaxation. Thus, the major contributors to relaxation of 
the phospholipids that dock into the active site should be spin labels on Cys71 and 
Cys124. Cys71 points into the active site pocket and can form a disulfide bond with the 
nucleophile Cys124 (Lee et al, 2002). If the site for PIP2 is near the active site it is likely 
to be relaxed; if it is further away (but still around the face thought to interact with the 
membrane interface) relaxation by spin-labeled PTEN will be smaller than for the PI in 
the active site. Although the large number of modified cysteine residues complicates 
interpretation of field cycling results, we can still use the method to compare the specific 
binding environments of different phosphoinositides. In particular, we can confirm a 
discrete binding site for a PIP2 molecule on PTEN. 
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Table 4.2 MS identification of PTEN cysteine modified by the MTSL spin label. The 
peptides in the tryptic digest containing spin-labeled Cys (C*) and unmodified Cys 
(C) are indicated. The number of the peptides detected in the sample is also shown. 
Peptide Cys number Number of digested peptides 
IYNLCAERHYDTAK 
C71 
 1 
IYNLC*AERHYDTAK  1 
FNCRVAQYPFEDHNPPQLELIK 
C83 
 1 
FNC*RVAQYPFEDHNPPQLELIK  4 
PFC*EDLDQWLSEDDNHVAAIHC* 
C105 C124 
1 
PFC*EDLDQWLSEDDNHVAAIHC*K 7 
MMFETIPMFSGGTCNPQFVVCQLK 
C211 C218 
2 
MMFETIPMFSGGTC*NPQFVVC*QLK 6 
FMYFEFPQPLPVCGDIK 
C250 
 1 
FMYFEFPQPLPVC*GDIK  10 
VENGSLCDQEIDSICSIERADNDK 
C296 C304 
3 
VENGSLC*DQEIDSIC*SIERADNDK 3 
4.2.4.2 Fixed field NMR study of spin-labeled PTEN binding to phospholipids 
The effect of spin-labeled PTEN on different short-chain phosphoinositides was explored 
first (Table 4.1). Although the contribution of dipolar relaxation to relaxation of 31P at 
high fields is small, the large dipole of the unpaired electron on the spin-label should 
enhance relaxation of the phosphorus nuclei in a distance-dependent manner. We can 
look at monomer concentrations of the phospholipids at fixed high fields so this allows us 
to gauge proximity. As expected, the spin-labeled PTEN had only small effects on diC8PI 
and diC8PI(4,5)P2 above what is seen with non-labeled PTEN. The increase in the 
linewidth for 0.25 mM diC8PI specifically caused by spin-labeled PTEN was 10 Hz; the 
increase was only 1.5 Hz for 0.25 mM diC8PI(4,5)P2. This result also confirmed that the 
field cycling NMR experiment is necessary to detect a substantial paramagnetic 
relaxation enhancement (PRE). 
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4.2.4.3 Field cycling of short-chain phospholipids binding to PTEN  
PRE can be extremely useful for analyzing the dynamics and proximity of soluble ligands 
binding to macromolecules with spin-labels (Pu et al, 2009b). However, extracting only 
the dipolar relaxation becomes more quite difficult in a membranous system, in part 
because of the dominance of chemical shift anisotropy (CSA) as the main relaxation 
mechanism at high magnetic fields. High resolution field cycling 31P methods can 
provide a unique window on phospholipid dynamics and interactions (Roberts & 
Redfield 2004a; 2004b). In the PTEN case, since more than one cysteine was labeled, we 
used the low field correlation time (τP-e) and extent of relaxation provided by the spin-
label extrapolated to zero field (ΔRP-e(0)) to calculate a parameter proportional to an 
averaged rP-e6. The effects of all the spin-labels are included, but most of the relaxation is 
due to the ones closest to the active or activator site. This parameter, which is normalized 
to the ratio of protein to phospholipid is the following:  
 (τP-e/ΔRP-e(0))×([PTEN-SL]/[PL]) 
There are a few key assumptions in the use of this parameter to extract an rP-e.: we 
assume (i) fast exchange between free and enzyme-bound ligands; (ii) a given site on the 
enzyme is saturated with 2-5 mM ligand; and (iii) correlation times for the 31P-electron 
interaction are long enough to characterize a discrete complex. Concentrations of 
phopholipids were 2-5 mM - the bulk of the diC8- phospholipids at these concentrations 
will be micellar, for diC6- phospholipids, monomers will exist. For protein/micelle 
complexes, a low field dispersion should reflect overall tumbling of a complex and 
differences in profiles for PIP2 versus PI will reflect differences in where the lipids bind.  
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(1) Monomeric phospholipids  
I(1,4,5)P3 is a soluble molecule that mimics the PIP3 head group and might be expected 
to bind into the active site or perhaps a discrete PIP2 site of the protein. However, there 
was no effect of spin-labeled protein on the 31P resonances of this molecule compared to 
the unlabeled protein (Figure 4.4). Therefore IP3 did not bind to the protein, which was 
consistent with the observation that IP3 had virtually no inhibitory effect on enzymatic 
activity. It appears that an acyl or alkyl chain(s) is needed for the ligands to bind to PTEN. 
Next, we examined diC6PI and diC6PI(4,5)P2. DiC6PI has a CMC around 10-14 mM 
(Lewis et al, 1993). The concentration of the diC6PI and diC6PI(4,5)P2 used in the field 
cycling experiment was 3 mM, suggesting the bulk of these two lipids were monomeric 
in solution. The ratio of PI to PTEN was 555:1 (4.9 µM PTEN and 2.7 mM diC6PI) in 
one case and 612:1 in another (same protein concentration and 3 mM diC6PI). As 
expected, unlabeled PTEN had no effect on the diC6PI 31P relaxation behavior at low 
fields at these ratios of protein to phospholipid. The relaxation enhancement (ΔR1) 
induced by the spin-labeled protein at different magnetic fields was calculated by the 
subtraction of R1 for the ligand in the presence of unlabeled protein. The field 
dependence of ΔR1 is shown in Figure 4.5 (upper graph, the inset has the full field 
dependence from 0.004 to 11.7 T). There is an enhancement of the 31P R1 by the presence 
of spin-labeled protein at fields below 1 T. 
 114 
 
 
Figure 4.4 The magnetic field dependence of the spin-lattice relaxation rate, R1, of 
31P resonances of I(1,4,5)P3 (3 mM) in the presence of 4.9μM spin-labeled PTEN: C4 
phosphate (a, ●), C1 phosphate (b, ○), and C5 phosphate (c, □). Note that none of the 
31P exhibit the low field rise in R1 indicative of a small molecule/protein complex. 
This indicates that little of the inositol triphosphate is bound to PTEN. 
Several interesting features of the protein-lipid complex were observed. First, τP-e is 
172±21 ns, a value significantly larger than expected for a single PTEN molecule. This 
indicates that presence of the diC6PI ligand in the active site causes protein/phospholipid 
aggregates to form, even though by itself the diC6PI is monomeric. We have observed 
that the protein loses activity gradually when stored in the absence of substrate, product 
or analogues at 4 °C for one week. Most of our field cycling experiments were run for 24 
hours at room temperature. Since we do not see precipitation of protein at the end of the 
field cycling experiment, we believe the bulk of the protein is still in an active 
conformation when the experiment is finished. ([PTEN]/[PIPx])×(τP-e/ΔRP-e(0)) is 3.07 
×10-10 s 2, suggesting moderate proximity of the lipid to spin-labels on the protein. 
However, this is surprising since the diC6PI is binding at the active and near two spin 
labels. It is certainly possible that the PTEN active site is not saturated with diC6PI. A Km 
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has not been determined for diC6PI, but the value for diC8PI is around 0.1-0.2 mM. If 
chain length is critical for binding this could be the case. 
 
 
Figure 4.5 Top: The relaxation enhancement (ΔR1) of 31P of diC6PI (3mM) caused 
by 4.9 μM spin-labeled PTEN. The inset shows the raw relaxation rates (R1) of this 
phosphodiester from 0.004 to 11.7T; ∆R1 represents the relaxation rate once the 
data for this lipid with non-spin-labeled protein is subtracted. Bottom: The field 
dependence of R1 for the 31P resonances of diC6PI(4,5)P2 (3 mM) in the presence of 
by 4.9 μM spin-labeled PTEN: phosphodiester, PDE (●), C4 phosphate, P4 (Δ), and 
C5 phosphate, P5 (▲). 
DiC6PI(4,5)P2 binding to spin-labeled PTEN was also examined. There is little low field 
effect of the spin-labeled protein on the PIP2 phosphorus resonances (Figure 4.5, bottom). 
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This could be explained by a binding site much further from the spin-label sites or by 
poor binding of this ligand to the protein in the absence of an interface (which did form 
with submicellar concentration of diC6PI). The PTEN kinetics indicated that such a short-
chain length lipid is a poor activator of similar chain length monomeric substrate. 
Therefore, it is more likely that the activator molecule has a weaker affinity for the 
secondary site. 
(2) Micellar versus monomeric ligands 
The effect of spin-labeled PTEN on diC8PI and diC8PI(4,5)P2, which form micelles at 3 
mM, was examined next. By comparing the effects of these dioctanoyl lipids to the 
results of PTEN binding to diC6PI and diC6PI(4,5)P2, we can assess the effect of the lipid 
aggregation state, micellar versus monomeric ligands, on the protein/lipid interaction. As 
shown in fixed field studies, the diC8PI 31P resonance was significantly broadened in the 
presence of PTEN (not spin-labeled). The line broadening was larger than expected at 
high fields (14.1 T) for a protein of the size of PTEN binding a ligand in the fast 
exchange regime, indicating binding is in the intermediate exchange regime on the NMR 
time-scale. 
The field cycling profile for unlabeled PTEN and diC8PI showed a low field component 
significantly greater than for diC8PI alone and similar to phosphatidylinositol micelles 
(Wang et al, 2008). This indicated that PTEN interacts with the longer chain PI and forms 
larger micelles than the PI by itself. The curve for PI with unlabeled protein had both a 4 
ns (postulated to represent phospholipid wobbling) and 190 ns (representing particle 
rotation) dispersion. Field cycling with 3 mM diC8PI and 0.1 mg/ml spin-labeled PTEN 
([PTEN[/[PL] = 7.09×10-4 ) showed a large enhancement of 31P relaxation (Figure 4.6A). 
 117 
 
The relaxation from unlabeled PTEN was subtracted from the one with spin-labeled 
protein and the resulting ΔR1 field dependence fit to assess the relaxation due specifically 
to the spin-labels. As shown in Figure 4.6B, the data could be fit with a single correlation 
time, τP-e, of 33±10 ns; τP-e/ΔRP-e(0) = (1.77±0.40) x10-8 s2, and normalizing this value to 
the ratio of PTEN to phospholipid yielded (1.26±0.80) × 10-11 s2, a value consistent with 
close proximity of the major spin-label site(s) to the bound diC8PI. 
 
Figure 4.6 Magnetic field dependence of (A) the spin-lattice relaxation rate (R1) and 
(B) the paramagnetic relaxation enhancement (ΔR1) for the 31P of diC8PI (3.0 mM) 
caused by 2.0 μM recombinant PTEN (○) and 2.0 μM spin-labeled PTEN (●). 
The effect of spin-labeled PTEN (4.9 µM) on 3 mM diC8PI(4,5)P2 was also examined 
(Figure 4.7). For these micelles, more spin-labeled protein was needed to get effective 
relaxation. With this small amount of protein, there was no effect on the diC8PI(4,5)P2 
relaxation in the absence of spin-labeling (the multiply phosphorylated molecule forms 
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much smaller micelles on its own). The excess relaxation caused by the spin-labeled 
protein was fit as for diC8PI. The average correlation time from the three 31P resonances 
for the phospholipid/protein complex is 119±17 ns. This was significantly larger than 
what we observed for diC8PI interacting with the spin-labeled protein. It suggested that 
binding of this ligand caused formation of a moderately large micellar complex. The τP-
e/ΔRP-e(0) normalized to the amount of phospholipid and PTEN is (1.36±0.97) ×10-10 s2 
for the phosphodiester resonance of diC8PIP2 (the ratio for the two phosphomonoesters is 
a little over twice that). The roughly 10-fold difference in this ratio for diC8PI and 
diC8PI(4,5)P2 indicated that PIP2 is occupying a different site on the protein, and it is 
further away from spin label sites. Another feature of PI(4,5)P2 binding is that the 
phosphomonoester peak attached to C4 of the inositol ring has a higher normalized τP-e 
/RP-e(0) value than that attached to C5, indicating the phosphate at C5 is closer to spin 
labels. 
Kinetics with monomers strongly suggested that diC8PI(4,5)P2 at moderate 
concentrations was a competitive inhibitor. Some of the relaxation of PIP2 31P resonances 
could be caused by this ligand binding to the active site. To assess this, we examined a 
sample of 3 mM diC8PI, 3 mM diC8PI(4,5)P2 and 0.25 mg/ml protein that was not 
completely spin-labeled. Under these conditions, phosphodiester resonances for both 
diC8PI and diC8PIP2 were separable and R1 values could easily be evaluated for both in 
the same micelle with protein. If the PI(4,5)P2 relaxation was because it is in the active 
site, then the presence of the diC8PI should reduce it substantially. If the two molecules 
were binding to discrete sites, then the ratio of the τP-e/∆RP-e(0) values for the two 
phosphodiesters should be the same as when the lipids are mixed separately. 
 119 
 
 
 
Figure 4.7 The field dependence of (left) R1 and (right) the relaxation enhancement 
(Δ R1) for 31P of diC8PI(4,5)P2 (3.0 mM) in the presence of 4.9 μM spin-labeled 
PTEN (solid symbols) and 5.0 μM recombinant PTEN (open symbols): 
phosphodiester (●), P4 (▲) and P5 (). 
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If more completely spin-labeled PTEN is used, it is difficult to obtain a complete enough 
field dependence profile for the diC8PI phosphodiester since it relaxes so quickly. Instead, 
we can use the diC8PI(4,5)P2 monophosphates as probes for active site binding. The 
values of the ration τP-e/∆RP-e(0) for the PI phosphomonoesters are the same in the 
absence and presence of diC8PI, indicating that PI(4,5)P2 is binding to a site spatially 
distinct from the active site (Figure 4.8).  
 
Figure 4.8 The field dependence of R1 for the phosphomonoesters, P4 and P5, of 3 
mM diC8PI(4,5)P2 in the absence (open symbol) and presence (filled symbol) of 3 
mM diC8PI and 4.9 μM not fully spin-labeled PTEN. 
We can also compare the profiles for other PTEN products that are thought to bind to the 
active site and not the activator site. The phosphoinositide diC8PI(4)P could not activate 
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the enzyme for diC8PI(3,4)P2 hydrolysis (Campbell et al, 2003), while placement of the 
phosphate on the 5-position of the inositol ring generates a lipid that could activate the 
protein to some degree (Wang et al, 2008). Fixed field studies of diC8PI(4)P and 
diC8PI(5)P indicated an intermediate increase in phosphodiester linewidth when these 
two monomeric lipid were incubated with PTEN (Table 4.1). Field cycling studies of 
these two lipids, now presented in a micelle, binding to PTEN showed an increased ∆R1, 
especially for phosphodiester peak, at low magnetic fields. However, each sample had 2.5 
times the amount of protein used with diC8PI, so that the comparable values for ∆RP-e(0) 
are really lower. The normalized τP-e/ΔRP-e(0) values for the phosphodiesters of 
diC8PI(4)P and diC8PI(5)P were 6.3×10-11 and 3.8×10-11 s2 (Table 4.3). This suggests that 
these PTEN products do not bind in exactly the same way as diC8PI. Presumably the 
presence of each phosphomonoester drives the orientation of the inositol ring in the 
active site. Alternatively they might indicate that the diC8PI(5)P has some affinity for 
both sites and so we observed an average reflecting some portion of both sites being 
occupied. Interestingly, the phosphomonoester P5 was affected more strongly than P4, 
which was also observed in diC8PI(4,5)P2 binding (Table 4.3). From modeling a substrate 
headgroup into the PTEN crystal structure on top of the tartrate in the active site, it 
appeared that the P5 was oriented away from the active site and thus should be less 
affected by a spin-label in Cys124 than P4 (Lee et al, 1999). This inconsistency indicates 
either the inaccuracy of the modeling or that PI(4)P and PI(5)P bind to the protein with 
slightly different orientations than the substrate.  
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Table 4.3 Effect of spin-labeled PTEN on relaxation parameters of short-chain 
phospholipids as measured by high resolution 31P field cycling 
Ligand [PTEN]/[PL] τP-e (ns)  ΔRP-e(0) ([PTEN]/[PL]) ×τP-e/ΔRP-e(0) 
r (Å) a 
diC6PI 0.00157 172±21 0.88±0.05 3.07x10-10  
 0.00141 107±19 0.45±0.03 3.35x10-10  
diC6PI(4,5)P2 0.00177     
PDE  37±18 0.19±0.04 3.45x10-10  
P-4  35±15 0.09±0.01 6.88x10-10  
P-5  32±9 0.11±0.01 5.15x10-10  
diC8PI 0.00071 33±10 1.85±0.16 0.13x10-10 36±3 
diC8PI(4,5)P2 0.00162    52±4 
PDE  128±26 1.53±0.15 1.36x10-10  
P-4  131±18 0.52±0.03 4.08x10-10  
P-5   99±22 0.58±0.06 2.76x10-10   
diC8PI/diC8PI(4,5)P2 0.00162    48±3 
PDE b  103±20 1.47±0.13 1.14x10-10  
P-4  169±21 0.45±0.03 6.08x10-10  
P-5  153±19 0.53±0.03 4.68x10-10   
diC8PI(4)P 0.00177    48±2 
PDE  103±15 2.88±0.22 0.63x10-10  
P-4   52±11 0.47±0.04 1.96x10-10   
diC8PI(5)P 0.00177    36±2 
PDE  43±5 2.01±0.10 0.38x10-10  
P-5   55±8 0.66±0.04 1.48x10-10   
diC7PC c 0.00106 120±15 3.96±0.24 0.32x10-10 51±2 
diC7PC/TX-100 c 0.00106 118±17 1.68±0.15 7.44x10-10 50±2 
diC7PC/diC8PI(4,5)P2      
PDE/PC d 0.00066 110±13 1.79±0.11 0.41x10-10 49±2 
P-4 0.00177 93±20 0.55±0.03 2.99x10-10  
P-5 0.00177 56±15 0.62±0.07 1.60x10-10  
a This r is an estimate of the average PTEN/micelle complex size obtained by relating τP-e to an isotropic 
diffusion constant, τP-e = 1/(6×D) where D = kT/(8πηr3) (Shi et al, 2009). 
b Overlap of the two phosphodiesters occurs. However, with this higher amount of protein, the diC8PI 
component is relaxed well before the PIP2 compound, hence the measured R1 reflects the diC8PI(4,5)P2. 
c The dispersion for diC7PC was fit with a single τP-e.  
d For the diC7PC/diC8PI(4,5)P2 (5 mM: 3 mM) sample, the total phosphodiester concentration is 8 mM and 
this is used in estimating the ratio PTEN to a particular phospholipid. Both phosphodiesters are used since 
each compound can bind to the active site. 
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(3) Other ligands 
Kinetics with the synthetic short-chain PIs showed that diC7PC was very inhibitory while 
TX-100 had little effect on the observed rate. The Triton X-100 was suggested to bind to 
a hydrophobic pocket adjacent to (but not in) the active site, the AHS (Wang et al, 2010). 
The complication with interfacial enzymes is that altering the surface concentration of 
substrate could have large effects on the rate and lead to surface dilution inhibition (Pu et 
al, 2009a). Alternatively, reduced activity as a diluent increased could indicate that the 
molecule was binding to or near the active site and acting as a competitive inhibitor.  
With this in mind we explored the effect of spin-labeled PTEN on zwitterionic diC7PC 
micelles in the absence and presence of diC8PI(4,5)P2, which presumably binds mainly to 
the activator site. We also examined the effect of spin-labeled PTEN on diC8PI with a 
large excess of TX-100 present. 
For 5 mM diC7PC micelles interacting with 5.3 µM spin-labeled PTEN, there was a large 
effect on the 31P resonance. The value for [PTEN]/[PL])×(τP-e/ΔRP-e(0))was 3.22x10-11 s2 
for this sample (Table 4.3), which was about twice the value for diC8PI, closed enough to 
suggest that diC7PC must be in part of the active site (hence its potent inhibition of PTEN 
kinetics). 
Addition of TX-100 reduced the effectiveness of the spin-labeled protein on diC7PC. The 
([PTEN]/[PL])×(τP-e/ΔRP-e(0))value was reduced to 7.44×10-10 s2 (Table 4.3). Triton X-
100 binding in the AHS reduces diC7PC binding to the active site, presumably because 
the PC occupies both the active site and the AHS. This is consistent with the PTEN 
kinetics that showed that Triton could lessen diC7PC inhibition of diC8PI(3)P hydrolysis.  
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We also examined the effect of Triton X-100 on diC8PI binding to spin-labeled PTEN 
(diC8PI/TX-100 = 3 mM /6 mM). DiC8PI/TX-100 mixed micelles altered (increased) the 
average micelle size, and the unlabeled protein control showed a larger contribution of 
relaxation. Once this was subtracted, the dependence of excess R1 (due to spin-label) on 
field was best fit with a correlation time of 68±10 ns; the ([PTEN]/[PIPx])×(τP-e/ΔRP-e(0)) 
ratio was 4.34x10-11 s2 (Table 4.3). The surface concentration of diC8PI had decreased 3-
fold with the added TX-100, which was about the same amount as the increase in the 
ratio of ([PTEN]/[PIPx])×(τP-e/ΔRP-e(0)). That most of the strong relaxation was observed 
indicated there was still a specific interaction of PI with the active site.  
After demonstrating that diC7PC could bind to the active site, we examined the effect of 
diC7PC on the PIP2 interaction with PTEN. The sample had 3 mM diC8PI(4,5)P2, 5 mM 
diC7PC amd 5.3 µM spin-labeled protein. Although the PC phosphodiester dominated the 
PIP2 resonance, we could at least examine how the phosphodiester behaved versus the 
phosphomonoesters of the phosphoinositide. Interestingly, τP-e for the phosphodiester was 
85-110 ns and RP-e(0) decreased when the PIP2 was present (Table 4.3). In other words, 
the PIP2 competed with the diC7PC. However, the two PIP2 phosphomonoester peaks 
actually showed a decrease in τP-e with PC added with little effect on ΔRP-e(0). Addition 
of the zwitterionic PC reduced the τP-e/ΔRP-e(0) ratio for the phosphomonoesters. At the 
very least, these 31P resonances were still well-relaxed by spin-labeled protein regardless 
of whether diC7PC was added to dilute the surface. The net result was that diC7PC did 
bind to the protein around/in the active site and inhibited the enzyme but the binding did 
not appear particularly tight and had only minor effects on PIP2 binding. DiC7PC also 
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interacts with the AHS since inclusion of Triton X-100 in the micelles altered its 
relaxation by the spin-labeled protein. 
By using high resolution field cycling NMR, we explored the effect of spin-labeled 
PTEN binding PI, PI(4,5)P2 and PC lipids as well as the effect of TX-100 on this 
phospholipid binding. The head group of PI lipids, I(1,4,5)P3 does not bind spin-labeled 
PTEN and shorter chain PIs (diC6PI and diC6PI(4,5)P2) have much weaker interactions, 
consistent with what were observed in kinetics and fixed field NMR results. DiC8PI, a 
product of PI(3)P dephosphorylation and an inhibitor of PTEN, binds in the active site. 
The fixed field study indicated this lipid binds to the protein in an intermediate exchange 
regime. If its off-rate is slower, we may not be measuring its relaxation at very low fields. 
This could explain why the correlation time, τP-e, for diC8PI was usually lower than for 
diC8PI(4,5)P2. Nonetheless, the 31P in this lipid is the closest to the spin-labels in PTEN. 
A major result of this work is that there is a discrete binding site for PI(4,5)P2 on PTEN 
that is near but distinct from the active site.  
4.2.4.4 Field cycling NMR study of PTEN mutants 
For comparison to the field cycling studies of wild type PTEN, we also examined several 
mutant proteins, choosing those where PIP2 activation was affected (Table 4.4). K13E is 
not activated by PI(4,5)P2 indicating the activator site was disrupted. C124S is 
catalytically inactive Since Cys71 is near the active site, it should still be spin-labeled and 
can be used as an indicator for nearby bound 31P.  
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Table 4.4 Effect of spin-labeled PTEN K13E (4.9 µM) on relaxation parameters of 
diC8PI (3 mM) and/or diC8PI(4,5)P2 (3 mM) as measured by high resolution 31P 
field cycling. 
Ligand [K13E]/[PL] τP-e (ns)  RP-e(0) (s-1) 
([K13E]/[PL]) 
×τP-e/ΔRP-e(0) 
r (Å) 
diC8PI  0.00071 144 ±26 3.87±0.40 0.26x10-10 54±3 
diC8PI(4,5)P2 0.00148     
PDE  96±18 0.71±0.07 2.00x10-10 47±3 
P-4  58±13 0.23±0.02 3.73x10-10  
P-5  69±18 0.17±0.02 6.01x10-10  
diC8PI(4,5)P2 0.00141     
PDE  109±14 0.94±0.06 1.64x10-10 49±2 
P-4  137±21 0.39±0.03 4.95x10-10  
P-5  127±13 0.33±0.02 5.43x10-10  
diC8PI/diC8PI(4,5)P2 0.00141     
PDE  46±10 0.72±0.07 0.90x10-10 37±3 
P-4  32±14 0.21±0.04 2.15x10-10  
P-5  46±26 0.13±0.03 4.99x10-10  
PI  87±24 3.81±0.79 0.32x10-10 46±4 
a r is an estimate of the average PTEN/micelle complex size obtained by relating τP-e to an 
isotropic diffusion constant, τP-e = 1/(D×6) where D = kT/(8πηr3) (Shi et al, 2009). 
 
The field dependence profile for diC8PI binding to K13E was similar to that for wild type 
protein (Table 4.4). The τP-e is large, 144 ±26 ns, for the K13E /diC8PI complex, a value 
comparable to what was observed with wild type PTEN binding diC8PI(4,5)P2. The 
normalized ([K13E]/[PIPx])×(τP-e/ΔRP-e(0))ratio was 2.6×10-11 s2, about double that for 
the wild type PTEN/PI complex. However, this normalized τP-e/RP-e(0) is still much lower 
than that for PTEN binding diC8PI(4,5)P2. The effect of spin-labeled K13E on 
diC8PI(4,5)P2 was also examined. Contrary to the thought that this mutation eliminates 
PI(4,5)P2 binding, our field cycling results clearly show that diC8PI(4,5)P2 is still bound 
to the protein. The average of two separate sample of 0.25 mg/ml K13E plus 3 mM 
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diC8PI(4,5)P2 led to a normalized τP-e/RP-e(0)value for phosphodiester of 1.81×10-10 s2, a 
value fairly similar to the value of 1.36×10-10 s2 for the wild type protein. The normalized 
τP-e/ΔRP-e(0) values for the two phosphomonoesters were 4.34 ×10-10 s2 and 5.72×10-10 s2 
for P4 and P5, respectively (Table 4.4). These values are larger than the values observed 
with wild type and with this mutant, P5 is not relaxed as efficiently as P4. These results 
clearly indicate that K13E still binds diC8PI(4,5)P2, but not exactly in the same position 
as for spin-labeled wild type protein. The larger the normalized τP-e/RP-e(0), the longer the 
average distance of the 31P from the nitroxide, so that removal of Lys13 does affect the 
position of the PIP2 on the protein. When both 3 mM diC8PI and 3 mM diC8PI(4,5)P2 are 
incubated with spin-labeled K13E, the field cycling parameters describing the interaction 
are the same as for the individual lipids. Kinetics studies with K13E indicated this mutant 
was not activated by this PIP2, but NMR results, both fixed field and field cycling 
experiments, still show diC8PI(4,5)P2 molecules could interact with the protein. The field 
cycling shows two discrete changes in lipid binding to this mutant protein. The 
correlation time of the protein-lipid complex, τP-e, is shorter for mutant (41.4±8.5 ns). P5 
is now slightly further from the spin-labels compared to P4 – the opposite of what is seen 
with spin-labeled wild type protein These changes suggest that the K13E mutation may 
be altering the lifetime of the bound diC8PI(4,5)P2 and may also induce small changes in 
the orientation of that lipid when bound to the protein so that it no longer affects enzyme 
activity. 
Spin-labeling of C124S should still place a nitroxide near the active site, on Cys71. This 
is likely to be the closest point of spin-label attachment for enhancing PI 31P relaxation. 
As expected, the PRE is reduced when C124S is bound to diC8PI and diC8PI(4,5)P2, 
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partially due to the loss of the unpaired electron dipole on spin-labeled Cys124 compared 
to wild type protein. The ([C124S]/[PIPx])×(τP-e/ΔRP-e(0)) value for diC8PI was 3.05× 10-
11 s2, around 3 times of what for PTEN wild type bound diC8PI. If we assumed the ΔRP-
e(0) difference between C124S and wild type bound diC8PI is from the single unpaired 
electron on Cys124, then τP-e = 5.2×10-8 s and ∆∆RP-e(0) = 0.623 s-1. From these 
parameters, the normalized τP-e/ΔRP-e(0) is 5.64×10-11 s2, and this can provide an estimate 
of the distance between a spin-label attached to Cys124 and the 31P of the bound PI as 9.4 
Å. What is actually observed for C124S and PI should mostly reflect the distance 
between the label on Cys71 and the bound phosphodiester 31P. This value would then be 
estimated as 8.4 Å.  
The PRE effect of spin labeled C124S on diC8PI(4,5)P2 was also measured. The 
normalized τP-e/ΔRP-e(0) values are considerably larger for both the phosphodiester and 
phosphomonoester 31P resonances. This stresses that the PIP2 binding site is indeed near 
the active site. For the phosphodiester resonance about of half the ΔRP-e(0) of the labeled 
wild type protein is caused  by Cys124 labeling. With τP-e ~160 ns and ∆∆RP-e(0) = 0.60 
s-1, the normalized τP-e/ΔRP-e(0) = 3.78×10-10 s2. The distance between the spin-label 
attached to Cys124 and diC8PI(4,5)P2 is estimated as 12.9 Å. These data clearly show 
that diC8PI(4,5)P2 binds to a discrete site on PTEN that is near the active site of the 
protein.  
4.3 Discussion 
The major difference between the allosteric and interfacial activation mechanisms 
proposed to explain PI(4,5)P2 activation of PTEN is that the allosteric mechanism 
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invokes a specific binding site, other than active site, while the interfacial mechanism 
proposes alterations in the interface that affect protein binding and accessing its substrate. 
Here we used kinetics and NMR methods to demonstrate that there is a discrete PI(4,5)P2 
binding site on PTEN. In fixed field NMR experiments, the difference in PTEN-induced 
line broadening of diC8PI and diC8PI(4,5)P2 clearly reflected the different binding 
properties of these two lipids. Mixtures of an active site binding lipid (L-3,5-dideoxy-
diC8PI) and activator lipid diC8PI(4,5)P2 showed the linewidth changes were the same as 
when both were examined separately. The different proximity to active site between PI 
and PI(4,5)P2 in field cycling NMR studies provides independent proof for a discrete 
activator binding site. By using this method to measure average distances between the 
spin-label and 31P in molecules bound to the protein, we have shown that the PI(4,5)P2 
activator binding site is not very far from the active site. This is consistent with the 
kinetics for R47G that showed a loss of diC8PI(4,5)P2 activation, since we know the AHS, 
to which Arg47 contributes, is close to the active site. 
Along with providing evidence for a discrete activator binding site, field cycling studies 
also indicated what is critical for a phosphoinositide to bind to the PTEN active site. The 
superimposition of I(1,3,4,5)P4 with tartrate in PTEN crystal structure generated a model 
of how the phosphoinositides substrates could be bound to the protein (Lee et al, 1999). If 
this in silico extrapolation is correct, it is reasonable for PI(4,5)P2 to bind to the PTEN 
active site since its head group, I(1,4,5)P3, has only one phosphate group missing from 
I(1,3,4,5)P4. Our results indeed demonstrated PI(4,5)P2 monomers have an affinity for the 
PTEN active site. The kinetics show that monomeric PI(4,5)P2 inhibits PTEN activity 
with PI(3)P as the substrate, although the PI(4,5)P2 effect is substrate and concentration 
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dependent. In the diC8PI(3,4)P2 monomer system, diC8PI(4,5)P2 enhances enzyme 
activity, and in the long chain PI(3,4)P2/PI(4,5)P2 vesicle system, low concentrations of 
PI(4,5)P2 activate PTEN while high surface concentrations of PI(4,5)P2 inhibit the 
enzyme. We believe the different effects of PI(4,5)P2 in different substrate system was 
due to the different affinity of the substrates. As reported previously (Myers et al, 1998), 
the specific activity of PTEN towards PI(3,4)P2 is higher than that towards PI(3)P; our 
kinetic studies agree with this as well. PI(3,4)P2 is likely to have a higher affinity for the 
protein active site than PI(3)P, a reasonable assumption since the PTEN active site has 
more lysines than other protein tyrosine phosphatases and prefers highly acidic substrates 
(Lee et al, 1999; Myers et al, 1997). The addition of the phosphate on the inositol C4 
would provide more electrostatic contacts within the PTEN active site. Presumably, the 
lower affinity of PI(4,5)P2 compared to PI(3,4)P2 for the active site reflects a preferential 
binding of the phosphate on C3 and perhaps a misalignment with phosphates only at C4 
and C5. The lower affinity of PI(4,5)P2 for the active site allows it to bind to the activator 
site in the presence of PI(3,4)P2. An interfacial activation mechanism for PIP2 activation 
of PTEN could not explain the observation that a higher percentage of PI(4,5)P2 in 
substrate-containing vesicles lowers PTEN specific activity. According to that 
mechanism, as the PI(4,5)P2 fraction in substrate vesicles increases, interaction of PTEN 
with the vesicles increases leading to higher enzymatic activity. However in our system, 
excess PI(4,5)P2 can compete with substrate PI(3,4)P2 in binding to the active site. So 
more than just driving the enzyme to the interface is involved.  
The N-terminal loop was suggested to be the PI(4,5)P2 binding site since this loop has the 
consensus sequence for protein binding to PI(4,5)P2. This short N-terminal loop was 
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found to be important for PTEN membrane binding and cellular function. The effect of 
deleting this binding site or mutation at this site has been widely studied, and proteins 
with perturbations of this site do not bind to membranes and are dysfunctional in cells 
(Walker et al, 2004; Vazquez et al, 2006; Rahdar et al, 2009). The mechanism for the loss 
of PIP2 activation of PTEN in Lys13 mutants was suggested to be the elimination of this 
cationic binding (Redfern et al, 2008). Our kinetic results demonstrate the loss of 
activation of K13E in both substrate monomer and vesicle assay systems. However, 
similar line broadening of diC8PIP2 by K13E and wild type protein in fixed field NMR 
indicate that the ‘activator’ molecule can still bind to the enzyme. The field cycling 
further shows that the diC8PI(4,5)P2 binds to K13E PTEN, but in a slightly different 
orientation from what is observed with the wild type protein. The loss of PIP2 kinetic 
activation of this mutant cannot be explained by the loss of binding but rather an altered 
binding site, where the conformation necessary for activation is no longer accessible. 
What do we know about this altered bound conformation? In the ‘correct’ PIP2 activator 
binding site, the phosphate at C5 of the inositol headgroup is characterized by a higher 
PRE effect than the phosphate at C4. Similarly, the monophosphate in diC8PI(5)P always 
exhibited a larger linewidth with added PTEN than the monophosphate in diC8PI(4)P. 
Both these are switched when PTEN K13E binds them.  
The acyl chain length of PI(4,5)P2 affects its ability to activate PTEN suggesting either a 
preference for an interfacial activator or perhaps a direct interaction of one of the acyl 
chains with PTEN. It was noted (Maehama et al, 2001) that the consensus sequence also 
contains some hydrophobic residues that could interact with the acyl chains of PI(4,5)P2. 
A search of the Protein Data Bank for structures containing diC8PI(4,5)P2 as ligand 
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introduced seven protein structures containing this molecule, three structures of the K+ 
channel Kir 2.2 wild type and its mutants, two structures of the GIRK2 K+ channel (Kir 
3.2), one structure of this ligand bound to the HIV-1 matrix protein, and one structure 
where the PIP2 is bound to the CALM N-terminal domain (N-terminal clathrin assembly 
lymphoid myeloid leukaemia  protein). In the Kir 2.2 structure, the specific binding site 
for P4 and P5 is contained within the conserved consensus sequence, while the P1, 
glycerol backbone and acyl chains bind nonspecifically in an pocket since they cannot 
insert into a membrane (Hansen et al, 2011). If PI(4,5)P2 binding to PTEN has similar 
interactions, especially between the headgroup, the phosphates at inositol C4 and C5, 
interact with cationic residues in the N-terminal loop with the consensus sequence: Lys6, 
Lys11 and Lys13 in PTEN are equivalent to Lys183, Arg186 and Lys188 in Kir 2.2 and 
should bind to the phosphate on inositol C5. Lys 14 in PTEN would be the equivalent of 
Kir 2.2 Lys189 and should bind to the phosphate on inositol C4. This predicts a stronger 
interaction of the protein with the C5 phosphate group. Consistent with this, there is 
always a stronger interaction between P5 and the protein than for P4. This binding mode 
would also explain the observation that PI(5)P can activate PTEN while PI(4)P does not. 
There is a binding pocket on Kir 2.2 for interaction with the PIP2 the acyl chain. This 
pocket was not identified in PTEN. It is possible that the hydrophobic residues in the N-
terminal consensus sequence, Ile8 and Val9, could interact with PIP2 acyl chains. 
However, our previous molecular dynamic simulations and the kinetic data in this work 
suggest the hydrophobic site adjacent to the active site (the AHS) could supply residues 
for acyl chain interactions. 
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Indeed, the AHS, which includes residue Arg47 must be involved in PIP2 activation, 
since PIP2 activation is lost in R47G and R47K. Triton X-100, which binds in the 
hydrophobic site, has no effect toward PIP2 activation. DiC7PC, which binds in the 
hydrophobic site but also partially in the active site (since it is a good inhibitor of PTEN 
activity), exhibited no alterations in field cycling parameters in the presence of 
diC8PI(4,5)P2. This would be consistent with occupation of active and activator / 
hydrophobic sites at the same time. Another possibility is that the loop with Arg47 might 
be involved in the conformational change that occurs during PIP2 activation, rather than 
directly interact with the activator molecule. If the loop is too flexible (R47G), the 
structural transition is impaired and no kinetic activation is observed. 
Phosphatidylcholine (PC) is one of the most abundant phospholipids in cell membrane. 
Micellar or monomeric diC7PC inhibit PTEN by binding in both the active site (the 31P is 
close to spin-labels at Cys124 or Cys71 similar to what is seen with diC8PI binding to 
PTEN) and the AHS (it is displaced by Triton X-100 in NMR experiments as well as in 
the kinetics). However, the acyl chains of diC7PC are critical to its binding to PTEN. 
Without occupation of the AHS (i.e., when excess Triton X-100 is added), the diC7PC 
headgroup association and subsequent relaxation are much smaller. This is consistent 
with the report that PTEN has lower affinity for pure PC vesicles (Redfern et al, 2008) 
and with plasma membranes of resting cells (Vazquez et al, 2006). 
The net result of this work is that there are three functionally distinct but spatially close 
sites for amphiphiles to bind: (1) the active site, (2) the PIP2 ‘allosteric’ site, and (3) the 
AHS (adjacent hydrophobic site). The discrete binding site for PI(4,5)P2 could involve 
the N-terminal peptide of PTEN (a region not detected in the crystal structure), since 
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perturbation of Lys13 causes loss of PIP2 activation. However, this binding site is also 
near the active site and its adjacent hydrophobic site since mutation of Arg47 in the latter 
abolishes PIP2 activation. The interplay / synergism of the three sites provides a variety 
of ways to regulate PTEN activity. Like many other signaling proteins that cycle on/off 
the membrane surface, PTEN possess a C2 domain that should transiently anchor it to the 
membranes via PS interactions. However, the presence of an active site, hydrophobic site, 
and activator binding site on the phosphatase domain provides novel ways to regulate 
PTEN activity when it is bound to interfaces.  
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Chapter 5  
 
Archaeoglobus fulgidus IMPase: 
thermoprotection by compatible solutes  
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5.1 Introduction 
As the most ancient domain of life, archaea usually reside in extreme environments. 
Thermophiles and hyperthermophiles thrive only at high temperatures (>60oC). 
Halophiles live in high salinity (>1 M salt), and methanogens live in anaerobic sites. In 
these harsh environments, the ability to maintain cellular function and respond to 
environmental changes is essential. The responses of microorganisms to salt and 
temperature stress often involve the accumulation of ions or small molecules. Archaea 
can accumulate a large amount of K+ to maintain the cell volume during osmotic stress. 
They also accumulate a group of small organic molecules either by uptake from the 
external media or de novo synthesis. These small organic molecules are often referred to 
as osmolytes or compatible solutes, the latter term since although they are accumulated at 
high concentrations they do not interfere with cell functions (Brown, 1976). The diversity 
and the functions of archaeal compatible solutes have been the subject of many reviews 
(Burg & Ferraris, 2008; da Costa et al, 1998; Roberts, 2005; Santos & da Costa, 2002; 
Santos et al, 2011). Common compatible solutes include polyols, sugars, amino acids and 
their derivatives. Along with maintaining the turgor pressure of the cells, it has been 
suggested that compatible solutes can stabilize archaeal proteins. The osmophobic effect 
was proposed to explain the mechanism of the protein structural stabilization (Bolen & 
Baskakov, 2001). It postulates that the interaction between protein backbone and the 
osmolytes is thermodynamically unfavorable. This leads to a more positive free energy 
for unfolded protein compared to in solution with high concentrations of osmolytes than 
unfolded protein in solution without those solutes. The osmolytes stabilize proteins by 
destabilizing the unfolded state. Non-specific interactions with the protein backbone were 
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shown at the single molecule level using atomic force microscopy (AFM) based single-
molecule force spectrometry (Aioanei et al, 2011). These experiments suggest that 
osmolytes may not play a structural role at the unfolding transition, rather they adjust the 
solvation quality for the protein chain. 
Archaeoglobus fulgidus is a hyperthermophile initially found in thermally heated water 
around a volcano (Stetter et al, 1987), but also found in marine sediment (Zellner et al, 
1989) and oil field water (Beeder et al, 1994). This archaeon can thrive in high 
temperatures ranging from 70 to 90°C with an optimal growth temperature around 83°C. 
It normally lives at these temperatures with NaCl equal to or less than 5% w/v in the 
medium, although a variant surviving higher salt in the growth medium (6.3% w/v NaCl) 
has been reported (Goncalves et al, 2003). The compatible solute pool of A. fulgidus has 
been studied under different conditions (Martins et al, 1997). Diglycerol-phosphate (DGP) 
was accumulated upon salt stress, while di-myo-inositol-1,1’-phosphate (DIP) was 
accumulated upon thermal stress (temperature elevation) (Goncalves et al, 2003; Martins 
et al, 1997). For the organism grown in high salinity (4.5% w/v NaCl) compared to lower 
salinity (0.9% w/v NaCl), intracellular DGP concentration increased 11-fold. The 
intracellular DIP concentration was low when the organism grew at 76°C, and after 
increasing the growth temperature to 87°C, intracellular DIP increased 30-fold. Along 
with DGP and DIP, other compatible solutes such as glutamate and 1-glyceryl-1-myo-
inosityl phosphate (GIP) were identified in these cells (Lamosa et al, 2006). Given the 
structures of these phosphoesters (which require significant energy for biosynthesis), it is 
worthwhile to study the roles of these specific compatible solutes in protecting A. 
fulgidus proteins. 
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A. fulgidus inositol monophosphatase (IMPase) is a dual-specificity phosphatase that can 
dephosphorylate inositol phosphates and fructose 1,6-bisphosphates (Stieglitz et al, 2002). 
This enzyme plays a role in the DIP biosynthetic pathway (Rodionov et al, 2007). 
Compared to IMPase proteins from eukaryotes and bacteria, archaeal IMPase 
homologues have structures with shorter loops and helices (Johnson et al, 2001; Stec et al, 
2000), which may account for their higher thermal stability. However, A. fulgidus IMPase 
is not as stable as the IMPase from Methanococcus jannaschii or Thermotoga maritima, 
possibly due to the smaller dimer interface and increased loop sizes (Stieglitz et al, 2002). 
A. fulgidus IMPase irreversibly denatures a little below 90°C (Wang et al, 2006), a 
temperature at which the organism can still live. This prompts the question of what 
stabilizes the IMPase at high temperatures. Previous kinetic studies in our lab of this 
enzyme showed the Km of A. fulgidus IMPase was reduced 8- to 10-fold when the 
temperature increased from 75°C to 85°C, facilitating high activity of this enzyme at the 
high temperatures where DIP is accumulated (Wang et al, 2006). However, the 
thermoprotection and the stabilization of this model enzyme by compatible solutes were 
not investigated. 
In this project, we tested the thermoprotection effect of DIP, DGP and other small 
organic molecules on A. fulgidus IMPase, to find a possible mechanism of how this 
particular enzyme was protected from thermal denaturation during this organism’s 
adaptation to increased temperature. Our results showed that: (1) both enantiomers of 
DIP protected A. fulgidus IMPase from thermal denaturation at temperatures well above 
the unfolding transition; (2) DGP protected A. fulgidus IMPase very effectively, most 
likely by binding in the active site; (3) higher concentrations of aspartate (Asp), 
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glutamate (Glu) and other dicarboxylates protected the A. fulgidus IMPase significantly 
from thermal unfolding, while monocarboxylates and a tricarboxylate were not very 
effective. These observations indicate there are differential effects of these small organic 
molecules, many of them common osmolytes, on the stability of a particular protein. We 
define these differential effects as the compatible solute specificity, whereby only some 
compatible solutes provide thermal protection to a particular protein, while others do not, 
although they may protect other proteins from thermal inactivation; (4) Glu (and Asp) 
ions bind to A. fulgidus IMPase at specific sites, but these specific binding sites on 
IMPase do not correlate with thermoprotection by Glu. However, these sites where Glu 
binds have large effects on the protein thermal stability providing insights into what 
stabilizes this dimer. 
5.2 Result  
5.2.1 DIP thermoprotection 
DIP is accumulated in A. fulgidus (Martins et al, 1997) as well as other thermophilic 
archaea, including Pyrococcus woesei (Scholz et al, 1992), Methanococcus igneus (Ciulla 
et al, 1994) and the bacterium T. maritima (Ramakrishnan et al, 1997), when the 
organism is grown above optimal temperature. It is possible that this molecule protects 
IMPase enzyme at high temperate. DIP is also an odd choice for an osmolyte. When DIP 
was initially identified it was said to be the chiral L,L-DIP enantiomer (Vanleeuwen et al, 
1994). Later studies, based on the biosynthetic pathway suggested that it was not chiral 
but the L,D-enantiomer (Rodrigues et al, 2007). With this in mind, we thought it would 
be useful to investigate if both of these enantiomers have similar effects or only one of 
them is biological relevant in thermoprotection.  
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Prior to testing the effect of DIP on IMPase thermostability, we examined the effect of 
KCl, NaCl and the glutamate salts of each cation (Figure 5.1) in protecting the IMPase 
activity from heating at 95oC for 15 min.  This treatment in the absence of compatible 
solutes nearly inactivated the enzyme; residual enzymatic activity was only 3%.  
Thermoprotection could be observed with 100 mM added salt, although the effects were 
much stronger at higher concentrations of the salts. With 500 mM KCl and K+-glutamate 
present during heating, protein residual activity was ~50% after heating.  Of particular 
interest was the observation that the sodium salts were virtually ineffective in this 
concentration range, while KCl and K+-glutamate were similar and much more effective 
at protecting IMPase activity.   
In order to get a measure of what each stereoisomer of the DIP anion might contribute to 
thermoprotection, we examined the effects of the Na+-salts of DIP (Figure 5.1, bottom).  
The two DIP enantiomers were chemically synthesized using a peptide asymmetric 
catalysis method by Christine Longo in the lab of Prof. Scott Miller at Yale (Longo et al, 
2009). We examined 100 mM of each Na+-DIP on IMPase activity after heating.  
Interestingly, both Na+-L,L-DIP and Na+-L,D-DIP were effective in reducing 
denaturation (17% and 11% residual activity, respectively). In comparison to the 
thermoprotection provided by KCl (18% recovery of activity), it is particularly notable 
that the sodium salts of DIP offer protection while NaCl is completely ineffective, further 
pointing to the thermoprotective properties of the DIP anions. As a control, 100 mM myo-
inositol was also examined for any thermoprotection of this enzyme; the inositol (which 
binds to the active site) alone had no effect. This would suggest that merely occupying 
the active site with inositol offers little thermoprotection when the protein is heated well 
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above its Tm. In addition, the Na+-salt of dimethylphosphate (DMP) offered no 
thermoprotection, indicating that the DIP anion on its own is unique and has significant 
thermoprotective effects. 
 
 
Figure 5.1 Effect of solutes on the residual activity of A. fulgidus IMPase, heated to 
95 °C for 15 minutes, then cooled and assayed at 85°C: ▲, KCl; Δ, NaCl; , K+-
glutamate; □, Na+-glutamate. The bottom figure shows the effect of the sodium salts 
of L,L- (○) and L,D- (●) DIP at 100 mm, as well as dimethylphosphate (DMP; ×) and 
myo-inositol (◊) compared to the K+ salts solutes(dashed lines) shown in the upper 
figure. 
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Due to the availability of only small amounts of DIP compounds, we did not measure if 
high concentration of DIP had any effect to IMPase enzyme activity. However, this 
IMPase can dephosphorylate P-DIP, the phosphorylated form of DIP in vitro, and DIP is 
the product of this dephosphorylation reaction (Rodionov et al, 2007). Based on this 
observation, we speculate that DIP might have affinity for the IMPase active site but this 
affinity should not be very high.  
5.2.2 DGP thermoprotectiont 
Along with DIP accumulation, A. fulgidus also accumulates DGP to balance increased 
salinity (Martins et al, 1997). Unlike the wide usage of DIP by thermophiles, DGP 
accumulation appears to only occur in the genus Archaeoglobus (Santos et al, 2011). We 
tested the effect of DGP, synthesized in the laboratory by Jessica Chao, on IMPase 
activity. However, in this experiment, the protein solution was not heated to 95oC, but to 
90oC. Incubation at a temperature a little above the Tm (87-89oC) is a less radical 
treatment; oxidation of two spatially close cysteine residues in the protein at high 
temperatures leads to loss of enzymatic activity (Stieglitz et al, 2003). Interestingly, DGP 
was found to be inhibitory in standard assays of the IMPase enzyme at 85oC. As little as 
0.4 mM DGP yielded 70% activity relative to samples with no DGP; with 10 mM DGP 
present, the enzyme activity was reduced to 5% of the control. Clearly DGP binds to the 
protein at or in the vicinity of the active site.  
To test the thermoprotective ability of DGP, the IMPase was first heated at 90°C for 30 
min. The protein in the absence of any solutes had 25% residual activity after heating. 
DGP was very effective in protecting the IMPase from the heat-induced loss of activity. 
10 mM DGP, which must be close to saturating its binding site in or near the active site, 
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led to 85% residual activity after heating; with 100 mM DGP the residual activity was 
more than 90% (Figure 5.2). 
 
Figure 5.2 Effect of DGP on the residual activity of A. fulgidus IMPase that has been 
heated at 90°C for 30 min, then cooled and assayed at 85°C 
The IMPase protein thermal stability in the absence or presence of DGP was also 
examined by measuring the melting temperature (Tm) of the protein using circular 
dichroism (CD) spectrometry. With 10 mM DGP (enough DIP to bind in the IMPase 
active site), the operational Tm of the protein increased from 89°C to above 95°C (Figure 
3). This result suggested that by binding in the active site, DGP helps maintain the 
protein secondary structure when the temperature is increased. The enhanced stability by 
DIP is very substantial. It should be mentioned that when the IMPase alone was heated to 
89°C, about 50% of the secondary structure was lost (Figure 5.3 upper), while heating 30 
min at 90°C caused the protein to lose nearly all its enzymatic activity. This finding 
suggested that specific regions of the tertiary structure, and perhaps quaternary structure 
(integrity of the dimer), may be critical for the enzyme activity. 
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Figure 5.3 Thermal stability of A. fulgidus IMPase in the absence (upper panel) and 
presence (bottom panel) of 10 mM DGP. The protein ellipticity in millidegrees at 
222nm was measured by CD spectroscopy as a function of temperature. The protein 
concentrations in these two experiments are 0.07 mg/ml and 0.04 mg/ml in 1ml 
0.01M borate buffer, pH8.0. 
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5.2.3 Effects of common compatible solutes  
Besides DIP and DGP, A. fulgidus also accumulates glutamate ions as one of its 
osmolytes (Martins et al, 1997). Could glutamate as well as other common amino acid 
compatible solutes have any thermoprotective effects on the IMPase? The results should 
reflect any specificity in how the compatible solutes protect this particular protein and 
might be useful in explaining the solute accumulation preferences of this organism. We 
measured the residual activity of the protein after heating at 90°C for 30 min with or 
without KCl, proline, glycine betaine, Na+-glutamate, K+-glutamate, Na+-aspartate and 
K+-aspartate with concentrations of solutes as high as 0.5 M (Figure 5.4). After heating, 
the activity of the heated protein was 25% of that of the untreated protein. Proline and 
glycine betaine offered little thermoprotection. Even at 500 mM, these two solutes could 
only increase the residual activity from 25 to 50% of the untreated protein. KCl showed a 
similar extent of protection to proline and betaine at low concentration with 30% residual 
activity observed with 100 mM KCl present. Better thermoprotection was observed when 
KCl was 500 mM (65% residual activity). K+-Glu, Na+-Glu, K+-Asp and Na+-Asp 
showed similar thermoprotection profiles for the IMPase. Increasing solute concentration 
from 0.05 M, where residual activity was 30%-40%, to 0.5 M yielded residual 
activities >90%. 
As part of the controls in these experiments, we tested the effects of high concentrations 
of different solutes in the standard enzyme assay at 85oC. Under these conditions, Glu 
could inhibit IMPase activity but not strongly. With 20 mM of Glu present, IMPase 
activity was 80% that of enzyme in the absence of Glu in the assay mixture; 300 mM Glu 
diminished the enzyme activity to 50%. The Glu inhibition might suggest Glu could also 
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bind into the protein active site albeit weakly, perhaps achieving thermoprotection by a 
mechanism similar to that of DGP. 
 
Figure 5.4 Effect of solutes on the residual activity of A. fulgidus IMPase, heated to 
90 °C for 30 minutes, then cooled and assayed at 85°C: ▲, KCl; Δ, NaCl; , K+-
glutamate; □, Na+-glutamate; ●, K+-aspartate; ○, Na+-aspartate; ◊, proline; ×, 
betaine. 
For this enzyme, all the effective thermoprotective solutes are anions – either 
phosphodiesters or dicarboxylate amino acids. In order to test if the two carboxylates in 
Asp and Glu were the key features for thermal protection in this class of solutes, we 
measured the thermoprotective effect on IMPase of a number of other dicarboxylates 
(tartrate, succinate, methyl-succinate, maleate and fumarate) along with isocitrate, a 
tricarboxylate. All the dicarboxylate molecules showed very similar thermoprotection 
patterns. Interestingly, the tricarboxylate isocitrate had no protective effect, and in fact 
appeared to destabilize the enzyme to heating (Figure 5.5). With 300 mM of these 
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dicarboxylates present, the protein residual activity after heating was 70 to 90% 
compared to the 25% without solutes. Isocitrate did not inhibit the enzyme in standard 
enzyme assays (the enzyme is not heat deactivated), implying it could not bind to / near 
the active site. In the presence of 130 mM isocitrate, IMPase still had 70% residual 
activity at 85oC when compared to enzyme in the absence of solutes. For the other 
dicarboxylates tested, around 20 mM of dicarboxylates present did not change the protein 
activity very much.  
 
Figure 5.5 Effect of 300 mM dicarboxylates on the residual activity of A. fulgidus 
IMPase heated to 90 °C for 30 minutes, then cooled and assayed at 85°C (solid 
columns); The relative activities of untreated IMPase in the presence of 24 mM 
glutamate, 24 mM tartrate, 18 mM succinate, 12 mM methylsuccinate, 12 mM 
maleate, 18 mM fumarate and 130 mM isocitrate are shown by the hatched columns. 
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5.2.4 Crystal structures of IMPase with Glu and NMR validation of Glu binding sites  
The crystal structures of A. fulgidus IMPase with 25 or 400 mM Glu were solved in our 
laboratory (Goldstein, R. Ph.D. thesis) as an attempt to explore where, if at all, Glu binds 
to the IMPase. In the structure of the IMPase protein cocrystallized with 400 mM Glu, 
each monomer of the protein dimer had four glutamate ions bound. As shown in Figure 
5.6, two Glu ions (Glu1 and Glu2) are bound in well-defined cationic pockets, one 
between Arg11 and Arg18, the other interacting with Arg92, Asn151, Arg165 and 
Lys164. Glutamates occupying these two binding sites were also observed in the crystal 
structure of the IMPase co-crystallized with 25 mM Glu. Two other Glu anions, only 
observed in the structure with 400 mM Glu, were bound in the dimer interface region and 
participated in an extensive hydrogen bonding network in the IMPase structure: Glu3 
interacted electrostatically with Arg18 and Glu4 with Arg29. Since Glu3 and Glu4 
binding sites were empty in the structure of IMPase with 25 mM Glu, these must be 
weaker affinity sites. Interestingly, none of the Glu anions visualized in the crystal 
structures were in the active site. 
The crystal structures identified specific binding sites for Glu on the IMPase protein, but 
at low temperature compared to the growth temperature of the organism. Occupation of a 
binding site in a crystal does not necessarily mean the same site is occupied in solution or 
at higher temperatures. To demonstrate Glu ions were bound to the protein in solution, 
we used high resolution 13C field cycling NMR to detect [1-13C]Glu binding. Since the 
binding is thought to be moderately weak, the sensitivity for detecting interactions was 
dramatically enhanced by using IMPase spin-labeled on cysteine residues with MTSL. 
The 1000-fold larger dipole for an unpaired electron compared to a 1H means that it will 
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dominate the dipolar relaxation of any nearby nuclei. When a ligand is bound to the 
protein it is relaxed by the spin-label, but when it is free in solution that interaction is lost.  
What is observed is a weight averaged relaxation rate. The closer the spin-label is to 
nuclei of the bound ligand, the greater the relaxation. Binding is detected by an increase 
in R1 due to the spin-labeled protein. Since dipolar relaxation for 13C-carbonyls is not 
very effective (the carbonyl carbon of Glu has no directly bonded protons), it is easy to 
detect a low field rise (where the relaxation is dipolar and not chemical shift anisotropy) 
if binding occurs (Pu et al, 2009b).  
 
Figure 5.6 Crystal structure of A. fulgidus IMPase co-crystallized with 400 mM 
sodium glutamate. The protein dimer structure is shown in grey; Glu1 is in yellow, 
Glu2 in cyan, Glu3 in magenta, and Glu4 is shown in green. 
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Each IMPase monomer contains 4 cysteines (Figure 5.7). As shown before, Cys150 and 
Cys186, which are in close proximity (S atoms within 4 Å of one another) form a 
disulfide bond when the protein was oxidized; this abolishes enzyme activity (Stieglitz, 
2003). These two cysteines are difficult to chemically modify with sulfhydryl reagents. 
The other two cysteines, Cys102 and Cys177, are readily accessible to thiol reagents; 
their modification does not inactivate the enzyme. After treating IMPase with MTSL, 
each monomer of the dimeric protein should have a nitroxide attached to Cys102 and 
Cys177. Although the spin-labels on these two Cys are not directly next to any of the 
potential Glu binding sites, one of them (Cys177) is close enough for the unpaired 
electron to contribute to the low field dipolar relaxation of Glu ligands that bind to the 
protein. As shown in Figure 5.7, one of the spin-labels is closest to the Glu3 site (one of 
the ‘weak’ sites in the crystal structure), but it is also not that far from Glu2, a tight site 
occupied in the crystal structure with ‘low’ (0.025 M) Glu and a bit further from the other 
sites. Furthermore, the spin-label on one monomer is close to the Glu3 on each monomer, 
so when this weaker affinity site is occupied, there should be substantial relaxation of the 
13C by the spin-label (i.e., at high Glu). Neither spin-label is very close to Glu1 and Glu4 
sites, although there may be some effect on relaxation of Glu that bind here. The other 
labeled Cys is far from all the Glu sites and since R1 due to the unpaired electron depends 
on r-6, it will not have much of an effect on Glu occupying any of the binding sites. 
 151 
 
 
Figure 5.7 A. fulgidus IMPase dimer showing the four glutamate binding sites on the 
protein (where orange, blue, green and red Glus bind) and the two Cys per 
monomer that are spin-labeled. The two attached nitroxide structures are shown as 
yellow sticks on one of the monomers (Goldstein, R., Ph.D. thesis) 
The 13C-labeled carbonyl carbon of Glu has no directly bonded protons, so its dipolar 
relaxation is not very effective, and R1 is quite low (typically 0.02 s-1) at low fields. In the 
absence of spin-labeled protein, the R1 field dependence profile of 25 mM α-13C-Glu 
(Figure 5.8) shows no low field rise, indicative of the small molecule binding to the much 
larger protein. Even with unlabeled IMPase added, there is no significant effect of the 
protein on R1. However, with the spin-labeled protein, there is a detectable rise in R1 
below 4 T that reflects Glu binding to the protein. For the initial experiment, 10 mM Glu 
was used and 1 mg/ ml (0.036 mM) of the spin-labeled protein (Figure 5.9). The field 
dependence of the 13C-Glu R1 was measured at 25°C. With 10 mM Glu, at most Glu will 
occupy sites 1 and 2 if the Glu sites seen in the crystal structure are also occupied in 
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solution. As seen in Figure 5.9A, there is a small but measurable increase in R1 below 4T 
compared to the sample with either unlabeled protein or no IMPase. Extrapolation to 
zero-field of R1 yields a parameter, ∆RC-e(0), that reflects how close the spin-label is to 
the α-carbonyl of any bound Glu. This small effect suggested that a larger amount of 13C-
Glu (for better signal-to-noise and also to perhaps increase occupancy of Glu binding 
sites on the protein) and spin-labeled protein (to make sure a robust PRE was seen) 
should be used.  
 
Figure 5.8 Spin-lattice relaxation rate for free α-13C-labeled Glu in the absence (●) 
and presence (×) of unlabeled IMPase. 
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Figure 5.9 (A) Spin-lattice relaxation rate, R1, for the 13C-labeled α-carboxylate of 
glutamate as a function of magnetic field in the absence (○) and presence  (●) of 
spin-labeled IMPase (1 mg/ml = 0.036 mM). (B) The relaxation rate, ΔR1 = 
R1(+IMPase-SL) – R1(-IMPase), specifically attributed to the presence of the spin-labeled 
protein. 
Figure 5.10A shows ∆R1 as a function of field for 25 mM 13C-Glu in the presence of 3 
mg/ml (0.11 mM) spin-labeled IMPase. The profile is shown for two temperatures, 25 
and 45oC. Although the correlation times for the interaction have a fair amount of error, 
the ∆RC-e(0) values are clearly different. Increasing the temperature appears to populate 
more Glu sites on the protein. We can also show that the effect is specific to protein 
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binding. Alanine is neither an osmolyte nor a ligand for the IMPase. In a sample of 25 
mM α-13C-alanine and α-13C-glumatate, the low field rise is significant for the Glu 
whereas only a very small effect (within the error in measuring the relaxation rates) is 
seen for Ala (Figure 5.10B). 
 
Figure 5.10 (A) Spin-lattice relaxation rate attributed to spin-label, ∆R1, for the 13C-
labeled α-carboxylate of 25 mM glutamate at 25 and 45°C. (B) ∆R1 for 25 mM 
glutamate (●) or alanine (○) as a function of magnetic field in the presence spin-
labeled IMPase (3 mg/ml = 0.11 mM) 
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We can get a sense as to average binding affinities of Glu for the IMPase by determining 
∆RC-e(0) for different concentrations of Glu and normalizing the value to the ratio of Glu 
to spin-labeled protein. The resultant parameter, vC-e, is a normalized measure of Glu 
binding (somewhat like the specific activity of an enzyme (Pu et al, 2009b)). If there 
were a single site, the dependence of this on Glu concentration should saturate.  
vC-e = [Glu][IMPase-SL] × ∆RC-e(0) 
If there are multiple Glu sites with not only different affinities but different distances 
from spin-labels the concentration dependence will be much more complex. As shown in 
Figure 5.11, the plot of vC-e versus [Glu] is neither hyperbolic (for a single Glu site) or 
sigmoidal, but rather shows two distinct regimes. Below 30 mM the dependence of νC-e, 
on glutamate concentration is approximately hyperbolic. At higher concentrations there is 
a much steeper rise in this parameter that does not look hyperbolic. It likely represents 
occupation of a weak site that is fairly close to the spin-label, most likely Glu-3. Thus, 
the field cycling 13C-NMR experiments show that (i) multiple Glu with different affinities 
bind to the spin-labeled IMPase in solution, and (ii) a weak site is closer to the spin-label 
(on Cys177) than to either tight Glu site. 
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Figure 5.11 Binding of [1-13C]Glu to spin-labeled IMPase (0.1 mM) as a function of 
glutamate concentration. 
5.2.5 Mutation of Glu binding sites and effect on thermoprotection by Glu  
In order to see if the specific binding of Glu correlates with its thermoprotection of the 
IMPase, mutations were constructed to remove each of the specific Glu binding sites. 
Single mutants, R18A, R29A, R92Q, K164E, double mutant R11A/R18A, R92Q/K164E, 
and quadruple mutant R11A/R18A/R92Q/K164E were produced. As used with wild type 
protein, field cycling 13C NMR was also used to detect if the Glu binding was lost by 
disruption of the interaction between the protein side chains and glutamate ions. The 
mutant IMPase R92Q/K164E was constructed to remove the ‘tight’ Glu 2 binding site. 
This is not the closest Glu to the spin-label sites in the structure, so one would expect that 
13C-Glu is still able to bind to some sites and is relaxed. When this mutant protein, which 
is essentially as active as wild type IMPase, was spin-labeled and then used in an field 
cycling-C-NMR experiments, there was about a 40% decrease in ∆RC-e(0) (Figure 5.12). 
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This indicates that relaxation of ‘tightly’ bound Glu 2 contributes significantly to overall 
13C-Glu relaxation. The rest of the relaxation has contributions from Glu 1, likely 
significantly occupied, and perhaps a smaller amount from partially occupied Glu at sites 
3 and 4. We could even estimate rC-e, as long as 25 mM Glu saturated site 2. 
 
Figure 5.12 R1 for 25 mM α-13C-Glu as a function of field with 0.1 mM spin-labeled 
(○) IMPase or (●) R92Q/K164E. 
Before we tested the Glu and Asp effect on the mutant proteins, the mutant protein 
thermal stability in terms of the melting temperature (Tm) was first measured by CD 
spectrometry. Surprisingly, except for a single variant (K164E) all mutations of the Glu 
binding sites decreased the protein Tm by 7 to 20°C compared to the protein wild type 
(Table 5.1), with R11A/R18A and the quadruple mutant having the lowest melting 
temperature, 69°C, which is 20°C lower than that of protein wild type. This is a striking 
result since the mostly cationic residues modified are on the surface of the IMPase. 
K164E had higher Tm, > 95°C, which could not be measured accurately. Initially in 
studying this enzyme, we purposely tried to reduce the Tm by replacing large aliphatic 
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groups in secondary structure with alanine, an approach thought to reduce overall protein 
stability (Szilagyi & Zavodszky, 2000). Mutations of internal hydrophobic residues to 
Ala included L57A, V142A and L148A. These three hydrophobic mutant proteins 
showed little effect on Tm, at most a 5° drop (Table 5.1).  
Table 5.1 Mid-point of the thermal denaturation temperature (Tm) of A. fulgidus 
IMPase wild type and mutants determined from CD measurements at 222 nm as a 
function of temperature. The denaturation is irreversible so the apparent Tm cannot 
yield a true thermodynamic parameter but serves as a way to compare mutant 
protein stability to wild type protein (WT). The Glu binding site(s) thought to be 
disrupted by the mutation are indicated. 
A. fulgidus IMPase Tm °C Glu binding site disrupted 
WT 89  
R18A 85 Glu3 
R29A 82 Glu4 
R92Q 75 Glu2 
K164E ~95 Glu2 
R11A/R18A 69 Glu1 
R92Q/K164E 71 Glu2 
R11A/R18A/R92Q/K164E 68 All sites 
   
L57A 84  
V142A 89  
L148A 89  
 
The effect of mutations on the Tm complicated testing for thermoprotection by Glu. In 
order to test if the loss of Glu binding sites causes the loss of Glu thermoprotection, we 
first adjusted the heating temperature for every mutant so that all mutants except K164E 
had 25% residual activity detected after heating for 26-30 min without any Glu or Asp 
anions. Next we tested the thermoprotective effect of Glu and Asp on all these variants 
except K164E. The mutant proteins were all still well protected by Na+-Glu and Na+-Asp 
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with the solute concentration dependence similar to the wild type protein. With 100 mM 
Glu or Asp present, at least 50% residual activity was observed; with 500 mM solutes, 
the mutant protein activity after heating was completely recovered (Figure 5.12). Since  
 
 
Figure 5.13 Effect of sodium aspartate (upper panel) and sodium glutamate (bottom 
panel) on the residual activity of A. fulgidus IMPase wild type (●), R18A (), R29A 
(♦), R92Q (▲), R11A/R18A (□), R92Q/K164E (Δ) and R11A/R18A/R92Q/K164E (×). 
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the thermal stability of the K164E variant was better than that of the wild type protein 
(after heating at 95°C for 30 min, 60% residual activity was seen in the absence of 
solutes), we could not test if Glu and Asp still had any thermoprotective ability.  
The experiments with these Glu-site mutants indicated that although Glu ions could bind 
to IMPase protein at very specific sites, those binding sites could not account for the Glu 
and Asp thermoprotection. Rather, the residues in these sites were important for 
maintaining the protein stability. For Glu binding site mutants, Glu still protected the 
enzymes from thermal denaturation, although the mutants were as not as thermally stable 
as the protein wild type. 
5.3 Discussion 
For all three kingdoms of life, it is necessary to adapt to environmental fluctuation, such 
as changes in temperature, salinity, pH or pressure. Organisms in all three kingdoms 
(archaea, bacteria and eukaryotes) accumulate compatible solutes as part of the response 
to these environmental changes (Burg & Ferraris, 2008). There are some compatible 
solutes that are seen everywhere - glutamate and betaine are accumulated by 
representative organisms in all domains while other osmolytes are only accumulated by a 
subset of organism. A good example of the latter is the accumulation of DIP and DGP by 
thermophiles and hyperthermophiles (Santos & da Costa, 2002). In general, methanogens 
prefer to accumulate organic anions under high salt stress, and one often sees a switch in 
the osmolyte composition from zwitterionic and nonionic solutes to anions with 
increasing salt (Ciulla et al, 1994; Robertson & Roberts, 1991). The reasons for this 
specificity of osmolytes accumulation are not known, although it has been suggested that 
evolutionary selection is the origin of this specificity (Santos et al, 2011). Along with 
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understanding the effects of specific solutes, the study of how compatible solutes 
stabilize proteins has much practical use. Compatible solutes could help protein folding 
and suppress protein aggregation, thus they could be used as additives to enhance protein 
expression in vitro, or as potential therapeutic agents for diseases caused by protein 
folding defects or protein aggregation (Rajan et al, 2011). In this project, we studied 
compatible solute thermoprotection effects on the model enzyme IMPase from the 
archaeon Archaeoglobus fulgidus.  
5.3.1 DIP – a solute generated in response to very high temperatures 
First we tested an unusual compatible solute, DIP, restricted to hyperthermophiles. 
Although L,D-DIP is now generally accepted as the natural product accumulated by 
hyperthemophiles (Rodionov et al, 2007), our studies of DIP thermoprotection of A. 
fulgidus IMPase showed both the L,D-DIP and L,L-DIP had similar effects. Both of these 
two enantiomers protected the IMPase enzyme from thermal denaturation. Since both 
molecules were effective, either the stereochemistry of this compatible solute is not 
critical or only part of the molecule (perhaps only one of the inositol rings and the 
phosphate) is important in thermoprotection. The latter could be the case if the DIP 
interacted with the protein active site which has room for one inositol ring but not two. 
More generally, the fact that the two DIP enantiomers were more or less equivalent is 
very intriguing since it suggests that the lack of chirality of the natural product, at least in 
this case, arises from biological synthetic convenience, not the more conventional 
thought of evolutionary optimization. Neither myo-inositol or dimethylphosphate had any 
thermprotective effect in the same conditions, an indication that something binding to the 
active site or a negative charge (in this case another phosphodiester) are the critical 
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components of DIP thermoprotection, For this system, there is concrete evidence for 
compatible solute specificity in acting as a thermoprotectant for the A. fulgidus IMPase. 
DIP thermprotection of other proteins has been reported.  For example, 115 mM DIP 
could enhance the thermal stability of glyceraldehyde-3-phosphate dehydrogenase 
(Scholz et al, 1992). But it is also surprising that in some cases DIP destabilizes proteins. 
The study of DIP effects on the model enzyme rabbit muscle lactate dehydrogenase 
(LDH) showed LDH residual activity after heating with DIP present was much less than 
that when the protein was heated alone, although they also mentioned that the 
thermostabilization effect of a compatible solute was dependent on the experimental 
conditions used in measuring (Borges et al, 2002). So the effect of DIP may depend on 
individual enzyme. Nonetheless it should be stressed that DIP is specifically accumulated 
in hyperthermophiles when subjected to supraoptimal temperatures. It is a complex solute 
to synthesize needing as starting material two glucose-6-phosphate and a CTP molecule. 
Given that high energy cost, it must be very effective in the organisms that accumulate it, 
although we do not have details about its mechanism of thermoprotection. 
Detailed studies supporting the osmophobic or osmolyte effect have suggested that the 
hydrogen bonding between the protein backbone and the solvent plays a crucial role in 
determining if an osmolyte is protective to protein or not (Bolen & Rose, 2008). When 
transferring the protein from buffer solution to osmolyte solution, the overall transfer free 
energy is determined by the free energy of transferring protein backbone from aqueous 
solution to the osmolyte solution, which is in turn controlled by the free energy difference 
between forming the backbone-solvent hydrogen bonds and the backbone-backbone 
hydrogen bonds. In aqueous solution, since forming intramolecular hydrogen bonds in 
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protein is more thermodynamically favorable than forming the hydrogen bonds between 
the backbone and water, protein is more stable in the folded or native state. The presence 
of the protecting osmolytes diminishes the water solvent quality that further disfavors the 
hydrogen bond formation between the protein backbone and solvent, resulting in the 
stabilization of the protein native state. The ability of an osmolyte to change solvent 
quality has been confirmed by recent studies, both experimentally (Aioanei et al, 2011) 
and theoretically (Aioanei et al, 2012). If we apply this theory to our results with DIP, it 
is possible that increased temperature breaks the hydrogen bonding in proteins to lead to 
protein denaturation, while DIP enhances intramolecular hydrogen bond formation in the 
protein thereby stabilizing it in its native state. This enhancement is achieved by lowering 
the solvent ‘quality’ of activity. Although the details of this solvent quality change are 
not known, it is possible that at high temperatures the formation of hydrogen bonds 
between DIP and water molecules is more favorable than forming hydrogen bonds 
between water and the protein backbones, which in turn promotes intramolecular bond 
formation in protein and leads to protein stabilization. 
5.3.2 DGP – a very effective thermoprotectant because it binds to the IMPase active 
site 
DGP is the compatible solute accumulated by A. fulgidus when the salt concentration in 
the environment is increased. The intracellular concentration of DGP in A. fulgidus 
grown in high salinity conditions (4.5% NaCl, 76°C) was reported as 1.4 μmol/mg 
protein, equal to an intracellular concentration of 350 mM (Lamosa et al, 2000). Our 
DGP studies suggested that this molecule is an excellent thermoprotectant of the IMPase. 
However, if the intracellular DGP concentration is 100 mM or higher (as suggested from 
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analyses of osmolyte content in A. fulgidus), the enzymatic activity of the IMPase would 
be extremely low because DGP is such an effective inhibitor of the enzyme. This 
observation may explain why intracellular DIP concentration does not increase 
dramatically when the external salt concentration is increased.  
The highly protective effect of DGP has been reported for other proteins. 100 to 200 mM 
DGP minimized the activity lost by rabbit muscle LDH and baker’s yeast alcohol 
dehydrogenase (ADH) upon heating (Lamosa et al, 2000). Similar concentrations of DGP 
(100 mM) also protected Desulfovibrio gigas rubredoxin for thermal denaturation 
(Lamosa et al, 2000; Lamosa et al, 2003). By using computational methods, researchers 
suggested DGP protected D. gigas rubredoxin by specifically binding to a loop which 
was important for protein activity and restraining its movement in order to retain the 
protein activity during heating (Micaelo et al, 2008). 
Our kinetic studies provide evidence that DGP can bind into the active site of IMPase. 
The crystal structure of DGP with IMPase (Goldstein, R., unpublished) had a DGP 
molecule in the active site in each monomer. The increase in the protein denaturation 
temperature with DGP present (form 89 to >95oC) indicated that DGP bound at the active 
site stabilizes the protein secondary structure during heating. These observations provide 
a likely mechanism for DGP thermoprotection of A. fulgidus IMPase. At high 
temperatures, DGP binds into the protein active site and increases the overall protein 
stability so that much higher temperatures would be needed for heat denaturation. 
Relatively little (compared to typical osmolyte concentrations) DGP is needed to stabilize 
the IMPase.  DGP may be critical to the survival of the A. fulgidus at 90°C as it starts to 
divert resources to synthesizing DIP. DGP protection of rubredoxin suggested rigidifying 
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the protein is the critical event. DGP could have a similar effect on IMPase, possibly by 
binding in the active site and restricting motion of a mobile loop that contributes a ligand 
for Mg2+ binding (Li et al, 2010). 
Glutamate ions could also protect IMPase from thermal denaturation. Since Glu is 
accumulated by this organism (Martins et al, 1997), this solute also aids in thermal 
stabilization. In fact, Glu is one of the common ions used in all three domains of life to 
counteract osmotic and thermal stress. However, Glu was not an effective compatible 
solute for IMPase once a large amount of loss of secondary structure occurred. When the 
cells were incubated for 30 min at 95oC, the unfolding transition with a Tm of 89°C, was 
nearly complete. We showed that when the protein was heated to 95oC, very little 
enzymatic activity was recovered if the denaturation was done with glutamate. In contrast, 
heating with DIP served as a much more effective thermoprotectant. Heating the sample 
to 90oC leads to loss of a little over half the secondary structure and loss of most of the 
catalytic activity. Under these conditions, the presence of glutamate could stabilize the 
protein. However, 300 mM Glu was needed to protect the protein to the same extent as 10 
mM DGP.   
The identification of Glu binding sites on the IMPase by crystallography can provide 
insight into the specificity of compatible solutes in protecting a particular protein, 
although the conditions were very different for measuring Glu protection of enzymatic 
activity and for obtaining a crystal and collecting diffraction data (done in cryo 
conditions). Glu thermoprotection residual activities were assayed at 85°C, while protein 
was crystallized with Glu at 20°C. Glu sites in a crystal may not be occupied at high 
temperatures. 13C field cycling NMR experiments showed two types of sites exist in 
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solution ant up to 45oC. At the moment that is the safe upper temperature limit for 
cycling, although current alterations of the machine may allow us to examine data up to 
65o and possibly higher. Increasing the temperature often weakens the binding of ligands 
to a protein, and this could be the case here. Further studies are warranted in exploring 
this aspect of Glu sites on the A. fulgidus IMPase. 
One of the surprising outcomes of this work was that the mutation of several of the Glu 
binding sites dramatically reduced IMPase thermal stability. Normally it is suggested that 
thermophilic proteins have higher stability by reducing the size of any cavities, the length 
of surface loops, and increasing the number of salt bridges or hydrophobic contacts 
(Szilagyi & Zavodszky, 2000). Our results link surface cationic sites to thermal stability 
of the native protein. The only exception to a decrease in Tm in the series of mutants that 
we examined was K164E. Its Tm increased compared to normal protein. The reason for 
this is clear when one examines the crystal structure of this protein. An additional salt 
bridge can be formed by the new Glu residue at position 164 with Arg165. Adding two 
salt bridges in the dimer significantly enhances IMPase stability.  
According to conventional wisdom, mutation of internal hydrophobic residues (Val, Leu 
and Ile) to Ala should reduce the hydrophobic contacts in the protein and lead to 
destabilization. We created several of these mutations to destabilize the IMPase. L57A 
was the only one with a significantly lower denaturation temperature. However, this 
mutation only reduced Tm by 5°C. In contrast, mutation at a Glu binding site could reduce 
Tm by as much as 20°C, which was very surprising. It was reported that mutation of 
charged surface residues of Alicyclobacillus acidocaldarius esterase 2 disrupted the ion 
network on the protein surface and reduced Tm of the protein (Pezzullo et al, 2013). But 
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for R11A/R18A mutant, which had the lowest Tm, the sites for Arg11 and Arg18 are on 
the protein surface and not involved in any salt bridges with other residues. Therefore, 
using salt bridge disruption to explain what we observed for the IMPase Tm change is not 
viable. Superimposition of the crystal structure of R11A/R18A with that of wild type 
protein shows little difference, so the decreased Tm is not caused by structural change of 
the protein. One possible explanation that cannot be excluded is that an important water 
network that links the two monomers in the dimer is linked to these Arg on helix A, and 
once disrupted the protein is less stable. Another possible explanation is that mutation of 
surface arginines to alanines increases the likelihood of IMPase aggregation as some 
regions of the protein unfold transiently at high temperatures. 
The results of the thermoprotection of the Glu mutants were equally surprising. Crystal 
structures of the mutants clearly indicated the loss of specific Glu binding sites. In one 
mutant (R11A/R18A) three of the four Glu sites were abolished (R. Goldstein, Ph.D. 
thesis). Thus, the Glu sites we see in the crystal do not appear to be directly linked to 
thermoprotection. However, in the Glu thermoprotection assay controls, we noticed that 
high concentrations of Glu could inhibit IMPase activity. Furthermore, a crystal structure 
of IMPase wild type protein with Asp, which also protected protein, showed that an Asp 
molecule occupied the active site (R. Goldstein, Ph.D. thesis). These results suggested 
Glu might protect IMPase in the similar way to DGP – it works by binding around or in 
the active site to stabilize the protein, possibly by restraining the mobile active site loop 
that provides a ligand for one of the three Mg2+. Since the affinity of Glu for the protein 
active site, as measured by inhibition of catalytic activity, is weaker than that of DGP, it 
would be expected to be a less potent thermoprotectant. However, Asp is a more potent 
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inhibitor of IMPase activity but has the same thermoprotective effect as Glu. This would 
argue that active site binding is not necessarily the only reason behind thermoprotection. 
For the archaeal IMPase proteins that have higher thermal stabilities, it was suggested 
that it was due to a shorter mobile active site loop (Stieglitz et al, 2002) (Figure 5.14). 
This mobile loop is important for metal ion binding and protein activity (Li et al, 2010). 
When protein bound to substrate and metal ions, the mobile loop became less flexible and 
structured (Stieglitz et al, 2002). Glu (and other solutes) may interact with this loop at 
higher temperatures to stabilize the protein structure during heating (Figure 5.14 left). It 
is difficult to demonstrate involvement of the mobile loop in compatible solute 
thermoprotection, since mutations in this mobile loop will lower the protein activity. 
Although we did not detect a bound Glu interacting with this mobile loop in the crystal 
structure, the mobile loop of A. fulgidus IMPase contains two lysines at residues 37 and 
43, and Lys31 occurs right before the beginning of the mobile loop (Figure 5.14 right). It 
is possible that at very high temperatures transient interactions between Glu anions and 
the mobile loop occur. 
There is well-defined specificity in what solutes protect this IMPase. Diverse 
dicarboxylates protected IMPase protein from thermal denaturation, while 
monocarboxylates (betaine, proline, acetate) or a tricarboxylate (isocitrate) could not. It 
has been noted that negatively charged compatible solutes provide better protection of 
proteins from thermophiles than neutral / zwitterionic ones (Borges et al, 2002; Santos et 
al, 2011). In our experimental conditions, all these carboxylates were negatively charged 
(heating and residual activity measurement were conducted at pH 8). The isocitrate 
anions even had three negatively charged carboxylates, so just a net negative charge 
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could not explain the difference in effectiveness of thermoprotection. It is possible (and 
in fact probable) that the non-amino acid dicarboxylates could bind to the Glu binding 
sites on the IMPase. However, binding of Glu at those sites does not correlate with 
thermoprotection. Perhaps dicarboxylates can interact weakly with the mobile loop and 
reduce its flexibility, while the isocitrate can chelate Mg2+ if it is near the active site and 
reduce the enzyme activity by depleting the effective concentration of Mg2+, and a 
monocarboxylate does not had two separate negatively charged groups that appear to be 
important for thermoprotection. 
 
Figure 5.14 Left: IMPase monomer with 4 glutamates (colored orange, blue, green 
and red) binding. The mobile loop (residue 32-43) is highlighted in magenta. Right: 
IMPase monomer with mobile loop in magenta. The side chains of Lys37 and Lys43 
in the mobile loop as well as Lys 31 before the mobile loop are shown. The side 
chains of residues Arg11, Arg18, Arg29, Arg92 and Lys164 are also shown with 
nitrogen atoms colored in blue. 
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The osmophobic effect theory explains compatible solute thermoprotection in terms of 
protein folding thermodynamics. The strength of the stabilizing effect of the osmolyte is 
dependent on the energy difference of the protein backbone interacting with water and 
with the osmolyte molecules, which was negatively correlated with the fractional polar 
surface area of an osmolyte. Thermoprotective osmolytes are excluded from the protein 
surface since their interactions with the protein backbone are less favored than water 
interacting with backbone (Bolen & Baskakov, 2001; Street et al, 2006). In this study of 
the thermoprotection effect of compatible solutes on our model protein, A. fulgidus 
IMPase, Asp and Glu have well defined binding sites on the protein. However, these 
specific sites are not needed for thermoprotection by the osmolytes. While this result 
appears more consistent with the osmophobic effect, invocation of that nonspecific 
interaction does not explain the observed specificity in osmolytes. Perhaps, both types of 
interactions occur in this particular system.  
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Chapter 6  
 
Future Directions 
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My thesis work has provided answers to questions in two important (and very different) 
biological systems. It has also suggested new interesting questions to be answered. In the 
PTEN hydrophobic site studies, we demonstrated the importance of Arg47 in providing 
hydrophobic interactions with lipid substrates. Besides Arg47, Asn48 is also well 
conserved among species (see Figure 3.6). Furthermore, Asn48 mutations (N48I, N48D, 
and N48K) in patients have also been reported (Liu et al, 2000; Reis et al, 2000; Vega et 
al, 2003). These results indicated the importance of this particular residue, and this can be 
revealed by studying the kinetics and lipid binding of Asn48 mutants. Along with Asn48, 
in the pβ2-α1 loop where Arg47 resides, there are two hydrophobic residues, Val45 and 
Tyr46 right before Arg47. Do these two residues also contribute to the hydrophobic 
interaction with acyl chains? The answer, based on the MD simulations of substrate 
diC8PI(3)P binding to the PTEN phosphatase domain, is that they probably are important, 
but this should be demonstrated experimentally. In the simulations, Val45 interacted with 
short-chain substrate PI(3)P acyl tails (Wang et al, 2010). Studying mutations of these 
two residues should provide more details about the role of this hydrophobic site in PTEN 
lipid membrane binding. 
In PI(4,5)P2 activation studies, we used field cycling 31P NMR to provide more evidence 
for a discrete binding site for PIP2. However, due to the multiple labeling of PTEN 
cysteines with MTSL spin-labeling reagents, we could not directly calculate accurate 
distances between PIPx and the active site Cys124. It would be ideal if Cys124 or Cys71 
were the only site where spin-label is attached. This is hard to achieve, and one possible 
way is to mutate the other nine cysteines into serines. This method will have high risk 
since there is no guarantee that after all the mutations the protein will be properly folded 
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and still active. After an accurate distance between PIP2 and Cys124 is obtained, 
computer simulations could help build a model for the PIP2 site. This information may 
provide insight into the relative position of the N-terminal loop, the most probable PIP2 
binding site, with the protein active site as the reference.  
The conformational change of PTEN induced by binding PI(4,5)P2 is another aspect 
worth investigating. Preliminary IR results reported by Redfern et al (2008) only 
provided very rough information about this conformational change. Other methods can 
also be used. One promising method is hydrogen/deuterium exchange mass spectrometry 
(HXMS) (Marcsisin & Engen, 2010). This method utilizes mass spectrometry to measure 
the rate of protein amide protons exchanging with deuterium under different conditions 
and is very useful to study protein folding, protein-lipid and protein-protein interactions. 
The incorporation of the deuterium into pepsin digested peptide fragments can be 
detected by the shift of peptide m/z value, and the H/D exchange rate of a defined region 
of the protein (characterized by the specific peptic digested peptides) is a measure of the 
extent of their solvent exposure. The protein conformational change upon activation 
detected by HXMS has already been reported in many cases, such as Akt (Guo et al, 2009) 
and PI3K (Burke et al, 2012). Very preliminary data for PTEN HXMS was done when I 
worked in Prof. Patrick Wintrode’s laboratory when he was at Case Western Reserve 
University. It was shown that about 60% of peptides fragments generated by PTEN 
peptic digestion could be detected by mass spectrometry (Figure 6.1). This result proved 
the feasibility of using HXMS method to study PTEN conformational changes upon 
activation. This could be achieved by comparing the exchange files of PTEN with or 
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without PI(4,5)P2 to probe regions where the conformational changes occur upon binding 
of that phospholipid and subsequent activation. 
 
Figure 6.1 Peptide coverage map of PTEN after peptic digestion. 5 μg PTEN was 
mixed with 200 μl 100mM NaH2PO4, pH 2.5. Protein was digested by 5 μg pepsin in 
100 mM NaH2PO4, pH 2.5, at 0°C for 5 min. The digested sample was injected into a 
micropeptide trap connected to a C18 HPLC column coupled to a Finnigan LCQ 
quadrupole ion-trap mass spectrometer. Fragment peptides were eluted using a 
gradient of acetonitrile in water (2%-45% CH3CN, 60min) and sequenced by 
tandem mass spectrometry experiment. The fragments were identified using the 
search algorithm SEQUEST and manual inspection. Identified peptides are 
indicated by blue bars under the protein sequence. Helices are shown as cylinders 
and β-sheets as arrows. Positions of the N-terminal PIP2 binding motif (PIP2), the 
hydrophobic site (phobic), the P loop, WPD loop, TI loop, CBR3 loop and PDZ 
binding domain (PDZb) are shown in grey boxes. 
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In searching for mechanisms for the thermoprotection of A. fulgidus IMPase, we found 
evidence that both DGP and DIP likely are very effective because they bind to the active 
site. However, glutamate has little affinity for the active site. I proposed that one possible 
protection mechanism for glutamate ions was to stabilize the mobility of the mobile loop. 
Interactions of glutamates with that mobile feature could occur by their interactions with 
positively charged residues in the mobile loop. There are three candidate residues in the 
loop: Lys31, Lys37 and Lys43. It is worth mutating each or all of them and measuring the 
effect of glutamate on the IMPase thermostability at 90oC. If there is a loss in 
thermoprotection by the glutamate, then we would imply motions of the mobile loop are 
a major problem as the temperature is increased. Glutamate and many of the 
dicarboxylates could transiently interact with this region to keep the loop from unraveling 
more of the protein. A discretely bound glutamate need not persist. Since the wild type 
IMPase is still quite stable, these experiments might be best done with one of the Glu-site 
mutant IMPase proteins. Overall, these results should provide tests of our proposed role 
for all the dicarboxylate compounds. 
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AppendixI  
 
Study of PTEN binding to phospholipid 
vesicles by fluorescence spectroscopy 
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1. Introduction 
In the PI3K/Akt signaling pathway, PTEN is the gatekeeper, requiring it to bind to lipid 
membranes to dephosphorylate PI(3)P molecules thus preventing generation of PIP3. In 
resting cells, most PTEN protein is in the cytosol. Clearly an important question is how 
PTEN binds to the membrane. To test PTEN membrane binding, we used lipid vesicles as 
the membrane model, and used fluorescence energy transfer spectroscopy (FRET) to 
detect the interactions between the PTEN protein and the membrane vesicles. Tryptophan 
residues in PTEN, excited at 285 nm, would be expected to transfer that excitation energy 
to an appropriate fluorophore in vesicles if the distance between the protein and the 
vesicles is within the effective distance of FRET (usually within 30 Å). If FRET is 
observed when mixing PTEN and fluorophore-containing vesicles together, the protein 
has bound to the vesicles. Different kinds of phospholipids were mixed with POPC, 
which served as the matrix, to assess their necessity for protein binding. 
2. Results 
(1) Effect of vesicles composition to PTEN binding 
As a control, only matrix POPC vesicles were used for PTEN binding studies. After 
adding 2 mol% of PE with a dansyl group on the amino group (dansyl-PE) into POPC 
vesicles, emission of Trp fluorescence at 340 nm was decreased and emission of the 
dansyl fluorophore at 520 nm was observed, indicating energy transfer from Trp to the 
dansyl group. The energy transfer was measured by the decrease in Trp emission. As 
more dansyl-labeled vesicles were added, Trp emission continued to decrease. Binding of 
PTEN to the POPC vesicles was weak with no saturation of the curve showing the loss of 
intensity via FRET. A problem with such weak binding is that LUVs scatter light and this 
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alters the fluorescence signal as the LUV concentration increases. For weak binding, it is 
extremely difficult to estimate a meaningful apparent dissociation constant (Kd) (Figure 
Apx 1). 
 
Figure Apx 1 The fluorescence energy transfer from PTEN to 2 mol% Dansyl-PE 
containing vesicles. 0-3 mM LUVs of 98 mol% POPC LUVs (●) and 10 mol% soy 
PI/88 mol% POPC (), 0-2 mM LUVs of 10 mol% DOPA/88 mol%POPC (♦) and 10 
mol% DOPS/88 mol%POPC (×) were titrated into 1.5 μM PTEN, and the fraction 
of Trp emission decrease (I0-I) to the initial emission ((I0-I)/I0) was calculated. The 
data were fitted with a simple hyperbolic expression. 
Different anionic phospholipids were added to the POPC matrix to test the effect of 
charge on protein binding. These vesicles contained 10 mol% PI, PA or PS. Compared to 
the zwitterionic PC molecules, PI, PA and PS have a net negative charge, and PTEN 
could bind to these lipid containing vesicles by electrostatic interaction since the protein 
has many positively charged residues on surface (Das et al, 2003). However, the FRET 
for the protein binding to these anionic lipid containing vesicles showed a similar pattern 
compared to PTEN binding to POPC alone (Figure Apx 1). This result indicated that 
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mere electrostatic interactions were not the main source for protein binding to vesicles (at 
least with only 10 mol% of anionic lipids in the LUVs). We then tested PTEN binding to 
25 mol% PS containing vesicles (Figure Apx 2). Compared with 10 mol% PS/PC vesicles, 
increasing the negatively charged component did not enhance protein binding, 
confirming that electrostatic interactions could not provide enough driving force for 
PTEN binding to the membranes. 
 
FigureApx 2 Binding of PTEN to 2 mol% Dansyl-PE containing 10 mol%DOPS 
/POPC (●) and 25 mol% DOPS/POPC (□) LUVs. 
PTEN can be activated by PI(4,5)P2, and the activation was possibly induced by 
conformational change upon binding to PI(4,5)P2 (Campbell et al, 2003). This fact raises 
the possibility that adding PI(4,5)P2 into vesicles may enhance PTEN binding. So 5 mol% 
brain PI(4,5)P2 was incorporated into 10 mol% PS/POPC mixtures and the protein 
binding was measured. Compared to PS/POPC vesicles, adding PI(4,5)P2 enhanced the 
extent of the FRET (Figure Apx 3). At the same concentration of total vesicles, the 
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protein bound fraction was larger when PI(4,5)P2 was present. This result provided the 
hint that adding PI(4,5)P2 may enhance protein binding to the vesicles. However, the 
change in fluorescence due to the FRET did not level off at higher vesicle concentrations 
(again possibly due to increased light scattering), making extraction of a binding constant 
difficult.  
 
Figure Apx 3 PTEN binding to 2 mol% Dansyl-PE containing 10 mol% 
DOPS/POPC (●) and 10 mol% DOPS/5 mol% brain PI(4,5)P2/POPC (□) LUVs. 
(2) Effect of membrane curvature to PTEN binding: LUVs vs. SUVs 
Most of the binding studies of PTEN have been done using lipid LUVs, which are 
relatively large (100 nm diameter) and less curved. In order to test if the curvature of the 
vesicles affects the protein binding, SUVs of 10 mol% PS/PC were used. SUVs have a 
smaller size (average 30 nm diameter) and large curvature. Compared to PTEN binding 
to PS/PC LUVs, introducing more curvature only induced very small changes (Figure 
Apx 4). Light scattering is much less of a problem with SUVs. There is a sense that the 
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binding curve would eventually saturate with the PS/PC SUVs, but the apparent Kd 
would be rather high.  
 
Figure Apx 4 PTEN binding to 10 mol% DOPS/2 mol% Dansyl-PE/88 mol% POPC 
LUVs (●) and SUVs (□). 
(3) Effect of binding conditions: pH and salts concentration 
The measurement of the PTEN protein binding to vesicles so far has been done at pH 8.0 
with 150 mM NaCl present. The effect of pH was first tested by measuring the binding at 
pH 8.0 and pH 7.0. The theoretical pI of PTEN is 6.3, so changing pH from 8 to 7 should 
not influence the binding very much. As expected, PTEN binding to 10 mol% PS/PC 
LUVs was very similar at both pH values (Figure Apx 5, upper pannel). Binding was 
weak in both these two conditions. The higher ionic strength in physiological conditions 
serves to disrupt nonspecific or weak electrostatic interactions and amplify hydrophobic 
interactions. Therefore, we examined PTEN binding to LUVs in the absence or presence 
of NaCl equivalent to physiological conditions For 10 mol% PS/PC there was little 
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change with NaCl. For LUVs of 10 mol% PS/5 mol% PI(4,5)P2/PC, the FRET was 
greater with NaCl added (Figure Apx 5, bottom). However, the light scattering still made 
it extremely difficult to measure PTEN partitioning with any accuracy. 
 
 
Figure Apx 5 PTEN binding to 10 mol% PS LUVs at pH 7.0 (●) and pH 8.0 (○) 
(upper), and binding to 10 mol% PS (circles) and 10 mol% PS/5mol% PI(4,5)P2 
(squares) in the presence (empty symbols) and absence (solid symbols) of 150 mM 
NaCl (bottom).  
(4) Effect of florophore: dansyl-PE vs. pyrene-PE 
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Pyrene-PE as well as dansyl-PE were used as the FRET accepter. Both of the 
fluorophores are attached to the PE head group and should sense PTEN binding. The size 
of the pyrene group is bigger than that of dansyl group but if the pyrene-PE diffuses 
around the vesicle it should be as effective as the dansyl-PE in serving as a FRET 
acceptor with PTEN. 2 mol% pyrene-PE was incorporated into 10 mol% PS/POPC, or 10 
mol% PS/5 mol% PI(4,5)P2/PC LUVs, and PTEN binding to these vesicles was measured 
(Figure Apx 5). Compared to dansyl-PE containing vesicles, protein binding to pyrene-
PE containing vesicles appeared tighter, with a change in the apparent Kd from greater 
than 3 mM to less than 1 mM. This result indicated that the disposition of the pyrene 
group in the membrane is a better sensor of PTEN binding to the LUV. However, the 
binding was still not particularly tight so we opted to forgo further vesicle binding studies 
with PTEN.  
 
Figure Apx 6 PTEN binding to 2 mol% dansyl-PE containing (solid symbols) or 2 
mol% pyrene-PE containing (empty symbols) 10 mol% DOPS (circles) and 10 mol% 
DOPS/5mol% PI(4,5)P2 (squares) LUVs. 
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(5) Effect of the position of His tag on PTEN to vesicle binding 
The PTEN protein used in the fluorescence experiments has a hexa-His tag at the N-
terminus of the protein. Since we did not observe significant PI(4,5)P2 enhanced protein 
binding to vesicles (labeled with the dansyl-group), and PI(4,5)P2 was suggested to bind 
at the N-terminal loop, it is possible that the inability of PI(4,5)P2 induced binding 
enhancement was caused by His-tag interference with PI(4,5)P2 binding. In order to 
exclude this factor, PTEN with the His-tag on the C-terminus was produced, and binding 
of this protein to 5 mol% PI(4,5)P2/10 mol% PS/2 mol% pyrene-PE/83 mol% PC vesicles 
was measured by FRET. Compared to N-terminal His-tagged PTEN, this C-terminal His-
tagged PTEN protein had similar activities toward 0.5 mM diC8PI(3)P. However, 
changing the His-tag attachment did not affect PTEN binding to PI(4,5)P2 containing 
vesicles (Figure Apx 7). The apparent Kd values for these two proteins were very similar. 
 
Figure Apx 7 The effect of His-tag place to PTEN binding. The binding of PTEN 
protein with His-tag on N-terminus (●) or C-terminus () to 5 mol% PI(4,5)P2/10 
mol% PS/2 mol% pyrene-PE/83mol % POPC LUVs monitored by measuring the 
FRET from the protein to pyrene-PE in the LUVs. 
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3. Discussion 
In this study, PTEN protein binding to phospholipid vesicles with different components 
under different conditions was measured by fluorescence spectroscopy. In all the 
measurements shown above, PTEN had very weak binding to dansyl-PE containing 
phospholipid LUVs, but significantly stronger (although still not very tight) binding to 
LUVs incorporating a pyrene-PE as the FRET acceptor. Assessing PTEN binding to 
vesicles with fluorescence has been reported previously (Redfern et al, 2008). In that 
study, pyrene-PE was used as the fluorophore. Combined with our findings, it is hard to 
determine whether the pyrene group in the lipid vesicles enhanced PTEN binding, the 
presence of dansyl group reduced protein affinity to vesicles, or the orientation and 
position of the fluorophore on the membrane was very different for the dansyl group and 
the pyrene and this alters FRET efficiency. My results also suggested that using FRET to 
measure PTEN binding to fluorophore labeled lipids vesicles is problematic. These early 
studies were one of the reasons that we utilized NMR to study PTEN/lipid interaction 
(and chose a short-chain PI system). 
We also found that incorporation of PI(4,5)P2 did not dramatically enhance PTEN 
binding to phospholipids, which appears controversial to what was reported (Redfern et 
al, 2008). However, we noticed that except for the original paper and subsequent reports 
from that group, the importance of PI(4,5)P2 in PTEN membrane association was 
demonstrated based on the fact that deletion or mutation of N-terminal loop or depletion 
of PI(4,5)P2 in plasma membrane eliminates PTEN binding. There is no concrete 
evidence that PIP2 is needed for PTEN binding. To our knowledge, there is no other 
report, especially in vivo studies, showing that increasing PI(4,5)P2 content in the plasma 
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membrane enhanced PTEN binding. Clearly, a thorough understanding of PTEN has a 
long way to go.  
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